Scientific Programme

Wednesday, 06 November 2019

Industry sponsored session
08:00 - 12:00  

Industry sponsored session
(For more details, please visit the <a href="https://eacs-conference2019.com/index.php?article_id=166" target="_blank">conference website</a>)

Pre-conference workshop/course
09:30 - 16:00  

EACS pre-educational course
Convener: EACS

Chairs:
Tristan Barber, United Kingdom
Laura Waters, United Kingdom

Coffee break
09:30 - 10:00

Introduction
Tristan Barber, United Kingdom
Laura Waters, United Kingdom

Zzzzzzz: Sleep issues beyond efavirenz

Clinical case
Nina Vora, United Kingdom

Overview
Hugh Selsick, United Kingdom

Questions
Panel
10:50 - 11:00

Non-AIDS respiratory issues

Clinical case
Jochen Schneider, Germany

Overview
James Brown, United Kingdom

Questions
11:40 - 11:50

Lunch break
11:50 - 12:20

Dermatology in the modern era of HIV

Clinical case
Tala Ballouz, Switzerland
12:20 - 12:40
17th European AIDS Conference
November 6-9, 2019
Basel, Switzerland

**Scientific Programme**

**Overview**
Stefan Esser, Germany

12:40 - 13:00

**Questions**
Panel

13:00 - 13:10

**Chem sex: East and West**

**Eastern European perspective**
Magdalena Ankiersztejn-Bartczak, Poland

13:10 - 13:30

**Western European perspective**
Dominic Rowley, Ireland

13:30 - 13:50

**Questions**
Panel

13:50 - 14:00

**Tea break**

14:00 - 14:20

**Using new ARVs in real life**

**Clinical case**
Rocio Montejano Sanchez, Spain

14:20 - 14:40

**Overview**
Jose Arribas, Spain

14:40 - 15:00

**Questions**
Panel

15:00 - 15:10

**YING session**

**EACS Educational programme and opportunities**
Sanjay Bhagani, United Kingdom

15:10 - 15:30

**Intro/background to YING**
Tristan Barber, United Kingdom

15:30 - 15:40

**Introduce YING Faculty and panel discussion/Q&A**
Laura Waters, United Kingdom

15:40 - 15:55

**Close**
Tristan Barber, United Kingdom
Laura Waters, United Kingdom

15:55 - 16:00

---

Pre-conference workshop/course
10:00 - 13:00

**WAVE workshop - Women against viruses in Europe**
Convener: EACS

**SESSION 1 - If women are more mature... - menopause and ageing**
Chairs:

Yvonne Gilleece, United Kingdom
Antonella d'Arminio Monforte, Italy
Justyna Kowalska, Poland
Scientific Programme

Welcome remarks  10:00 - 10:05
Karoline Aebi-Popp, Switzerland

WAVE 2017-2019 report including WWC  10:05 - 10:15
Karoline Aebi-Popp, Switzerland
Sonia Ganai, United Kingdom

Menopause: Patient’s perspective  10:15 - 10:25
Sophie Strachan, United Kingdom

Clinical cases #1 and 2: Menopause and ageing  10:25 - 10:35
Lesia Ostapiuk, Ukraine
Umbelina Caixas, Portugal

Menopause: Everything we know or not about women living with HIV  10:35 - 11:00
Shema Tariq, United Kingdom

Discussion  11:00 - 11:20

Networking  11:20 - 11:35

SESSION 2 - If women are missing clear guidelines... - PrEP and breastfeeding Chairs:
Fiona Mulcahy, Ireland
Karoline Aebi-Popp, Switzerland

PrEP for women in Europe  11:35 - 11:45
Ben Collins, United Kingdom

PrEP for women: Facts and figures  11:45 - 12:00
Yvonne Gilleece, United Kingdom

Discussion  12:00 - 12:05

Clinical case #3: Breastfeeding  12:05 - 12:10
Marta Lipińska, Poland

Patient’s view on breastfeeding  12:10 - 12:20
Franziska Borkel, Germany

How to counsel and manage women living with HIV who are breastfeeding?  12:20 - 12:35
Christian R Kahlert, Switzerland

Discussion  12:35 - 12:45

Wrap up + Plan 2019-2021  12:45 - 13:00

Access to and models of care

ePosters  12:45 - 20:00
Exhibition hall

PE1/1  Barriers in TB services for people living with HIV and overcoming them according to the health care workers opinion in the TB facilities in Russia (sociological study)
Zinaida Zagdyn, Russian Federation
Scientific Programme

PE1/2 Investigating the impact of peer counseling intervention on access and use of sexual and reproductive health services in women living with HIV in Nepal: a prospective cohort study
Khem Pokhrel, Nepal

PE1/3 Health care delivery for HIV-positive people with tuberculosis in Europe
Adrian Bentzon, Denmark

PE1/4 A survey of physicians on circumstances and factors influencing testing for HIV in Lithuania
Raimonda Matulionyte, Lithuania

PE1/5 Experiences of forgiveness and unforgiveness of HIV-specific offenses among people living with HIV/AIDS in Ghana
Judith A. Osae-Larbi, Ghana

PE1/6 Time to antiretroviral therapy: service model adaptation during an outbreak of HIV in people who inject drugs (PWIDs)
Harrison Stubbs, United Kingdom

PE1/7 HIV infection hospital-based active case finding in Sardinia, Italy: results from the SHOT project
Maria Sabrina Mameli, Italy

PE1/8 Retention activities based on home visits as a tool of return and keeping in care of low adhered patients. Results of work 2016-2019 Krasnoyarsk AIDS clinic
Konstantin Kandlen, Russian Federation

PE1/9 Pilot project of shared assistance with primary care for patients with HIV infection
Adrián Ferre, Spain

ePosters
12:45 - 20:00 Exhibition hall

Antiretroviral observational studies

PE2/1 A study of the effect of antiretroviral therapy on sexual risk behavior in a high-risk cohort of Congolese women
Samuel Bita, Congo, the Democratic Republic of the

PE2/2 Coagulation system and HIV infection: a review
Nnamdi Nwachukwu, Nigeria

PE2/3 Effectiveness, persistence and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF), F/TAF+3rd agent or rilpivirine/F/TAF (R/F/TAF) in treatment-naive HIV-1 infected patients - 24-month results from the German TAFNES cohort study
Hans-Jürgen Stellbrink, Germany

PE2/4 “Attracting men” - extended clinic hours as differentiated model of care in an urban Malawian cohort
Sam Phiri, Malawi

PE2/5 HIV care in India: a systematic review of barriers to anti-retroviral therapy adherence
Charu Kohli, India

PE2/6 Comparing NRTI-sparing dual regimens using data from the Swiss HIV cohort study
Jim Young, Switzerland
Scientific Programme

PE2/7  Physicians' opinions on generic antiretroviral drugs and single tablet regimen (STR) de-simplification for the treatment of HIV infection: a multicentre survey in Spain
Inés Suárez-García, Spain

PE2/8  Simplifying salvage regimens with darunavir-based dual therapy in HIV-infected individuals harboring multidrug-resistance
Pilar Vizcarra, Spain

PE2/9  Clinical outcomes among HIV-infected Africans with advanced disease in Spain
Adrià Ramírez-Mena, Spain

PE2/10 The Treatment of Primary HIV (TopHIV) cohort: a prospective multicenter cohort in Germany
Melanie Stecher, Germany

PE2/11  No decrease in CD4/CD8 ratio after 36 months therapy in patients who were switched to two dual regimens containing rilpivirine
Cecilia Tortajada, Spain

PE2/12  Clinical experience of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) in real life practice: data from the Turkish HIV-TR cohort
Volkan Korten, Turkey

PE2/13  Real world utilisation of raltegravir 1200mg once daily (The RETRO Study)
Christine Mackay, United Kingdom

PE2/14  Effectiveness, persistence and safety in treatment-naive and treatment-experienced HIV-1 infected patients receiving elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) - 12-month evaluation of the French TARANIS cohort
Jean-Luc Meynard, France

PE2/15  24-month evaluation of the German TAFNES cohort - Effectiveness, persistence and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF), F/TAF + 3rd agent or rilpivirine/F/TAF (R/F/TAF) in treatment-experienced HIV-1 infected patients
Heribert Knechten, Germany

PE2/16  Effectiveness, safety and tolerability of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in HIV-1 infected adult patients in routine clinical practice - 6 months results of the BICSTaR cohort
Stefan Esser, Germany

PE2/17  Short-term increase in Body Mass Index and systolic blood pressure elevation in treatment naive persons starting INSTI-based antiretroviral therapy
Ronald Galdamez, Spain

PE2/18  Baseline characteristics in JUNGLE, a German observational cohort study of Juluca as 2-drug Regimen in virologically suppressed patients, compared to the phase-3 SWORD 1 & 2 study populations
F. Schabaz, Germany

PE2/19  Examining the efficacy in clinical practice of the dual antiretroviral therapy regimen of boosted protease inhibitors with maraviroc
Abhishek Katiyar, United Kingdom

PE2/20  Good efficacy but side effects including hypercholesterolemia and body weight gain after switching to dolutegravir plus booster protease inhibitor regimen among treatment experienced HIV-positive patients
Yu-Lin Lee, Taiwan, Republic of China
### Scientific Programme

**PE2/21**  
Rates of DTG/ABC/3TC discontinuation in a real-life setting: no surprises found in reported adverse events  
Ana Gorgulho, Portugal

**PE2/22**  
Low baseline HIV viral loads with a history of PrEP use - how should these patients be managed?  
Victoria Tittle, United Kingdom

**PE2/23**  
Lamivudine-based maintenance 2-drugs regimens: an algorithm for the estimation of 2-years risk of virological failure in clinical practice  
Alberto Borghetti, Italy

**PE2/24**  
Adding raltegravir to a bPI failing regimen was not associated with higher virologic suppression  
Monica Maria Gomes-da-Silva, Brazil

**PE2/25**  
Neuropsychiatric tolerability of bictegravir combined with FTC/TAF in clinical practice  
Christian Hoffmann, Germany

**PE2/26**  
Real-world clinical outcomes of patients switched from complex multi-tablet regimens to TAF-based single-tablet regimens plus a boosted protease inhibitor  
Charlotte-Paige Rolle, United States

**PE2/27**  
Dual therapy with fixed dose combination of darunavir/ritonavir plus raltegravir in HIV-infected patients in Argentina  
Diego Martin Cecchini, Argentina

**PE2/28**  
Detectability of HIV residual viremia despite therapy is highly associated with treatment with protease inhibitor  
Gilles Darcis, Belgium

**PE2/29**  
Prediction of virological failure in patients with low level HIV-1 viremia using a joint latent class model  
Enrique Bernal, Spain

**PE2/30**  
Comparing effectiveness and tolerability of emtricitabine/tenofovir alafenamide (F/TAF) with emtricitabine/tenofovir disoproxil fumarate (F/TDF) in HIV-1 infected adult patients in routine clinical practice: a cross cohort analysis  
Stefan Esser, Germany

**PE2/31**  
Effectiveness of Dolutegravir-based antiretroviral therapy in a real-world setting in a Belgian cohort of 4101 HIV patients  
Rakan Nasreddine, Belgium

**PE2/32**  
Characterizations of weight gain following antiretroviral regimen initiation in treatment-naive individuals living with HIV  
Ricky Hsu, United States

**PE2/33**  
How to RESPOND to modern challenges for people living with HIV: a new cohort collaboration  
Bastian Neesgaard, Denmark

**PE2/34**  
ART simplification: use of dual therapy for HIV in a public health reference center (CRT-DST/Aids) in São Paulo, Brazil  
Roberta Schiavon Nogueira, Brazil
Simplification to dual (2D) antiretroviral therapy (ART) with lamivudine and dolutegravir in HIV-infected patients with solid organ transplantation (SOT): a preliminary single-center experience  
Juan Ambrosioni, Spain

Comparable effectiveness of Raltegravir-based dual therapy versus other regimens in patients switched for maintenance  
Karen Martin, Germany

Comparison of a two-drug regimen (dolutegravir/rilpivirine) to standard three-drug regimens in virologically suppressed, treatment experienced individuals in the real world  
Gerald Pierone, United States

Effectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir in treatment-experienced patients: a multicentre cohort study  
Inés Suárez-García, Spain

High persistence of dolutegravir-containing 2-drug regimens in routine clinical care  
Sebastian Noe, Germany

Virologic, immunologic and clinical outcomes in antiretroviral treatment (ART) naïve individuals in the RESPOND cohort collaboration  
Amanda Mocroft, United Kingdom

A retrospective analysis of the EuResist data set assessing HIV dual therapy success in a real-life context  
Michael Böhm, Germany

The real-world impact of switching to tenofovir-alafenamide (TAF) on metabolic comorbidities in PLWH aged over 60s  
Ming Jie Lee, United Kingdom

Effect of simplification to INSTI-based dual therapy on residual inflammation and viral reservoir  
Giulia Marchetti, Italy

Changes in LDL after switch from TDF to TAF in the U.S.  
Paddy Mallon, Ireland

A retrospective analysis of the EuResist data set assessing if NRTI resistance impairs INSTI based treatment with NRTI backbone  
Michael Böhm, Germany

Impact of archived M184V/I mutations on the effectiveness of switching to coformulated elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide among virologically suppressed HIV-positive patients  
Chien-Ching Hung, Taiwan, Republic of China

Central nervous system (CNS) side effects and viral blips post cART switch from atazanavir boosted with ritonavir (ATZ/r) to atazanavir boosted with cobicistat (ATZ/c)  
Stephanie Tyler, United Kingdom

Quantitation of cellular HIV-1 DNA levels by droplet digital PCR in virologically-suppressed patients switching to dolutegravir plus lamivudine: a prospective study  
Francesca Lombardi, Italy
PE2/49  Evaluation of weight gain in incarcerated individuals living with HIV/AIDS after switching to a raltegravir-based regimen  
Melissa Badowski, United States

PE2/50  Determinants of viral non-suppression among people living with HIV (PLHIV) in rural setting, Neno: a retrospective cohort study  
Potiphar Damiano, Malawi

PE2/51  Risk of developing HIV resistance in patients with low level viraemia in a large London cohort  
Naomi Fitzgerald, United Kingdom

PE2/52  Virological outcomes of first line regimens in women living with HIV from Icona cohort: comparison with clinical trial data  
Cristina Mussini, Italy

PE2/53  Well-being in people living with HIV/AIDS (PLWHA) according to cART exposure: data from IOCONA cohort  
Antonella Cingolani, Italy

PE2/54  Body composition changes in HIV: do INSTI matter?  
Giovanni Guaraldi, Italy

PE2/55  Dolutegravir-based regimens are associated with weight gain over two years following ART-initiation in ART-naive people living with HIV (PLWH)  
Heidi Crane, United States

PE2/56  Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in combination with boosted darunavir (DRV) in treatment experienced patients with HIV  
Lucas Hill, United States

PE2/57  Real world data of using Triumeq (dolutegravir/abacavir/lamivudine; DTG/ABC/3TC): final outcomes of the 3-year German TRIUMPH cohort show good virologic effectiveness and safety in clinical routine  
Nils Postel, Germany

PE2/58  The effectiveness of E/C/F/TAF in treatment-naive (TN) or treatment-experienced (TE) adult HIV-infected patients in a real-world setting, results from southern Turkey  
Dilara Inan, Turkey

PE2/59  Comparison of efficacy and safety of a switch to fixed-dose combination FTC/TDF-TAF/RPV versus fixed-dose combination 3TC/ABC/DTG in HIV-1-infected, treatment experienced and virologically suppressed patients: a cohort study  
Gaetana Sterrantino, Italy

PE2/60  COPEDOL: a 2-year French multicentric, observational, longitudinal retro-prospective study, in pretreated HIV-1-infected patients starting dolutegravir based regimen due to treatment failure  
Roland Landman, France

PE2/61  Drug-drug interactions with recommended first-line antiretroviral therapy in real-world settings  
Wang-Huei Sheng, Taiwan, Republic of China

PE2/62  Determinants of switching to TAF-based cART or dual combinations (DC) from TDF-based regimens in a cohort of HIV-infected individuals with controlled viral load≤50 copies/mL  
Alessandra Vergori, Italy
An early proactive switch to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/T/TAF) is effective in maintaining virologic control and improving quality of life (QoL) in patients with a primary HIV-1 infection (PHI). An interim analysis of a phase IV clinical trial (ESTER study)
Marta Camici, Italy

Prevalence of neuropsychiatric conditions in patients living with HIV-1 treated with antiretroviral therapies - a perspective from US Medicaid
Wing Chow, United States

Switch to dolutegravir dual regimens and inflammation mediated by annexin
Claudio Ucciferri, Italy

Efficacy of dual antiretroviral therapy (ART) as intermittent short cycle regimen in virologically suppressed HIV-infected patients: an observational cohort
Romain Palich, France

Modelling time varying viral load and CD4 cell counts response to antiretroviral therapy in a cohort of HIV naive patients
Margarida Tavares, Portugal

Impact of switching to E/C/F/TAF on lipid profile and renal function in HIV-infected patients
Bilgul Mete, Turkey

Genital HIV-1 RNA and DNA shedding in virologically suppressed individuals switching from triple- to dual- or monotherapy: pooled results from two randomized controlled trials
Laurent Hocqueloux, France

Comparison of the Ease of Swallowability of B/F/TAF placebo compared to DTG/ABC/3TC placebo
John Ernest McKinnon, United States

Evaluation of total HIV-DNA changes in HIV-1 infected patients who continue a 2-drug regimen with dolutegravir plus one reverse transcriptase inhibitor or switch to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide enrolled in the Be-One Study
Maria Mercedes Santoro, Italy

Phase-3 trials of new antiretrovirals are not representative of the global HIV epidemic
Toby Pepperrell, United Kingdom

Impact of susceptibility scoring on virologic response in heavily treatment-experienced participants with HIV-1 receiving a fostemsavir-based antiretroviral regimen: results through week 96 from the randomized cohort of the Phase 3 BRIGHTE study
Peter Ackerman, United States

Reversibility of dolutegravir/lamivudine/abacavir neuropsychiatric toxicity after 24 weeks of switching to elvitegravir/cobicistat/emtricitabine/tenofovir-alafenamide (E/V/c/FTC/TAF).
The DREAM Clinical Trial
Ignacio Pérez-Valero, Spain
Scientific Programme

PE3/7 A switch to dolutegravir in combination with boosted darunavir is safe and effective in suppressed patients with HIV - a predefined psychosocial subanalysis of the DUALIS study
Christoph Spinner, Germany

PE3/8 Tenofovir alafenamide versus tenofovir disoproxil fumarate - is there a true difference in safety?
Toby Pepperrell, United Kingdom

PE3/9 Biologic sex is not the only difference between men and women: data from the Doravirine phase 2/3 clinical trials
Sharon Walmsley, Canada

PE3/10 No metabolic or renal benefits when switching to an NRTI-free dolutegravir-containing 2 drug regimen (2DR) - a subanalysis of the DUALIS study
Christoph Boesecke, Germany

PE3/11 Sustained viral suppression with dolutegravir monotherapy during 9,899 patient weeks of follow-up in individuals starting combination antiretroviral therapy during primary HIV infection (EARLY SIMPLIFIED): a randomized, controlled, multi-site, non-inferiority trial
Dominique Laurent Braun, Switzerland

PE3/12 Rapid initiation of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in patients with human immunodeficiency virus (HIV)-1 infection: age, race/ethnicity, and gender subgroup analyses from the DIAMOND study
David Anderson, United States

PE3/13 A systematic review and meta-analysis evaluating the risk of central nervous system adverse events in randomised controlled trials of dolutegravir
Khadija Muniath Chowdhury, United Kingdom

PE3/14 Long-term efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in ART-naïve adults
Chloe Orkin, United Kingdom

PE3/15 Switching from a 3-drug tenofovir alafenamide (TAF)-based regimen (TBR) to a 2-drug dolutegravir/lamivudine (2DR, DTG/3TC FDC) was not associated with a higher frequency of intermittent viremia in suppressed patients in the TANGO study
Ruolan Wang, United States

PE3/16 Phase 3 randomized, controlled DISCOVER study of daily emtricitabine/tenofovir alafenamide (F/TAF) or emtricitabine/tenofovir disoproxil fumarate (F/TDF) for HIV pre-exposure prophylaxis (PrEP): week 96 results
Peter J Ruane, United States

PE3/17 Single doses of long-acting capsid inhibitor GS-6207 administered by subcutaneous injection are safe and efficacious in people living with HIV
Eric S Daar, United States

PE3/18 Long-term safety and efficacy of rilpivirine plus nucleoside/nucleotide reverse transcriptase inhibitors in HIV-1 infected patients: 7-year roll-over study from phase 2 and 3 clinical studies
Jean-Michel Molina, France

PE3/20 Prevalence of archived HIV-1 DNA resistance-associated mutations (RAMs) and their lack of effect on virologic outcome at week 96 in antiretroviral treatment (ART)-experienced, virologically suppressed patients receiving the once-daily, single-tablet regimen (STR) darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in the EMERALD phase III trial
Erkki Lathouwers, Belgium
Scientific Programme

PE3/21 Islatravir efficacy and safety for selected demographic and baseline subgroups from a Phase 2 trial in treatment naïve adults with HIV-1 infection
Jean-Michel Molina, France

Antiretroviral therapy preclinical

PE4/3 In vivo dissection of the effects of HIV and antivirals on mitochondrial function in chronic treated HIV
Theodoros Kelesidis, United States

PE4/4 The main barriers to “Test and Start” in Central Asia from the service providers’ and patients’ point of view
Yelena Kudussova, Kazakhstan

PE4/5 Preclinical aspects of an anti-HIV molecule targeting vimentin
Celia Berta Fernandez-Ortega, Cuba

PE4/6 PK/PD modelling of bnAbs for HIV treatments identifying knowledge gaps
Mark Baker, Switzerland

PE4/7 A new inhibitor of HIV-1 infection exploiting host intracellular signaling to alter viral RNA processing
Raymond Waiman Wong, Canada

Behavioural interventions

PE5/1 Close group social media network and social gatherings for comprehensive HIV services among adolescent MSM in Lagos Nigeria
Orobosa Enadeghe, Nigeria

PE5/2 Good hygiene practices post circumcision: a case for low adverse events in VMMC
Timothy Kipkosgei, Kenya

PE5/3 Challenges of implementing HIV counselling and testing (HCT) campaigns for higher education distance learning students at University of South Africa
Nkay Pascal Kiabilua, South Africa

PE5/4 Enhancing effective HIV prevention among girls by fighting child marriage and sexual and gender based violence in Karonga district, Malawi
Shora Manuel Kauluka, Malawi

PE5/5 Effectiveness of rapid HIV and HCV testing programmes based on mobile units
Ekaterina Zinger, Russian Federation

PE5/6 It can´t happen to me - tackling cognitive mistakes and HIV using a national campaign
Arian Diskovic, Croatia
Is mobility still a HIV/STI associated vulnerable factor in the changing sex work dynamics among female sex workers in India? - Emerging evidence
Priyanka Dixit, India

“Amare con Sapienza”: an Italian digital ambient media prevention campaign in one of the largest European University to increase U=U, PreP, TasP knowledge
Serena Vita, Italy

Assessing high risky sexual behaviors in vulnerable women in northern Uganda: baseline results of “Pe Atye Kena, no longer alone” study
Antonella Cingolani, Italy

HIV/AIDS educational program for secondary school female students in Iran: a school-based randomized controlled trial
Farid Yousefi, Iran, Islamic Republic of

Self-reported non-receipt of HIV test results: a silent barrier to HIV epidemic control in Mozambique
Didier Mugabe, Mozambique

Improvement in ART initiation in different regions of Ukraine from 2010 to 2014
Tetiana Salyuk, Ukraine

The HIV treatment cascade in Azerbaijan, 2018
Natig Zulfugarov, Azerbaijan

Seven years of European Testing Week: impact of a regional awareness campaign on increase in awareness and testing activities in Europe
Lauren Combs, Denmark

Impact of integrated family planning and HIV services on early postpartum contraceptive use among women with HIV in the Eastern Cape, South Africa
Oladele Vincent Adeniyi, South Africa

The first report of Prevention of Mother-to-Child Transmission (PMTCT) of HIV in Islamic Republic of Iran
Ebrahim Ghaderi, Iran, Islamic Republic of

New HIV diagnosis and linkage to care in two outpatient units in South Europe
Alessio Pampaloni, Italy

The HIV- and HCV-cascade in Swiss opioid agonist treatment (OAT) patients - the SAMMSU-cohort
Andrea Bregenzer, Switzerland

Increased Integrated testing for HIV and HCV in health care facilities: examples from the INTEGRATE activities in Lithuania and Romania
Raimonda Matulionyte, Lithuania
PE6/10  AIDS and late presentation follows testing gaps in Poland - data from Test and Keep in care (TAK) Polska project
Justyna Kowalska, Poland

PE6/11  Loss to follow-up and re-linkage to care in a single cohort study: who do we re-link to care?
Laura Magnasco, Italy

PE6/12  Expanding access to HIV tests in 13 cities in Indonesia: an interrupted time series investigating effect of HIV policy intervention using six years population data
Yane Tarigan, Australia

PE6/13  Link HIV-infected injection drug users after the imprisonment to continuum of HIV care program in Taiwan
Wei-Wei Wu, Taiwan, Republic of China

PE6/14  HIV continuum of care by sex and mode of transmission in Spain, 2016: use of different sources of information
Victoria Hernando, Spain

PE6/15  Temporal trends in time from HIV diagnosis to viral load suppression in CoRIS
Belén Alejos, Spain

PE6/16  Navigation of HIV positive clients. Reasons of gaps in HIV cascade among PWID
Oksana Pashchuk, Ukraine

PE6/17  Tracing the patterns of HIV-1 transmission among individuals with different time to diagnosis in Greece
Evangelia-Georgia Kostaki, Greece

PE6/18  Late diagnosis and delayed presentation in Korean HIV/AIDS cohort
Shin Woo Kim, Korea, Republic of

PE6/19  Interruption of HIV care: understanding the predictors and outcomes in the Belgian national HIV cohort
Dominique Van Beckhoven, Belgium

PE6/20  The HIV continuum of care: current situation and advances. A systematic review
Georgia Vourli, Greece

PE6/21  The contribution of a partnership with a civil society organization (SCO) to early HIV diagnosis and UNAIDS goals
Antonio Diniz, Portugal

PE6/22  HIV cascade of care in Turkey: data from the HIV-TR cohort
Deniz Gökengin, Turkey

PE6/23  Cascade analysis of anonymous voluntary HIV counseling and testing among HIV-infected patients in Taiwan
Chun-Yuan Lee, Taiwan, Republic of China

PE6/24  Late presentation of HIV in Armenia
Trdat Grigoryan, Armenia

PE6/25  Oral self-testing for individuals absent or refusing testing during home-based HIV testing - a cluster-randomized trial in Lesotho (HOSENG trial)
Tracy R Glass, Switzerland
Scientific Programme

PE6/26  Acceptability of rapid tests for migrants during the medical consultation at the migration point
Martin Duracinsky, France

PE6/27  Evaluation of the “test and treat” strategy in an high-income setting: data from a multicenter Italian cohort
Gianmaria Baldin, Italy

PE6/28  Pill box return as a predictor of treatment outcome to antiretroviral therapy in PLHIV: a prospective cohort study
Robert Ndege, Tanzania, United Republic of

PE6/29  Potentially missed opportunity to diagnose HIV with standard testing algorithm among adult patients with ongoing mononucleosis-like illness
Anna Vassilenko, Belarus

PE6/30  HIV Continuum of Care Cascade in Cluj County, Romania. Comparative situation of the years 2016, 2017, 2018
Adriana Topan, Romania

PE6/31  People living with HIV lost to follow up in the Paris region area and actions carried out by HIV care centers
Nicolas Vignier, France

PE6/32  Far from 90-90-90 goals in Latin America
Maria Greco, Argentina

PE6/33  Barriers to involving patients in ART as a challenge to the national health system in Ukraine
Serhii Riabokon, Ukraine

PE6/34  Index testing and intensified case finding for efficiency in HIV testing in Rwanda
Eric Remera, Switzerland

ePosters
12:45 - 20:00  Exhibition hall

Clinical case

PE7/1  Disseminated histoplasmosis in HIV, a key point of interest in Latin America
Nelson Delgado, Ecuador

PE7/2  H-ART to Heart: a 43 year old body builder with HIV on anti-retroviral therapy with recurrent myocardial infarctions (5 heart attacks)
Gavin Paul Raphael Manmathan, United Kingdom

PE7/3  Immune reconstitution inflammatory syndrome presenting as toxoplasma macular retinochoroiditis of eyes
Dombu Guiafaing Reine Charlye, Cameroon

PE7/4  Invasive pulmonary aspergillosis and pulmonary tuberculosis in newly HIV diagnosed patients without prior ART exposure: differential diagnosis difficulties, treatment strategy
Katerina Lytvin, Ukraine

PE7/5  Pseudotumor mimicking lung malignancy as a clinical presentation of Mycobacterium Avium infection in AIDS patient
Luka Jovanovic, Serbia
Scientific Programme

PE7/6 Use of ivalizumab in a heavily treatment-experienced HIV-1-infected subject harbouring a multidrug-resistant virus
Diana Canetti, Italy

PE7/7 Successful use of long-acting injectable cabotegravir and rilpivirine combination therapy in a patient with HIV-1 infection unable to absorb oral medication
Razan Saman, United Kingdom

PE7/8 Cutaneous malignancy in a Romanian HIV-infected patient: diagnosis and treatment challenges
Irina Cristiana Ianache, Romania

PE7/9 Autoantibodies, drugs and a failing liver
Sonia Raffe, United Kingdom

ePosters
12:45 - 20:00 Exhibition hall

Clinical trials of vaccines

PE8/1 Seroprevalance of vaccine preventable viral diseases and vaccine response among HIV positive patients
Fatma Sebnem Erdinc, Turkey

PE8/2 Could we recommend the current herpes zoster vaccine for patients living with HIV (PLHIV)?
Thomas Huleux, France

ePosters
12:45 - 20:00 Exhibition hall

Co-morbidities, ageing

PE9/1 Detectable subclinical myocardial abnormalities in people living with HIV: insights from cardiac magnetic resonance imaging (MRI)
Gavin Paul Raphael Manmathan, United Kingdom

PE9/2 Hypertension and ECG alterations in HIV positive patients in DREAM centres in Mozambique
Isotta Triulzi, Italy

PE9/3 Cardiovascular events are declining in men with HIV aged 50 years or older in Austria
Maria Kitchen, Austria

PE9/4 Prevalence of HIV-associated neurocognitive disorder (HAND) in Turkey and assessment of Addenbrooke's Cognitive Examination Revised (ACE-R) test as a screening tool
Volkan Korten, Turkey

PE9/5 Pilot study assessing the Rotterdam Healthy Aging Score in a cohort of HIV-positive adults
Sharon Walmsley, Canada

PE9/6 Obesity and HIV - the overlaping epidemics
Justyna Kowalska, Poland
PE9/7  Exhaled nitric oxide levels are higher in people living with HIV compared to uninfected controls suggesting increased eosinophilic pulmonary inflammation
Rebekka Faber Thudium, Denmark

PE9/8  Comparison of changes in bone microarchitecture with abacavir-lamivudine versus tenofovir disoproxil fumarate-emtricitabine in adults living with HIV
Roger Bedimo, United States

PE9/9  Limitations of FRAX equation for predicting low bone mineral density or bone loss progression among people living with HIV: the role of secondary causes of osteoporosis
Pilar Vizcarra, Spain

PE9/10 Elevated body mass index during pregnancy and gestational weight gain in HIV-infected women in Cape Town, South Africa: association with adverse birth outcomes
Hlengi Madlala, South Africa

PE9/11  Facilitating primary care non-antiretroviral drug prescribing in people living with HIV: the Think ARV project
Jaime Vera, United Kingdom

PE9/12 Characterization of moderate and severe anemia by peripheral blood smear in HIV infected patients in the Kilombero and Ulanga antiretroviral cohort
Vanesa Anton-Vazquez, United Kingdom

PE9/13 HIV infection and smoking: PET imaging reveals early pulmonary perfusion abnormalities
Puja Kohli, United States

PE9/14 Bariatric surgery in HIV obese patients: first results of the French ObéVIH ongoing study
Valérie Pourcher, France

PE9/16 Plasma cotinine cut-off for distinguishing smokers from non-smokers among people living with HIV (PLWH)
Omid Rezahosseini, Denmark

PE9/17 An analysis of HIV and co-morbidity profiles for adults accessing health care in Khayelitsha, South Africa
Richard Osei-Yeboah, South Africa

PE9/18 Femoral arteries better indicator than carotid arteries of cardiovascular risk in HIV/AIDS patients
Gordana Dragovic Lukic, Serbia

PE9/19 Cardiovascular risk assessment in PLWH over 50: agreement between cardiovascular risk predictors and Coronary Artery Calcium CT Scoring (CACS)
Branca Pereira, United Kingdom

PE9/20 Safety and tolerance of denosumab in HIV patients
Sara Vela, Spain

PE9/21 Lower incidence of liver steatosis in patients treated with lamivudine plus dolutegravir dual therapy
Davide Moschese, Italy

PE9/22 Correlations between computerised and standard cognitive testing in persons with HIV and controls
Davide De Francesco, United Kingdom
Whole body MRI detects high prevalence of incidental findings in older HIV-1-infected patients participating in a randomised, controlled trial of maraviroc and/or metformin for non-alcoholic fatty liver disease
Sarah Pett, United Kingdom

An analysis of potential drug-drug interactions in an aging HIV cohort
Pádraig Gardiner, Ireland

A standardized comparison of cardiovascular risk factor prevalence between people living with HIV and general population in Spain
Vicente Estrada, Spain

Subclinical atherosclerosis burden by ultrasound in carotid and femoral territories in HIV subjects: relationships with HIV and non-HIV related factors
Vicente Estrada, Spain

Subcutaneous adipose tissue modifications induced by a switch to dual raltegravir-maraviroc therapy in controlled HIV-infected patients: a sub-study of the ANRS-ROCnRAL157 clinical trial
Jacqueline Capeau, France

Results of 10 year experience of a specialist clinic for people living with HIV over 50 at Chelsea and Westminster Hospital
Branca Pereira, United Kingdom

Discordance in diagnosis of osteoporosis in HIV-infected patients: prevalence, characteristics, and impact on FRAX equation
Pilar Vizcarra, Spain

CD4/CD8 ratio is a better indicator of acute phase inflammation than absolute CD4 count during virally-suppressed HIV infection
Rodney Rousseau, Canada

Immune activation and chronic inflammation: is there an additional effect of HIV in a geriatric population?
Clotilde Allavena, France

Trends in cardiovascular risk factors and estimated 10-year cardiovascular risk score in a Spanish cohort of PLWH: 2010-2018
Francisco Fanjul, Spain

Prevalence of depression and associated psychosocial factors among HIV positive patients attending ART clinic at Gulu Regional Referral Hospital
Ronald Kiyemba, Uganda

Potentially inappropriate medications in older adults with HIV in the region of Madrid, Spain
Beatriz López-Centeno, Spain

Impact of the reproductive/hormonal status on weight, fat and insulin resistance in HIV-infected women switching from a PI regimen to dual raltegravir-etravirine therapy: results from the ANRS163-ETRAL trial at 48 and 96 weeks
Jacqueline Capeau, France

Age- and sex-related differences in concomitant diseases and use of co-medication in patients with treated HIV-infection in Germany
Karen Martin, Germany
Kidney transplantation in HIV-positive patients in Israel including the first case of HIV-positive living donor to HIV-positive recipient with a 7-year follow-up
Eugene Katchman, Israel

Vitamin D deficiency and frailty phenotype in HIV-infected men
Fiona Bhondoeikhan, United States

The UCSD performance-based skills assessment is associated to cognitive performance in HIV positive population with very good immunological condition
Valentina Delle Donne, Italy

Alcohol, smoking and the association with HIV virological non-suppression among people living with HIV on ART
Timothy Peter Wynne Jones, United Kingdom

Decreasing incidence of diabetes mellitus in HIV-positive Taiwanese patients on combination antiretroviral therapy from 2004 to 2011
Pei-Ying Wu, Taiwan, Republic of China

Incidental findings in PLWH over 50 undergoing coronary artery calcium scoring (CACS) for cardiovascular risk assessment
Maria Mazzitelli, United Kingdom

Aging biomarkers, inflammatory cytokines and development of cardiovascular ischemic events or diabetes in HIV-infected persons
Jose I Bernardino, Spain

Falls but not frailty are common in people living with HIV using an mHealth platform: issues of ageing within the EmERGE cohort
Tom Levett, United Kingdom

Perceptions of ageing and desire for ageding information amongst users of the EmERGE mHealth platform
Tom Levett, United Kingdom

Switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in adults aged >65 or older: week 48 results from a phase 3b, open-label trial
Franco Maggiolo, Italy

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in people with HIV aged 50 years and older
Hans-Jürgen Stellbrink, Germany

HIV testing in patients diagnosed with community acquired pneumonia or primary lung cancer from 2014 to 2018 in a tertiary reference hospital in Northern Spain
Teresa Rubio Obanos, Spain

Menopause in aging women living with HIV: changes in bone mineral density and trabecular bone score
Giovanni Guaraldi, Italy

Higher anti-CMV IgG concentrations are not associated with longitudinal brain injury in virally suppressed people with HIV
Jonathan Underwood, United Kingdom
Scientific Programme

PE9/55  Higher Prevalence of CKD in HIV+ individuals compared to the general population  
Stefan Esser, Germany

PE9/56  Effect of CMV viraemia on endothelial dysfunction over 42 weeks in Malawian adults initiating ART with advanced immune suppression  
Christine Kelly, Ireland

PE9/57  High prevalence of neurocognitive impairment in adults with perinatally acquired HIV infection  
Irene Portilla-Tamarit, Spain

PE9/58  Modeling 2018 AHA cholesterol guidelines in HIV  
Giacomo Ciusa, Italy

PE9/59  A multi-disciplinary Neuro-HIV Platform in managing patients with neurocognitive impairment  
Phanie Bidlingmeyer, Switzerland

PE9/60  Archi-Prevalat project. A national register of color-Doppler ultrasonography of the epi-aortic vessels in patients living with HIV  
Salvatore Martini, Italy

PE9/61  Preliminary results of a diagnostic-therapeutic work-up to early detect cardiovascular disease in HIV positive patients  
Giovanni Millotti, Italy

PE9/62  Bone mineral density changes in young African women on tenofovir disoproxil fumarate antiretroviral therapy and non-hormonal contraception  
Flavia Kiweewa Matovu, Uganda

PE9/63  Examination of HIV-infected patients regarding weight gain while using integrase inhibitors in Japan  
Ryoko Sekiya, Japan

PE9/65  Predictors of sarcopenia and its impact on components of the frailty phenotype in an Asian population living with HIV  
Grace Lui, Hong Kong

PE9/66  Failure to restore CD4 cell count with combination antiretroviral therapy is associated with increased systemic inflammation  
Rodney Rousseau, Canada

PE9/67  High prevalence of left ventricular systolic dysfunction assessed by speckle tracking in asymptomatic HIV patients  
Dimitris Basoulis, Greece

PE9/68  Polypharmacy and drug-drug interactions - prevalence in a Portuguese HIV Metabolic Clinic  
Joana Fragoso, Portugal

PE9/69  Bone density alterations in the HIV-infected patient - epidemiologic characterization of a Portuguese cohort  
Diogo Guerra, Portugal

PE9/70  Cigarette smoking disproportionately impairs nitric oxide signaling in pulmonary artery endothelial cells in HIV: role of viral and host factors  
Saurabh Aggarwal, United States
Scientific Programme

PE9/71  Frailty phenotype in older virologically suppressed PLWHIV is strongly correlated with specific comorbidities and tobacco use
Christina Katerina Psomas, France

PE9/72  HIV-FUNCFRAIL study: differences between women and men aging with HIV
Fátima Brañas, Spain

PE9/73  Prevalence, risk factors and outcomes of cardiovascular, metabolic and chronic kidney diseases in HIV-infected vs. uninfected adults in sub-Saharan Africa: a systematic review and meta-analysis
Ajibola Awotiwon, South Africa

PE9/74  People living with HIV are more likely to be screened for cardiovascular disease risk factors than other members of the general population in Botswana - a community based study
Onkabetse Julia Molefe-Baikai, Botswana

PE9/75  APOL1 high risk genotype has an adverse impact on kidney function in African HIV-infected patients with high viral load
Nongodo Firmin Kabore, France

PE9/76  Comparison of 2 frailty scores in PLWHIV aged 50 and over: SOF index and FRIED phenotype
Christina Katerina Psomas, France

PE9/77  Annexin V, Annexin A1 and cardiovascular risk in HIV population
Claudio Ucciferri, Italy

PE9/78  Could we consider the intima-media thickness (c-IMT) > 1mm as a risk factor for cardiovascular diseases in HIV+ subjects chronically treated with antiretrovirals?
Alessio Pampaloni, Italy

PE9/79  Immune reconstitution inflammatory syndrome (IRIS) in HIV-infected hospitalized patients with advanced disease
Alberto Díaz-de Santiago, Spain

PE9/80  Low Body Mass Index (BMI) in ART naive HIV-positive subjects and risk of virological failure and drug discontinuation: data from the ICONA Foundation Cohort
Roberto Rossotti, Italy

PE9/81  Sistatin C, KIM1 and NGAL as biological markers for detecting early kidney injury in HIV positive patients
Aslıhan Ulu, Turkey

PE9/82  Long-term AIDS survivors: comorbidities and polypharmacy a new challenge
María José Galindo Puerto, Spain

PE9/83  Risk Factors associated to immune reconstitution inflammatory syndrome (IRIS) in HIV-infected hospitalized patients with advanced disease
Alberto Díaz-de Santiago, Spain

PE9/84  Sleep disorders and depression through efavirenz to dolutegravir transition in Brazil: what really changed after all
Melissa Medeiros, Brazil

PE9/85  Patterns of inflammation and comorbidity in Human Immunodeficiency Virus (HIV) infection: a clustering analysis from the CARDAMONE study
Sonia Zebachi, France
Scientific Programme

PE9/86  Cognitive impairment in patients with HIV in a Mexican hospital
Lucia Carrazco Ibarra, Mexico

PE9/87  Clinical management of ageing people living with HIV in Europe: The view of the care providers
Marta Boffito, United Kingdom

PE9/88  Real-word characterization of the Portuguese population living with HIV who initiated Raltegravir based-regimen in the last three years - REALITY Study
Joana Almeida, Portugal

PE9/89  Long-term lipid-lowering-therapy in HIV is clinically effective
Henning Drechsler, United States

ePosters
12:45 - 20:00
Exhibition hall

Gender issues

PE10/1  Patient, clinical and virus genetic characteristics of migrants from Eastern, Central and Western Africa enrolled in the SHCS
Nadine Bachmann, Switzerland

PE10/2  Menopause impacts drug use and mental health in women with HIV in Switzerland
Anna Hachfeld, Switzerland

PE10/3  Gender-specific analysis of a German cohort of HIV-infected patients on Raltegravir-based therapy shows distinctive baseline co-morbidity profiles of women versus men but no impact on treatment outcomes
Karen Martin, Germany

PE10/4  Menopausal symptoms, sleep disorders and anxiety/depression among premenopausal and postmenopausal HIV-infected women: a multicenter cohort study in Spain
Ines Suarez, Spain

PE10/5  An evaluation of the care given to older women attending an HIV clinic in London
Claire Williams, United Kingdom

PE10/6  Anti-Mullerian hormone a plausible indicator of cardiometabolic risk in HIV-infected women
Umbelina Caixas, Portugal

PE10/7  Differences in sexual health among HIV infected and uninfected women of child-bearing age
Raffaella Marocco, Italy

ePosters
12:45 - 20:00
Exhibition hall

HIV and marginalised groups

PE11/1  Sexual behaviors and seroprevalence of HIV, HBV, and HCV among hill tribe youths of Northern Thailand
Tawatchai Apidechkul, Thailand
Scientific Programme

PE11/3  The blind spot: high HIV burden among slum-dwelling school-age girls in Kampala, Uganda
Jude Thaddeus Ssensamba, Uganda

PE11/4  Research of behavioral models of transgender people leading to high rates of HIV prevalence in Ukraine
Igor Medvid, Ukraine

PE11/5  Outreach services for HIV testing and prevention among female transgender commercial sex workers in Milan: different approaches for different populations?
Giuseppe Lapadula, Italy

PE11/6  The impact of unstable housing on HIV treatment outcomes in people living with HIV/AIDS in an urban setting of Southern Europe
Hernando Knobel, Spain

PE11/7  Reflection of sex work criminalization in court judgements targeting to protect health, sanitary and epidemiological well-being
Marina Avramenko, Russian Federation

PE11/8  Caring for the Transgender HIV-positive patient
Chiara Picarelli, Italy

PE11/9  Association of current Estradiol use with carotid intimal media thickness among transgender women: a cross-sectional study
Rodrigo Moreira, Brazil

PE11/10 HIV and migrants: a demographic and clinical characterization of migrants under follow up at an Infectious Diseases Department in Lisbon, Portugal
Marta Leal dos Santos, Portugal

ePosters
12:45 - 20:00  Exhibition hall

HIV cure

PE12/1  Comparison of three commercial kits for quantitative analysis of HIV-1 RNA produced in Russia
Ilya Lapovok, Russian Federation

PE12/2  Optimization of genotyping by phenotypic analysis of clinical HIV-1 subtype CRF01_AE isolates from South-East Asia
Nina Marty, Switzerland

ePosters
12:45 - 20:00  Exhibition hall

HIV drug resistance

PE13/1  Darunavir resistance among patients exposed to protease inhibitors failing ARV therapy
Luis Fernando Brigido, Brazil
Scientific Programme

PE13/2  **Prevalence and factors associated to the detection (population and next generation sequencing) of archived 3TC resistance mutations in aviremic HIV-infected adults (GEN-PRO)**
Lourdes Domínguez-Domínguez, Spain

PE13/4  **Monitoring the prevalence of transmitted HIV drug resistance in Hungary**
Eva Ay, Hungary

PE13/5  **Predominant reverse transcriptase resistance mutations as barriers to achieving elimination of mother-to-child transmission of HIV in South Africa**
Oladele Vincent Adeniyi, South Africa

PE13/6  **Virologic failure and human immunodeficiency virus drug resistance in adolescents on antiretroviral therapy in Yaounde and Douala**
Magaly Jeanne Estelle Moukoko Mbonjo, Cameroon

PE13/7  **Selection of integrase inhibitor (INI) resistance mutations in an INI experienced patient treated by Bictegravir**
Thanes Vanig, United States

PE13/8  **Impact of HIV-1 subtypes and integrase natural polymorphisms on virological response to first-line integrase inhibitors based regimens**
Daniele Armenia, Italy

PE13/9  **HIV-1 integrase inhibitor resistance associated mutations defined by majority and minority populations among individuals failing therapy**
Smitha Gudipati, United States

PE13/10  **HIV-1 diversity and antiretroviral resistance among bulgarian citizens infected abroad and foreigners registered with HIV/AIDS in bulgaria from 2012 to 2017 (preliminary analysis)**
Ivailo Alexiev, Bulgaria

PE13/11  **Analytical treatment interruption and its association with rearrangement of peripheral archived resistance mutations**
Claudia Alteri, Italy

PE13/12  **A low level of darunavir resistance-associated mutation emergence in patients with virological failure during long term use of darunavir in people living with HIV, the French ANRS CO3 Aquitaine cohort**
Fabrice Bonnet, France

PE13/13  **Patients infected with multi-class resistant HIV-1 and with viral suppression treated with no more than one active drug: comparison of historical resistance reports and drug resistance in proviral DNA**
Christian Hoffmann, Germany

PE13/14  **Non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance in people living with HIV-1 (PLWH) subtype non-B from the Swiss HIV Cohort Study (SHCS)**
Martina L. Reichmuth, Switzerland

PE13/15  **HIV-1 from antiretroviral-naïve and experienced patients lack capsid substitutions associated with GS-6207 in vitro resistance**
Anne-Geneviève Marcelin, France

PE13/16  **Long-term efficacy, safety and durability of ibalizumab in expanded access study**
Graeme Moyle, United Kingdom
Clinical impact of minority mutations in patients failing an integrase inhibitor-based regimen: what do clinicians do?
Smitha Gudipati, United States

Identification of HIV-1 transmission clusters in Croatia, 2014 - 2017: evidence for the forward spread of HIV-1 resistant variants
Josip Begovac, Croatia

High levels of resistance among HIV-1 treatment naive patients in Greece, a nationwide study: evidence for country and regional level transmission networks
Dimitris Chatzidimitriou, Greece

A phase 3b, open-label, pilot study to evaluate switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) in virologically-suppressed HIV-1 infected adult subjects harboring NRTI resistance mutations M184V/I +/- TAMs (GS-US-292-1824): week 24 results
Ignacio Pérez-Valero, Spain

Sustained viral suppression among participants with pre-existing M184V/I who switched to bictegravir/emtricitabine/tenofovir alafenamide
Kristen Andreatta, United States

Absence of naturally existing resistance against the HIV-1 capsid inhibitor GS-6207 in HIV-1 primary isolates
Christian Callebaut, United States

Impacts assessment of home based care program over adherence to ART among adolescence living with HIV and AIDS in Blantyre Malawi
Lesily Samson Kapile, Malawi

Correlation of results analysis drug resistance of HIV-1 among patients with virological failure by next-generation sequencing and traditional population sequencing
Alina Kirichenko, Russian Federation

Analysis of the latent reservoir of a patient infected with HIV under PrEP by single full-length HIV-1 amplification
Maximilian Damagnez, Germany

Drug resistance profile according to HIV-1 viral load after long-term exposure to antiretroviral treatment in the absence of routine virological monitoring: results from a programmatic cohort in sub-Saharan Africa
Giovanni Villa, United Kingdom

In vitro analysis of replicative capacity and phenotypic susceptibility of integrase mutant HIV-2 viruses
Quentin Le Hingrat, France

Treatment simplification with two-drug regimens: impact of transmitted drug resistance mutations in residents of South-East Austria
Evelyn Stelzl, Austria

Baseline resistance to Doravirine depends on the algorithm used for interpretation
Carlos Guerrero Beltrán, Spain

Baseline resistance to EACS first line recommended antiretroviral regimens in newly diagnosed patients in Spain
Federico García, Spain
Scientific Programme

PE13/31  A retrospective evaluation of a national home infusion provider’s approach to medication adherence of parenteral ibalizumab-uiyk in the alternate-site and homecare setting
Kathryn Andrusko-Furphy, United States

PE13/32  Prevalence of HIV-1 drug resistance among patients with antiretroviral therapy failure in Moscow region, Russia
Natalya Lebedeva, Russian Federation

PE13/33  HIV-1 drug resistance surveillance among parturient women on anti-retroviral therapy in the Eastern Cape, South Africa: implications for elimination of mother-to-child transmission
Oladele Vincent Adeniyi, South Africa

PE13/34  Antiretroviral Resistance patterns in HIV-1 infected patients failing to second-line in Bamako, Mali
Almoustapha Issiaka Maiga, Mali

ePosters
12:45 - 20:00
Exhibition hall

HIV-associated and non HIV-associated tumours

PE14/1  Prevalence of anal dysplasia among persons living with human immunodeficiency virus (HIV)
Adelaine Lopez, Philippines

PE14/2  HIV infection is associated with reduced survival among hepatocellular carcinoma cases from an urban referral hospital: Kampala, Uganda
Sara Nsibirwa, Uganda

PE14/3  High prevalence of anal and cervical dysplasia in a cohort of HIV-infected women, but low prevalence of concomitant lesions
Ana Gomez, Ecuador

PE14/4  Malignant and benign skin lesions in HIV-1 infected people
Alessandra Latini, Italy

PE14/5  Results of HPV-testing for anal screening in HIV-infected women
Anna Popova, Russian Federation

PE14/6  COHORT SDT (Granada): decrease of the incidence of HSIL+ in the anal mucosa of HIV+ patients MSM after the performance of a screening, diagnostic and therapeutic program (2010-2018)
Carmen Hidalgo-Tenorio, Spain

PE14/7  Prospective longitudinal study on immunogenicity and safety of vaccination against human papillomavirus (HPV) with the 9valent vaccine in HIV-positive women, the Papillon study: preliminary results on tolerance and safety
 Déborah Konopnicki, Belgium

PE14/8  Cancer trends and outcomes in a cohort of people living with HIV
Andrea De Vito, Italy

PE14/9  Rate of HCC occurrence and associated risk factors in a multicentric cohort of HIV/HCV co-infected patients treated with DAAs
Alice Toschi, Italy
Human genomics

**PE15/1** Genetic characterization of the near full-length genome of an HIV-1 A1/C/D/K/B unique recombinant form from the Eastern Cape, South Africa: a case report  
Oladele Vincent Adeniyi, South Africa

**PE15/2** Impact of KIR and their ligands (HLA allele) on susceptibility to selected viral opportunistic conditions and HIV plasma viral load in HIV+ patients  
Magdalena Leszczyszyn-Pynka, Poland

**PE15/3** The identification and causal analysis of aberrant CD4 counts in an HIV cohort in Southern Alberta, Canada  
Raynell Lang, Canada

**PE15/4** Placental gene expression profiles and pathways in HIV-1 positive Cameroonian women under ART  
Forgu Esemu Livo, Cameroon

**PE15/5** Functional clustering and association of HLA class I alleles to viral load in HIV-positive and ART-naïve participants from the INSIGHT START study  
Adrian Gabriel Zucco, Denmark

**PE15/6** miRNA expression profiling in subcutaneous adipose tissue of monozygotic twins discordant for HIV infection: validation of differentially expressed miRNA and bioinformatic analysis  
Nicola Squillace, Italy

**PE15/7** Factors influencing late presentation into care of HIV disease  
Bogusz Aksak-Wąs, Poland

Immunology

**PE16/1** Immunological and metabolic effects of dasatinib treatment in IL7-stimulated CD4+ T-cells subpopulations  
Humberto Erick De La Torre Tarazona, Spain

**PE16/2** New T- and B-lymphocytes production and T-cell receptor diversity in young adults perinatally infected by HIV  
Martina Properzi, Italy

**PE16/3** In Vivo modelling of mechanisms of HIV-1-related monocyte dysfunction  
Theodoros Kelesidis, United States

**PE16/4** Lectin-like oxidized low-density lipoprotein (LOX-1) is elevated in proinflammatory monocytes in chronic treated HIV  
Theodoros Kelesidis, United States

**PE16/5** In vivo dissection of the impact of HIV-1 versus antivirals on immune activation in chronic treated HIV  
Theodoros Kelesidis, United States
**Scientific Programme**

**PE16/6**  
**Differential impact of HIV-1 versus antivirals on systemic inflammation in chronic treated HIV**  
Theodoros Kelesidis, United States

**PE16/7**  
**Correlation between blood telomere length and CD4+ CD8+ T-cell subsets in HIV-1-positive individuals with long-term virological suppression on antiretroviral therapy**  
Javier Rodríguez-Centeno, Spain

**PE16/9**  
**Phenotypical recovery of the T-cell pool following switch to dual and triple INSTI-based cART**  
Camilla Tincati, Italy

**PE16/11**  
**Expression of PD-1 in a population of double-negative T cells (CD3+CD4-CD8-) in HIV-infected patients - the preliminary study results**  
Weronika Rymer, Poland

**PE16/12**  
**Targeting inflammation in chronic treated HIV with oral ApoA-I mimetics**  
Theodoros Kelesidis, United States

**PE16/13**  
**Poor recovery of T-cell receptor repertoire despite long-term antiretroviral therapy**  
James Brown, United Kingdom

---

**ePosters**  
12:45 - 20:00  
Exhibition hall

**Morbidity/mortality in the era of cART**

**PE20/1**  
**The association of rare HLA alleles with clinical disease progression in HIV-positive cohorts with varied treatment strategies**  
Christina Ekenberg, Denmark

**PE20/2**  
**Neutrophil-to-lymphocyte ratio compared to CD4+:CD8+ T-cell ratio as a predictor of non-AIDS events in treated people living with HIV**  
Nick Power, Ireland

**PE20/3**  
**Factors associated with virologic failure in women with HIV: Condesa specialized clinics, Mexico City**  
Teresita De Jesús Cabrera López, Mexico

**PE20/4**  
**Causes of death among a cohort of HIV-infected adults in rural Tanzania**  
Fiona Vanobbergen, Switzerland

**PE20/5**  
**Predictors of early mortality among adult HIV-infected patients on antiretroviral therapy in a Kenyan pastoralist community: a retrospective cohort study**  
Paul Yonga, Kenya

**PE20/6**  
**Trends in underlying causes of death in HIV-infected patients from 2016 to 2018 in Ukraine: a cohort study**  
Tetiana Kryuchenko, Ukraine

**PE20/7**  
**Dynamic of CD4+/CD8+ ratio in late presenters: impact on clinical outcomes**  
Marta Rava, Spain

**PE20/8**  
**Retrospective investigation into the causes of death in HIV-infected patients from Bonn in the era of combined Anti-Retroviral Therapy**  
Lukas Knieps, Germany
Reduced utility of early procalcitonin in HIV febrile patients admitted to the emergency department
Chiara Picarelli, Italy

Patients with HIV and HCV in intensive care treatment: admission criteria and trends in the intensive care unit (ICU) at the University Hospital of Bonn 2014-2019
Stefan Schlake, Germany

Burden of disease in PLWH harboring a 4-class drug resistant virus: data from PRESTIGIO Registry
Maria Rita Parisi, Italy

Changing pattern of hospital admissions due to medical conditions in HIV-infected subjects in a European public health care system with free access to antiretroviral treatment
Joan Raga Almudéver, Spain

Association of non-adherence to antiretroviral therapy with cardiovascular outcomes in virologically suppressed persons living with HIV: the Swiss HIV Cohort Study
Tracy R Glass, Switzerland

Differences in social and mental well-being of long-term survivors among people who inject drugs and other participants in the Swiss HIV Cohort Study: 1980 - 201
Katharina Kusejko, Switzerland

Low pre-ART CD4 count is associated with increased risk of clinical progression or death even after reaching 500 CD4 cells/µL on ART
Nikos Pantazis, Greece

A comparative analysis on blood pressure in HIV-infected individuals versus uninfected controls residing in Sub-Saharan Africa: a narrative review
Edith Phalane, South Africa

Causes of death in AIDS/HIV-infected patients at the hospital of infectious diseases in St. Petersburg, Russia
Olga Sokolova, Russian Federation

Dynamics and structure of mortality of HIV-positive people in Ukraine
Natalia Bugaienko, Ukraine

Assessment of non alcoholic fatty liver disease in a cohort of HIV mono-infected patients
Paola Columpsi, United Kingdom

Non-alcoholic fatty liver disease (NAFLD) and related metabolic disorders among HIV-infected patients in the country of Georgia
Lali Sharvadze, Georgia

Non-alcoholic fatty liver disease is a significant predictor of cardiovascular risk in HIV-infected patients
Adriana Cervo, Italy
Scientific Programme

PE22/4  Non alcoholic fatty liver disease diagnosed by non-invasive markers in HIV-infected patients
Carmen Busca, Spain

PE22/5  Global prevalence of liver impairment in HIV population in direct antiviral agents (DAA) era: the role of fatty liver disease
Matilde Sánchez-Conde, Spain

ePosters
12:45 - 20:00
Exhibition hall

Novel consultations, remote care - telemedicine, mobile applications

PE23/1  Harnessing mobile technology for health worker capacity building to improve quality of care in resource-constrained settings
Walter Joseph Arinaitwe, Uganda

PE23/2  Feasibility, uptake and acceptability of the EmERGE mHealth app in individuals living with stable HIV in five European countries
Jenny Whetham, United Kingdom

PE23/3  Attracting people who use drugs to HIV prevention and care programs via darknet and messengers: evidence from St. Petersburg, Russia
Aleksey Lakhov, Russian Federation

PE23/4  People living with HIV (PLHIV) and their doctors: adopters and sceptics, and those opened to e-health
Christine Jacomet, France

PE23/5  Fitness tracking wearable devices and a dedicated smart phone app (MySAwH App) to predict quality of life in PLWH: a multi-centre prospective study
Giovanni Guaraldo, Italy

PE23/6  The efficiency of introducing the EmERGE Pathway of care for stable Croatian PLHIV
Eduard J. Beck, United Kingdom

PE23/7  ‘The 4th 90’: a preliminary assessment of change in quality of life over 1 year of the EmERGE study: PROQOL-HIV and EQ-5D-5L, a descriptive analysis
Christopher Jones, United Kingdom

PE23/8  Measuring empowerment in EmERGE mHealth platform users: a descriptive analysis of interim data
Stephen Bremner, United Kingdom

ePosters
12:45 - 20:00
Exhibition hall

Other coinfections/Sexually transmitted infections

PE24/2  High rates of ocular and neurosyphilis in a large German, city-based university hospital: lessons learned on ocular syphilis
Laura Franziska Wagner, Germany
**Scientific Programme**

PE24/3  Decreasing rate of HIV and HBV co-infection in nationwide Korean HIV/AIDS cohort and its meaning  
Yoonjung Kim, Korea, Republic of

PE24/5  Prevalence of syphilitic hepatitis among HIV-infected patients in Istanbul, Turkey, a region with increasing incidence of syphilis and HIV infection  
Ozlem Altuntas Aydin, Turkey

PE24/6  Seroconversion rate after yellow fever vaccine in HIV- positive patients  
Charlotte Martin, Belgium

PE24/7  Low seroprevalence of syphilis infection among key populations in Togo in 2017: a national cross-sectional survey  
Fifonsi Gbeasor, Togo

PE24/8  Socio demographics, sexual behavior and clinical manifestations of HIV+ and HIV- patients diagnosed with syphilis, Brussels 2017-2019  
Agnès Libois, Belgium

PE24/9  Risk factors and prevalence of syphilis, gonorrhea and chlamydia infections in the Swiss HIV cohort study  
Catrina Mugglin, Switzerland

PE24/10  Predictors of serofast state after treatment for syphilis in HIV-infected patients  
Gregor Paul, Germany

PE24/11  A proactive approach to assess rising STIs among different at-risk groups of MSM in the early era of PrEP: a real-world clinical care setting  
Christina Katerina Psomas, France

PE24/12  Profiles of multidrug resistant gonorrhea in HIV-infected patients attending an urban hospital in Uganda  
Christine Katusiime, Uganda

PE24/13  Sexually transmitted diseases clinic in a Portuguese Infectious Diseases unit  
Joana Fragoso, Portugal

PE24/14  Quantification of DNA human papillomavirus 16 and 18 in anal cells improves the prediction of high grade anal intraepithelial neoplasia in HIV patients  
Marcos Diez, Spain

PE24/15  Primary prophylaxis against Pneumocystis jirovecii Pneumonia may be effective in preventing severe bacterial pneumonia in HIV-positive patients: findings from a large Italian center  
Alex Dusina, Italy

PE24/16  HHV-8 salivary shedding in individuals with different HIV status and sexual behaviour  
Elvira Domonova, Russian Federation

PE24/17  Insights into syphilis reinfection in HIV patients: predictors and role of serofast condition  
Chiara Picarelli, Italy

PE24/18  Infective endocarditis, a current health problem in Romanian injecting drug users  
Irina Cristina Ianache, Romania

PE24/19  Preventable risk factors and predictors of hepatic and non-hepatic co-morbidities among PLHIV  
Oluwakemi Odukoya, Nigeria
**Scientific Programme**

**PE24/20**  
Incidences of asymptomatic HAV infection among MSM living with HIV in South-Western Poland  
Aleksandra Szymczak, Poland

**PE24/21**  
Behavioural patterns to identify key populations for syphilis prevention  
Sara Andresen, Switzerland

**PE24/22**  
Evaluation of a systematic sexually transmitted infections screening pilot programme in HIV-positive men who have sex with men (MSM)  
Paula Prieto, Spain

**PE24/23**  
Chemsex in Barcelona: a descriptive approach about men who have sex with men (MSM) who use recreational drugs in a sexual context  
Lorena De la Mora, Spain

**PE24/24**  
Analysis of serum metabolite changes in early syphilis patients with or without serologic response after treatment  
Chia-Jui Yang, Taiwan, Republic of China

**PE24/25**  
Stable transmission of amoebiasis among newly diagnosed HIV-positive patients in Taiwan, 2009-2018  
Sung-Hsi Huang, Taiwan, Republic of China

**PE24/26**  
Mycoplasma genitalium resistance against macrolide antibiotics in the Berlin MSM cohort tested with the Allplex MG & AzIR Assay (SeeGene)  
Martin Obermeier, Germany

**PE24/27**  
Predictors of ureaplasma urealyticum urinary colonization in HIV+ pregnant women: a pilot study  
Iacopo Franconi, Italy

**PE24/28**  
No indication of decreased syphilis susceptibility with repeated syphilis episodes in HIV-infected men who have sex with men: a multicentre prospective cohort study on risk factors and the potential role of syphilis immunity  
Jan Roth, Switzerland

**PE24/29**  
The prevalence of high-risk anal HPV in HIV-positive MSM in Lebanon  
Nesrine Rizk, Lebanon

---

**ePosters**
12:45 - 20:00  
Exhibition hall

**Paediatric, adolescent**

**PE25/1**  
Effect of cluster of differentiation (CD4) on viral respiratory infection in children, between 0-5 years of age. A study conducted in Kwazulu-Natal, South Africa  
Temitayo Famoroti, South Africa

**PE25/2**  
Adolescent HIV and asymptomatic malaria parasitemia (AMP) co-infection  
David Segun Adeniyi, Nigeria

**PE25/3**  
Clinical features of viral diarrhea in the children of HIV  
Marufjon Salokhiddinov, Uzbekistan
High rate of rubella seronegativity in perinatally-infected HIV women of childbearing age: a case-control study
Nicolas Dauby, Belgium

Health outcomes in adolescents and young adults living with HIV before and after transition to adult care in Barcelona
Josep Ferrer Arbaizar, Spain

Correction of lipid abnormality by integrase inhibitor among children taking ART
Anna Samarina, Russian Federation

Increasing contribution of sexually-transmitted HIV diagnoses in adolescents in Spain
Enrique Bernal, Spain

Factors associated to late presentation of HIV newly diagnosed adolescents in Spain
Enrique Bernal, Spain

Comparison of antiretroviral treatment initiation in HIV newly diagnosed adolescents in Spain
Melchor Riera Jaume, Spain

Oral self-testing for adolescents and young adults absent or declining to test during home-based HIV testing - a mixed-method study embedded in a cluster-randomized trial in Lesotho (ADORE study)
Alain Amstutz, Switzerland

Preterm births in women living with HIV in Switzerland: a 13-year evaluation
Christian R Kahlert, Switzerland

Poor clinical outcomes in HIV-infected children who start antiretroviral therapy at an older age
Kevin P. McKenzie, United States

Prevalence and predictors of unintended pregnancies among HIV positive young adults (14-24 years) attending an urban HIV clinic in Uganda
Mackline Hope, Uganda

Microbiota composition in a cohort of underweight HIV-positive children aged 24-72 months in Cape Town, South Africa
Margaret Van Niekerk, South Africa

Influence of maternal parameters on birth outcome in HIV-exposed newborns - 11 year observation
Karolina Nowicka, Poland

Colonic microbiota exhibits disparate associations with HIV-infection and sexual practices
Eveline Verheij, Netherlands

Zonulin indicates loss of intestinal integrity and microbial translocation in HIV+ patients
Max Augustin, Germany
PE26/4  **Distinct pro-inflammatory and cardio-protective effects of antiretroviral drugs in vascular endothelial cells**
Akif A. Khawaja, United Kingdom

PE26/5  **Bacterial translocation kinetics in HIV-1 infection: from acute to chronic stages**
Paula Aranguren-Rivas, Spain

PE26/6  **Mitochondrial antioxidants attenuate In vivo liver fibrosis in chronic treated HIV**
Theodoros Kelesidis, United States

PE26/7  **Mitochondrial antioxidants attenuate In vivo mitochondrial dysfunction and exhaustion in T cells in chronic treated HIV**
Theodoros Kelesidis, United States

PE26/8  **Inhibition of caspase 1 reduces viral load, CD4 T cell depletion and immune activation in HIV-1 infected humanized mice**
Philipp Adams, Luxembourg

PE26/9  **Effect of early initiation of ART on alterations in natural killer cells in HIV infected pediatric patients**
Romsha Kumar, India

PE26/10  **HIV-DNA levels, HLA-B*27 and HLA-DRB1*13 among LTNPs, ECs and HIV controllers**
Arianna Gabrieli, Italy

PE26/11  **Macromolecule uptake across intestinal epithelia in HIV infection**
Carolin Grünhagen, Germany

PE26/12  **Immune cell activation as a risk factor for hypertension in people living with HIV in Sub-Saharan Africa using the recent American Heart Association and American College of Cardiology Guidelines**
Sepiso Masenga, Zambia

ePosters
12:45 - 20:00  
Exhibition hall

**Pharmacology, pharmacogenomics and drug interactions**

PE27/1  **Efficacy and safety of artemether-lumefantrine as treatment for Plasmodium falciparum uncomplicated malaria in adult patients on efavirenz based antiretroviral therapy in Zambia: an open label non-randomized interventional trial**
Mike Chaponda, Zambia

PE27/2  **Ritonavir-boosted darunavir plus two nucleoside reverse transcriptase inhibitors versus other regimens for initial antiretroviral therapy for people with HIV infection: a systematic review**
Tatevik Balayan, Armenia

PE27/3  **Towards individualization of antiretroviral therapy - more cost-effective than dose intensification in patients**
Bhavik Dalal, India

PE27/4  **The valproic acid - dolutegravir drug-drug interaction is based on displacement of protein binding and unlikely to be clinically relevant**
Henrieke Prins, Netherlands
**Scientific Programme**

**PE27/5**  
**BESIDE - clinical relevance and implications for management of antiretroviral therapy due to recreational drug use in PLWH in Germany**  
Karen Martin, Germany

**PE27/6**  
**Drug-drug interactions between antiretrovirals and carbamazepine or oxcarbazepine: a real-life investigation**  
Cristina Gervasoni, Italy

**PE27/7**  
**Drug-drug interactions between dolutegravir (DTG) and immunosuppressant drugs (IS) in HIV-infected patients with solid organ transplantation (SOT): a single-arm clinical trial (DTGSOT)**  
Christian Manzardo, Spain

**PE27/8**  
**Abacavir hypersensitivity reaction (HSR), associated to baseline false negative HLAB5701 screening, in antiretroviral treatment naive HIV-1 patient**  
Salvatore Martini, Italy

**PE27/9**  
**Central nervous system penetration of antiretroviral drugs in HIV-positive patients with neurocognitive impairment, assessed from paired plasma-CSF concentrations**  
Perrine Courlet, Switzerland

---

**ePosters**

12:45 - 20:00  
**Exhibition hall**

**PrEP**

**PE28/1**  
**Establishment of the service system of HIV pre-exposure prophylaxis/post exposure prophylaxis (PrEP/PEP) in a certain area of Southern Taiwan**  
Kuei Ying Wang, Taiwan, Republic of China

**PE28/2**  
**Systematic review of post-migration HIV acquisition within Europe: the case for PrEP interventions for migrants**  
Simran Mann, United Kingdom

**PE28/3**  
**Self-reported STI history and associated factors among German PrEP users**  
Uwe Koppe, Germany

**PE28/4**  
**PrEP implementation among MSM in Ukraine: results of pilot project in Kyiv**  
Roman Marchenko, Ukraine

**PE28/5**  
**Emergency post-exposure prophylaxis (PEP) seeking behaviors among men who have sex with men (MSM) with recent HIV risk exposure in Thailand**  
Tarandeep Anand, Thailand

**PE28/6**  
**The back side: Lymphogranuloma venereum in PrEP-users and PLWH**  
Sven Schellberg, Germany

**PE28/7**  
**Awareness and interest in pre-exposure prophylaxis (PrEP) among MSM population in Serbia**  
Vanja Subotic, Serbia

**PE28/8**  
**PrEP reimbursement and access in Europe: 2019 update**  
Krzysztof Tronczyński, Poland
PE28/9  Users’ perspective of an ideal service model for delivering pre-exposure prophylaxis (PrEP) to men who have sex with men
Shui Shan Lee, Hong Kong

PE28/10  Assessment of the trough concentrations of tenofovir in HIV-negative subjects on pre-exposure prophylaxis: a single center, real-life experience
Dario Cattaneo, Italy

PE28/11  No new HIV infections, but high incidence of syphilis among Pre-exposure Prophylaxis (PrEP) users in Georgia
Ekaterine Karkashadze, Georgia

PE28/12  Feasibility and acceptability of an oral pre-exposure prophylaxis (PrEP) program against HIV targeting female sex workers in Belgium
Florence Deneumoustier, Belgium

PE28/13  First results after 52 weeks of informal PrEP use in a cohort of MSM in Southern Spain
Alejandro Berto Moran, Spain

PE28/14  Clinical outcomes of pre-exposure prophylaxis from clinical center in Warsaw, Poland
Iwona Cielnia, Poland

PE28/15  Where are we with PrEP use in Central and Eastern Europe? - data from the ECEE Network Group
Josip Begovac, Croatia

PE28/16  Sexual risk and HIV preventative behaviours among men who have sex in men in London in the era of HIV pre-exposure prophylaxis, 2019
Fiona Burns, United Kingdom

PE28/17  Chemsex and mood disorders under HIV pre-exposure prophylaxis
Helene Peyriere, France

PE28/18  Pre-exposure prophylaxis one year after implementation in Portugal - the reality of a central hospital
Diogo Guerra, Portugal

PE28/19  DISCOVER in Europe: a sub-analysis of the phase 3 randomized, controlled trial of daily emtricitabine/tenofovir alafenamide (F/TAF) or emtricitabine/tenofovir disoproxil fumarate (F/TDF) for HIV pre-exposure prophylaxis (PrEP)
Frank Post, United States

PE28/20  The Good and Bad of PrEP: a 14 month follow up on awareness, adherence, efficacy and sexually transmitted diseases at Hospital de Curry Cabral
Marta Leal dos Santos, Portugal

PE28/21  PrEP for life: new challenges and barriers in PrEP uptake among men who have sex with men (MSM) and transgender people (TG) in Kyiv, Ukraine
Dzmitry Filippau, Ukraine

PE28/22  Analysis of the need for pre-exposure prophylaxis of HIV among people that have high risk to be infected
Vitaliy Andres, Ukraine

PE28/23  Lesson learnt from a combined HIV prevention using HIV self-testing and oral pre-exposure prophylaxis (PrEP) demonstration project in the United Republic of Tanzania
Neema Makyao, Tanzania, United Republic of
### Prevalence, incidence and dynamics of HIV epidemics

<table>
<thead>
<tr>
<th>PE29/1</th>
<th>Monitoring rates and accessibility of HIV and STI’s testing, HAV and HBV vaccination among men who have sex with men in Slovenia</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Miran Solinc, Slovenia</td>
</tr>
<tr>
<td>PE29/2</td>
<td>Data triangulation to re-shape interventions to improve the HIV response: comparing data from estimates, case reporting, and sentinel surveillance in Ukraine</td>
</tr>
<tr>
<td></td>
<td>Tetiana Salyuk, Ukraine</td>
</tr>
<tr>
<td>PE29/3</td>
<td>The impact of frequent cannabis use on injection drug use patterns among people who use drugs in a Canadian setting</td>
</tr>
<tr>
<td></td>
<td>Hudson Reddon, Canada</td>
</tr>
<tr>
<td>PE29/4</td>
<td>Predicting early loss to follow-up on ART: a retrospective review of clients' retention on ART in North-western Nigeria</td>
</tr>
<tr>
<td></td>
<td>Johnson Okolie, Nigeria</td>
</tr>
<tr>
<td>PE29/5</td>
<td>The increasing number of late HIV diagnosis among men having sex with men and transgender women in a key population-led HIV testing and treatment facility and its societal implication in the Philippines</td>
</tr>
<tr>
<td></td>
<td>Patrick Eustaquio, Philippines</td>
</tr>
<tr>
<td>PE29/6</td>
<td>HIV transmission network in a cohort of subjects with primary infection in a single clinical center in Rome</td>
</tr>
<tr>
<td></td>
<td>Lavinia Fabeni, Italy</td>
</tr>
<tr>
<td>PE29/7</td>
<td>Evaluation of a multiassay approach for determination recent HIV infection in the Russian Federation</td>
</tr>
<tr>
<td></td>
<td>Anastasia Murzakova, Russian Federation</td>
</tr>
<tr>
<td>PE29/8</td>
<td>Ongoing spread of HIV subtype A in Tel Aviv, Israel</td>
</tr>
<tr>
<td></td>
<td>Dan Turner, Israel</td>
</tr>
<tr>
<td>PE29/9</td>
<td>Simple clinical and laboratory based score may identify HIV infection recency and subsidize HIV surveillance in low and middle-income countries (LMIC), Santo André/Brazil experience</td>
</tr>
<tr>
<td></td>
<td>Elaine Monteiro Matsuda, Brazil</td>
</tr>
<tr>
<td>PE29/10</td>
<td>Clinical, epidemiological &amp; virological features of primary HIV-1 infection in an HIV reference center in Brussels: a ten years' review</td>
</tr>
<tr>
<td></td>
<td>Arthur Poncelet, Belgium</td>
</tr>
<tr>
<td>PE29/11</td>
<td>Current trends in HIV genetic diversity in Russia: increase of the unique recombinants prevalence</td>
</tr>
<tr>
<td></td>
<td>Anastasiia Antonova, Russian Federation</td>
</tr>
<tr>
<td>PE29/12</td>
<td>Analysis of risk factors in HIV/AIDS patients</td>
</tr>
<tr>
<td></td>
<td>Esra Zerdali, Turkey</td>
</tr>
<tr>
<td>PE29/13</td>
<td>Tracing the first HIV-1 epidemics in the Milan area</td>
</tr>
<tr>
<td></td>
<td>Alessia Lai, Italy</td>
</tr>
<tr>
<td>PE29/14</td>
<td>Analysis of the local HIV-1 epidemic in Vologda region, Russia: predominance of CRF03_AB and rapid expansion of URFs</td>
</tr>
<tr>
<td></td>
<td>Ekaterina Ozhmegova, Russian Federation</td>
</tr>
</tbody>
</table>
PE29/15 Identification of first near full length recombinant genome of HIV-1 in Korea  
Mee-Kyung Kee, Korea, Republic of

PE29/16 Characteristics of HIV infection among children in Georgia, 1989-2018  
Natela Chokoshvili, Georgia

PE29/17 HIV infection in older patients  
Barbara Belfiori, Italy

PE29/18 Seroincidence of the human herpesvirus 8 (HHV 8) infection among HIV-positive patients in Taiwan, 2016-2019  
Yi-Ching Su, Taiwan, Republic of China

PE29/19 Risk factors for late presentation for HIV care in 2019 in Ukraine  
Maryna Sukach, Ukraine

PE29/20 Incidence of hepatitis C virus infection among people living with HIV( PLHIV ): an Egyptian Cohort Study  
Rahma Mohamed, Egypt

PE29/21 High HIV prevalence following screening of subjects with HIV indicator conditions in a hospital setting  
Camilla Tincati, Italy

PE29/22 First decrease in new HIV diagnoses in 2018 among men who have sex with men (MSM), in the East PACA (Provence Alpes Côte-d’Azur) area in France  
Philippe Bouvet de la Maisonneuve, France

PE29/23 The collision of public health interventions on HIV-1 spread in Albania by molecular epidemiology  
Shkurti Enkelejda, Albania

PE29/24 Two decades of HIV infection late diagnosis: the experience of a Portuguese Hospital  
Sofia Jordão, Portugal

PE29/25 Characterization of HIV patients followed in a specialist consultation at a tertiary and university centre  
Fábio Videira Santos, Portugal

PE29/26 Trends in epidemiology and clinical picture of late presentation among patients of the Hospital for Infectious Diseases in Warsaw  
Joanna Pula, Poland

PE29/27 An evolutionary insight into a growing HIV subtype A epidemic in Serbia  
Marina Siljic, Serbia

PE29/28 Change of prevalence, diseases distribution and factors associated with the risk of AIDS presentation in Italy over last decade (2009-2018)  
Andrea Antinori, Italy

PE29/29 The effect of gender on late diagnosis of HIV infection in a high incidence European population  
Rita Filipe, Portugal

PE29/30 Two decades surveillance of HIV-1 transmitted drug resistance in Serbia  
Valentina Cirkovic, Serbia
Scientific Programme

PE29/31  3M-BRiHT - Manchester Cohort. Investigation of the feasibility and acceptability of rapid HIV testing in a European Emergency Department setting
Molly M. O’Kane, Ireland

PE29/32  HIV-1 A6 subtype: its challenging identification and Southern Russian molecular epidemiology
Saleta Sierra, Germany

PE29/33  Neurodevelopmental assessments to screen for HIV encephalopathy in newly diagnosed infants not on ART in Mozambique
Jyodi Mohole, United States

ePosters
12:45 - 20:00  Exhibition hall

Prevention of horizontal transmission, cART as prevention

PE30/1  Tolerability and treatment completion of tenofovir alafenamide/emtricitabine/rilpivirine (TAF/FTC/RPV) as HIV postexposure prophylaxis
Marie Chauveau, France

ePosters
12:45 - 20:00  Exhibition hall

Social and behavioural science

PE30/2  Priorities for behavioral interventions in a group of long term PLWHA - the experience of the Baylor Clinical Centre of Excellence in Constanta, Romania
Ana-Maria Schweitzer, Romania

PE30/3  Will HIV-infected patients taking oral ARV switch to long-acting injectable ART when it become available?
Marie-Aude Khuong-Josses, France

PE30/4  Time perspectives as predictors of depression and suicidal ideation amongst adolescents and young adults with HIV: the moderating role of resilience
Oluwapelumi Ashamu, Nigeria

PE30/5  Social support and quality of life of people living with AIDS receiving ART at BPKIHS
Ram Sharan Mehta, Nepal

PE30/7  Knowledge, attitudes, beliefs and HIV-related behaviour in metropolitan France: investigation in a festive place
Fernanda Medina, France

PE30/9  Injectable long acting antiretrovirals for HIV treatment or prevention: the ANRS CLAPT study
Laurence Slama, France

PE30/10  Quality of life in people living with HIV: a regional survey in Flanders
Gert Scheerder, Belgium
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Author(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PE30/11</td>
<td>Innovative strategies to sustain community participation in HIV vaccine trials, experience of Makerere University Walter Reed Project (MUWRP) in Kampala, Uganda</td>
<td>Jauhara Nanyondo, Uganda</td>
</tr>
<tr>
<td>PE30/12</td>
<td>Stigma among healthcare providers towards people living with HIV/AIDS in India</td>
<td>Akanksha Rathi, India</td>
</tr>
<tr>
<td>PE30/13</td>
<td>“I love my life, I don’t want to miss a thing”: motivators and Barriers to ART adherence among women living with HIV/AIDS in Iran</td>
<td>Nooshin Amirisani, Iran, Islamic Republic of</td>
</tr>
<tr>
<td>PE30/14</td>
<td>Medical students as potential sources of information about HIV/AIDS</td>
<td>Mykola Haras, Ukraine</td>
</tr>
<tr>
<td>PE30/15</td>
<td>Gender violence, intimate partner violence and domestic violence among HIV-positive patients in Alicante (Spain). Preliminary results of the VIHOLETA study</td>
<td>Jara Llenas-García, Spain</td>
</tr>
<tr>
<td>PE30/16</td>
<td>Influence of stigma and discrimination on psychosocial health in children affected by AIDS in Nepal: a cross-sectional study</td>
<td>Kalpana Gaulee Pokhrel, Nepal</td>
</tr>
<tr>
<td>PE30/17</td>
<td>The quality of life among people living with HIV in Taiwan in the era of STR</td>
<td>Chung-Ching Shih, Taiwan, Republic of China</td>
</tr>
<tr>
<td>PE30/18</td>
<td>Experiences of and factors influencing physical activity in people living with HIV: a qualitative systematic review</td>
<td>Megan Davies, United Kingdom</td>
</tr>
<tr>
<td>PE30/20</td>
<td>Perception of condom use in the era of pre-exposure prophylaxis (PrEP): a qualitative analysis</td>
<td>Shui Shan Lee, Hong Kong</td>
</tr>
<tr>
<td>PE30/21</td>
<td>Recommendations for enabling timely pregnancy disclosure to clinical staff of women living with HIV</td>
<td>Stefania Mihale, Romania</td>
</tr>
<tr>
<td>PE30/22</td>
<td>Health-related quality of life in a single center cohort of people living with chronic diseases: comparison between HIV and other clinical conditions</td>
<td>Antonella Cingolani, Italy</td>
</tr>
<tr>
<td>PE30/23</td>
<td>Experiences of Dutch obstetric healthcare providers with HIV-positive pregnant women: a qualitative study</td>
<td>Carlijn Damsté, Netherlands</td>
</tr>
<tr>
<td>PE30/24</td>
<td>Evaluation of knowledge, attitudes and practices among HIV positive pregnant women and their partners in four healthcare facilities in Malawi</td>
<td>Isotta Triulzi, Italy</td>
</tr>
<tr>
<td>PE30/25</td>
<td>Towards the 4th 90, measuring multi-dimensional quality of life in people living with HIV in Aquitaine, France: psychometric properties of the French version of the WHOQOL-HIV BREF</td>
<td>Diana Barger, France</td>
</tr>
<tr>
<td>PE30/26</td>
<td>Body size modifies the relationship between internalized HIV stigma and pain in people with HIV in the Southeastern USA</td>
<td>Kaylee Crockett, United States</td>
</tr>
</tbody>
</table>
Scientific Programme

ePosters
12:45 - 20:00
Exhibition hall

Standard of care

PE31/1  Exploring the attitudes of HIV-positive patients on single-tablet antiretroviral regimens towards generic de-simplification
Ciara Levey, Ireland

PE31/2  Comparison of Immunological and virological response to cART between HIV-1/O and HIV-1/M patients followed-up in France: the ANRS ORIVAO and COPANA studies
Guillemette Unal, France

PE31/3  From HIV diagnosis to antiretroviral therapy initiation in Croatia from 2013 to 2018
Nikolina Bogdanić, Croatia

PE31/5  Tetanus seroprotection in HIV-positive subjects living in Belgium: risk factors for seronegativity, evaluation of medical history and a rapid dipstick test
Nicolas Dauby, Belgium

PE31/6  The prevalence of virologic failure and resistance associated mutations in single and multi-tablet HIV treatment regimens
Chien-Yu Cheng, Taiwan, Republic of China

PE31/7  Development and validation of a risk score for predicting non-adherence to antiretroviral therapy
Hernando Knobel, Spain

PE31/8  Measles seroprevalence among HIV infected patients in central part of Poland - vaccination proposal
Ewa Siwak, Poland

PE31/9  Nurse-led annual health review - one year follow up
Marie-Pierre Klein, United Kingdom

PE31/11  Viral hepatitis in HIV-positive patients - testing, prophylaxis and treatment in Central and Eastern Europe
Kerstin Kase, Estonia

PE31/12  Evaluating a national pilot process for reviewing late HIV diagnoses in England and Wales
Ming Jie Lee, United Kingdom

PE31/13  GESIDA quality of care indicators for PLWH: report from two Spanish hospitals 2009-2017
Francisco Fanjul, Spain

PE31/14  Late presentation and barriers to the early HIV diagnosis in Central part of Ukraine
Tetiana Koval, Ukraine

PE31/15  Operational research of barriers and facilitators to harm reduction services for intravenous drug users (including female IDUs)
Tamar Zurashvili, Georgia

PE31/16  A seven-month prospective review of HIV admissions to a regional infectious disease unit in Manchester, UK
Hamzah Zahid Farooq, United Kingdom

PE31/17  Annual health review for people living with HIV - an evaluation
Sarah Edwards, United Kingdom
Scientific Programme

PE31/18  Analysis of adherence to HIV-positive quality of care indicators and their impact of service quality perceptions in patient: a Spanish cross-sectional study
Alejandra Gimeno García, Spain

ePosters
12:45 - 20:00
Exhibition hall

Tuberculosis and opportunistic infections

PE35/1  Nontuberculous mycobacteria infections in Russian HIV patients: clinical features and outcomes
Mikhail Savchenko, Russian Federation

PE35/2  Human immunodeficiency virus and the outcome of treatment for pulmonary tuberculosis: a retrospective study in Tehran, Iran
Mohammad Bagheri, Iran, Islamic Republic of

PE35/3  Rifampicin pharmacokinetics and pharmacogenetics in Ugandan patients with multi-drug resistant tuberculosis
Jackson K. Mukonzo, Uganda

PE35/4  Mycobacteria-induced immune responses by mucosal-associated invariant T (MAIT) cells are impaired in patients with tuberculosis (TB) and HIV-associated TB
Muki Shey, South Africa

PE35/5  Acute onset of cerebral toxoplasmosis in patients with HIV infection
Tatiana Ermak, Russian Federation

PE35/6  Association between immunological status and TB disease development in HIV-infected individuals with LTBI
Ngai Sze Wong, Hong Kong

PE35/7  Amoeba- a swiss army knife for diagnosis and mechanistic understanding of Legionella infection
Breanne M Head, Canada

PE35/8  Causes and outcomes of hospitalizations among HIV positive persons in Georgia´s referral institution, 2012-2017
Nino Rukhadze, Georgia

PE35/9  Population pharmacokinetic analysis of dolutegravir in HIV/TB co-infected people with and without rifampicin
Rajendra Singh, United States

PE35/10  Lung function and health-related quality of life among patients following pulmonary tuberculosis treatment in urban Uganda: a cross-sectional study
Josephine Zawedde, Uganda

PE35/11  Clinical and laboratory characterization of progressive multifocal leukoencephalopathy in HIV-infected patients in the intensive care unit
Anastasia Pokrovskaya, Russian Federation

PE35/13  Cryptococcal and tuberculosis coinfection: case series identified through the implementation of an advanced HIV disease package of care linked to a TB active case finding strategy in rural Mozambique
Alejandro Blanco-Arévalo, Spain
Scientific Programme

PE35/14  Trends in latent tuberculosis screening in a cohort of HIV-infected patients from a low tuberculosis incidence country  
Pedro Palma, Portugal

PE35/15  Drug-induced hepatic injury developed in tuberculosis / HIV co-infection treatment  
Sarah Silva, Brazil

ePosters  
12:45 - 20:00  
Exhibition hall

Vaccines and immune based therapies

PE36/2  Development of engineered nanocarrier for controlled delivery of a protease inhibitor  
Saurabh Bhargava, India

ePosters  
12:45 - 20:00  
Exhibition hall

Viral hepatitis

PE37/1  Acute hepatitis C infection in HIV-infected patients who achieved viral suppression: incidence and risk factors  
Hsin-Yen Ku, Taiwan, Republic of China

PE37/2  HBV infections among HIV infected HAART receiving mothers and their exposed infants in a tertiary hospital in Kenya  
James Kangethe, Kenya

PE37/3  Direct-acting antivirals (DAAs) improve liver stiffness measurements but do not improve the Veterans Aging Cohort Study (VACS) Index in HIV /HCV co-infected Egyptian patients: is improved discrimination needed?  
Ahmed Cordie, Egypt

PE37/4  HCV/HIV coinfection in the DAA era: which patients have not been treated for HCV?  
Fabian Dario Rodriguez-Monaco, Germany

PE37/5  Hepatitis E seroprevalence in HIV-positive patients  
Mustafa Altindis, Turkey

PE37/6  Success of unrestricted DAA therapy is limited by HCV reinfections and loss to follow-up in HIV-positive patients  
David Chromy, Austria

PE37/7  Efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide as maintenance treatment of patients with HIV and Hepatitis B Virus (HBV) coinfection  
Yu-Shan Huang, Taiwan, Republic of China

PE37/8  Effectiveness of hepatitis a vaccination among people living with HIV in Taiwan: is one dose enough?  
Chia-Jui Yang, Taiwan, Republic of China

PE37/9  HIV patients remain at high risk for advanced liver fibrosis after curing HCV infection  
Natalia Bolokadze, Georgia
17th European AIDS Conference
November 6-9, 2019
Basel, Switzerland

Scientific Programme

PE37/10  HIV/HCV coinfection in Spain: trouble will soon be over  
Juan Berenguer, Spain

PE37/11  Care cascade of incident HCV infection among HIV-positive patients in Taiwan  
Miao-Hui Huang, Taiwan, Republic of China

PE37/12  Current characteristics of HIV/HBV coinfected patients in a single HIV reference centre of Madrid  
Luz Martín-Carbonero, Spain

PE37/13  High HCV reinfection rate in MSM living with HIV in Barcelona: the need to focus on high risk population to achieve HCV elimination  
Maria Martínez-Rebollar, Spain

PE37/14  Liver disease in HIV-infected subjects in the post-HCV DAA treatment era  
Carmen Busca, Spain

PE37/15  Seroprevalence of hepatitis E in a Portuguese cohort of human immunodeficiency virus infected patients  
André Silva-Pinto, Portugal

PE37/16  Loss of seroprotection against hepatitis B virus (HBV) was associated with lower CD4 counts among HIV-positive patients who were born in the era of nationwide neonatal HBV vaccination  
Yi-Chia Huang, Taiwan, Republic of China

PE37/17  Improvement of immunity and hepatic fibrosis after HCV treatment with DAA in people living with HIV and HCV  
Montserrat Laguno, Spain

PE37/18  DAA treating Hepatitis C in HIV/HCV coinfected patients in two prisons of Rome: results and problems  
Sara Lardo, Italy

PE37/19  Progress towards eliminating mother-to-child transmission of HIV in the Macha area in Zambia from 2010-2018  
Mutinta Hamahuwa, Zambia

PE37/20  Evaluation of the hepatitis C care cascade in the country of Georgia: monitoring 4 years of progress towards elimination  
Tengiz Tsertssvadze, Georgia

PE37/21  Epidemiology of HIV, HBV and HCV co-infection in Israel  
Karen Olshtain-Pops, Israel

PE37/22  Hepatitis C treatment outcomes of HIV infected people who inject drugs in a real-world cohort  
Dimitris Basoulis, Greece

PE37/23  Treatment of acute HCV infection with direct acting antivirals (DAA) in HIV patients  
Cristina Gómez-Ayerbe, Spain

PE37/24  Hepatic fibrosis progression among HIV patients in Israel  
Karen Olshtain-Pops, Israel

PE37/25  Acute hepatitis B in persons living with HIV in a low hepatitis B prevalence area during the last two decades  
Luz Martín-Carbonero, Spain
Scientific Programme

PE37/26  Virological response to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in HIV-positive patients with lamivudine-resistant hepatitis B virus coinfection
Yu-Shan Huang, Taiwan, Republic of China

PE37/27  Impact of direct-acting antiviral (DAA) agents on T cell counts and liver stiffness in HIV/HCV-coinfected patients: a multicenter prospective observational cohort study
David Dalmau, Spain

PE37/28  Trends of HCV infection among HCV-seronegative, HIV-positive patients in Taiwan between 2011-2018
Li-Hsin Su, Taiwan, Republic of China

PE37/29  The micro-elimination approach to eliminating Hepatitis C: a Fast Track City project
Franco Maggiolo, Italy

PE37/30  Road to HCV elimination in HV/HCV coinfected patients by screening and universal access to DAA: baseline data from the first screening of NoCo (No-Coinfection) study
Antonella d'Arminio Monforte, Italy

PE37/31  HCV cascade of care for HIV/HCV coinfected individuals in Greece and HCV treatment considerations in clinical practice
Mina Psichogiou, Greece

PE37/32  Hepatitis B core-related antigen and anti-hepatitis B core antibody are not associated with liver fibrosis evolution in HIV-HBV co-infected patients during treatment with tenofovir
Romuald Cruchet, France

PE37/33  Antiretroviral therapy: a possible role in lipid changes after HCV eradication by DAAs
Alessandra Vergori, Italy

PE37/34  Treatment of cirrhotic monoinfected and HCV/HIV coinfected patients with direct acting antivirals (DAAs)
Fábio Videira Santos, Portugal

PE37/35  Predictors of vaccine efficacy after hepatitis B vaccination in people with HIV infection
Gerardo Ibarra, Germany

PE37/36  Long term response to mandatory anti-HBV vaccination: risks for disease acquisition and opportunities for re-vaccination within the ICONA cohort
Roberto Rossotti, Italy

PE37/37  The assessment of HBsAg serum concentration during chronic hepatitis B phases’ identification among HIV/HBV coinfected patients before antiviral therapy prescription
Tetiana Melnyk, Ukraine

PE37/38  Predictors of liver fibrosis improvement after HCV eradication in HIV+ patients: data from an Italian cohort
Alessandra Vergori, Italy

PE37/39  Long-term follow-up of people who use drugs (PWUD) following HCV infection therapy: drug use patterns among HIV co-infected versus mono-infected patients
Astou Thiam, Canada

PE37/40  Treatment outcome of HCV single vs multi tablet regimen in mono and HIV co-infected people who use drugs (PWUD): a long-term follow-up analysis
Astou Thiam, Canada
Scientific Programme

ePosters
12:45 - 20:00
Exhibition hall

Virology

PE38/1 Identification of an HIV-1 BC intersubtype recombinant form, which is circulating in Spain
Javier Enrique Cañada García, Spain

PE38/2 Viral reservoir dynamics in very early primary HIV infection (PHI) patients receiving an intensified antiretroviral regimen (ART): a pilot clinical trial
Juan Ambrosioni, Spain

PE38/3 Lamivudine-based two-drug regimens are not associated with an increased risk of detectable rectal HIV-RNA
Alberto Borghetti, Italy

PE38/4 Comparison of HIV-1 viral load and drug resistance mutations between cerebrospinal fluid and plasma in patients with HIV and Cryptococcal meningitis co-infection in Botswana
Namaeto Kelentse, Botswana

PE38/5 HTLV-II antisense protein Aph-2 negatively regulates HIV-1 transcription
Rajkumar Londhe, India

PE38/6 HIV compartmentalization between plasma and CSF and association with neurocognitive disorders
Alessandro Lazzaro, Italy

PE38/7 Determinants of neurocognitive impairments in a Romanian cohort of young adults with chronic HIV infection
Simona Ruta, Romania

PE38/8 Reconstruction of phylogeography for Indian HIV-1 sub-subtype A1
Ajit Patil, India

PE38/9 Broad and potent neutralizing antibody responses in HIV-1 infected Angolan patients: implications for vaccine design and efficacy
Francisco Martin, Portugal

PE38/10 The XbnAb cohort: a HIV-1 cohort of 304 bnAb inducers and matched controls tailored to study determinants of bnAb induction
Irene Abela, Switzerland

PE38/11 Performance of ‘Xpert® HIV-1 Qual assay’ for diagnosis of HIV-1 infection using Dried Blood Spot specimens
Swarali Kurle, India

PE38/12 HIV-1 infections belonging to transmission clusters originating in different countries are frequently detected in Spain among newly diagnosed individuals
Javier Cañada, Spain

Vulnerable groups
Scientific Programme

PE39/1  Boys having sex with boys: CD4 count as parameter to estimate the time of infection among HIV seropositive men having sex with men and its societal implications in the Philippines
Patrick Eustaquio, Philippines

PE39/2  Evaluating factors increasing the vulnerability of adolescent girls and young women to HIV/AIDS infection in selected communities, Akwa Ibom State
Jessie Inyang, Nigeria

PE39/3  Men’s perspectives on HIV self-testing in sub-Saharan Africa: a systematic review and meta-synthesis
Mbuzeleni Hlongwa, South Africa

PE39/4  Molecular-biological methods of diagnostics in the investigation of the case of transmission of HIV-infection
Diana Valutite, Russian Federation

PE39/5  Implementation of demedicalized and decentralized HIV testing project in Brussels: action test, project for vulnerable populations at high HIV risk in Brussels, including Subsaharan African Migrants (SAM)
Tresors Kouadio, Belgium

PE39/6  HIV prevalence, risk-taking behavior and self-testing potential among men who have sex with men and transgender people
Evgeniy Pisemskiy, Russian Federation

PE39/7  Political commitment matters in the elimination of the threat of HIV and HCV and TB among people who use drugs
Gefra Fulane, Portugal

PE39/8  Challenges in health and social care for migrant HIV patients in the Czech Republic
Elena Tulupova, Czech Republic

PE39/9  Integration of hepatitis C cure in housing facility Soleil Evant: health cost implications
Erika Castro, Switzerland

PE39/10  The role of sexual partners of people who inject drugs in better uptake of retention in HIV services
Marine Gogia, Georgia

PE39/11  Male sex workers and ICT: anthropological approach of male sex workers and the different practices online: bareback, PrEP and chemsex
Maxime Maes, Belgium

PE39/12  Portuguese League Against AIDS - mobile screening unit
Maria Eugênia Saraiva, Portugal

PE39/13  Detectable viraemia in the era of successful antiretroviral therapy; engagement with multidisciplinary services
Shimu Khamlichi, United Kingdom

PE39/14  Optimal HIV self-testing, potential strategies to increase HIV diagnosis in Tanzania
Neema Makyao, Tanzania, United Republic of
Scientific Programme

ePosters
12:45 - 20:00
Exhibition hall

Treatment in resource-constrained settings

PE34/2 Optimizing clients linkage into ART using family-centered differentiated approach (FCDA) in Kebbi state, northwestern Nigeria: successes and challenges
Johnson Okolie, Nigeria

PE34/3 A multi-stakeholder evaluation of the early implementation experiences of differentiated anti-retroviral therapy (ART) delivery roll-out across Uganda: a qualitative analysis
Henry Zakumumpa, Uganda

PE34/5 Evaluation of the financial cost of treating people living with human immunodeficiency virus in the United Kingdom versus matched HIV-negative controls in 2004, 2010 and 2017
Scott Francis, United Kingdom

PE34/6 Continuous quality improvement across the viral load testing spectrum at the Infectious Diseases Institute, Uganda
Harriet Tibakabikoba, Uganda

PE34/7 Pediatric HIV viral load suppression: qualitative insights of barriers and facilitators among caregivers of children on ART in high volume sites in Kisumu County, Kenya
Nicollate Okoko, Kenya

PE34/8 Boosting economic affordability of HIV medicines while considering safety and effectiveness within transition from donor funding. Enabling access to TAF regime with better safety profile in Ukraine through advocacy campaign of community organization
Zoia Zamikhovska, Ukraine

Mother-to-child transmission

PE21/1 HIV infection in pregnant women and children in Switzerland: how effective are measures for preventing mother-to-child transmission?
Martin Gebhardt, Switzerland

PE21/2 No evidence for induced glucuronidation of dolutegravir in HIV-infected pregnant women
Vera Bukkems, Netherlands

PE21/3 Comparative analysis of clinic and laboratory parameters and frequency of mother-to-child transmission of HIV among HIV-positive pregnant women with marked immunodeficiency and normal immunological status
Olga Mozaleva, Russian Federation

PE21/4 Analysis of perinatal HIV transmission cases in St. Petersburg
Anna Samarina, Russian Federation

PE21/5 Geopolitical assessment and relevance for acceptance of vaginal delivery in good controlled HIV-infected pregnant women in Japan
Kimikazu Hayashi, Japan

PE21/6 Pregnancy outcomes in HIV-positive women: a retrospective national cohort study from the “Grigorios AIDS Clinic” in Cyprus
Georgios Siakallis, Cyprus
PE21/7  
New-born infants from HIV positive women: five years experience of Infectious Diseases Hospital Iasi  
Alexandra Largu, Romania

PE21/8  
Risk factors for peripartum virological failure in South African pregnant women on anti-retroviral therapy: East London Prospective Cohort Study  
Oladele Vincent Adeniyi, South Africa

Industry sponsored session  
13:15 - 14:45  
Sydney

Industry sponsored session  
(For more details, please visit the <a href="https://eacs-conference2019.com/index.php?article_id=166" target="_blank">conference website</a>)

Pre-conference workshop/course  
14:00 - 17:00  
Samarkand

EATG workshop: STEPS - A community initiative to design the pathway to a long-term remission of HIV infection  
Convener: EATG

Welcome and introductions  
Giulio Maria Corbelli, Italy  
14:00 - 14:15

The role of bNAbs in research for long-term drug-free remission of HIV infection  
Annemarie Wensing, Netherlands  
14:15 - 15:00

RIO: UK study using dual long-acting bNAbs  
Simon Collins, United Kingdom  
15:00 - 15:45

The London patient and the Dusseldorf patient: procedures, hopes and challenges  
Giulia Marchetti, Italy  
15:45 - 16:15

Open discussion about the ethical challenges in HIV "cure" research and treatment interruptions  
16:15 - 16:45

Wrap up and conclusions  
Giulio Maria Corbelli, Italy  
16:45 - 17:00

Industry sponsored session  
15:00 - 16:30  
San Francisco

Industry sponsored session  
(For more details, please visit the <a href="https://eacs-conference2019.com/index.php?article_id=166" target="_blank">conference website</a>)
Scientific Programme

Ceremony
17:15 - 18:45  Event Hall

Conference opening

Session interpreted in Russian

Chairs:
Manuel Battegay, Switzerland
Jürgen Rockstroh, Germany

Opening welcome
Manuel Battegay, Switzerland
Jürgen Rockstroh, Germany

17:15 - 18:15

Address
Lukas Engelberger, Switzerland

17:30 - 18:30

90-90-90 goals in Europe: In action
Anastasia Pharris, Sweden

17:35 - 18:15

HIV care beyond 2019: How to address old and new challenges?
Jens D. Lundgren, Denmark

17:55 - 18:15

Community perspective: Inequalities in care
Alex Schneider, Switzerland

18:15 - 18:30

European AIDS Clinical Society Award for Excellence in HIV Medicine
Nathan Clumeck, Belgium

18:30 - 18:40

Ceremony
18:45 - 20:00  Exhibition hall

Welcome reception
Thursday, 07 November 2019

Industry sponsored session
07:30 - 08:30
San Francisco

Industry sponsored session
(For more details, please visit the <a href="https://eacs-conference2019.com/index.php?article_id=166" target="_blank">conference website</a>)

Workshop/Symposium
07:30 - 08:30
Sydney

**BRAHMS and the STIPnet (European HIV&STI Prevention Network) study meeting**

**Chairs:**
Hendrik Streeck, Germany

**BRAHMS and STIPnet - an update**
Hendrik Streeck, Germany 07:30 - 07:45

**Data analysis within the STIPnet study: possible projects**
Klaus Jansen, Germany 07:45 - 08:00

**PrEP and STIs among MSM in France**
Jean-Michel Molina, France 08:00 - 08:15

**Are we expecting an increase of STI because of PrEP uptake?**
Pep Coll, Spain 08:15 - 08:30

Meet-the-expert/Clinical cases
07:30 - 08:30
Samarkand + Osaka

**Public Health Topics: Supporting PrEP implementation in European settings**

**Chairs:**
Teymur Noori, Sweden
Milosz Parczewski, Poland

Meet-the-expert/Clinical cases
07:30 - 08:30
Shanghai 3

**TB** co-organised with the **European Society of Clinical Microbiology and Infectious Diseases (ESCMID)**

**Chairs:**
Emmanuelle Cambau, France
José M. Miro, Spain
Scientific Programme

Meet-the-expert/Clinical cases  
07:30 - 08:30  

How to get your biomedical paper published  
Organised by Karger  

Chairs:  
Paul Lavander, Switzerland

Meet-the-expert/Clinical cases  
07:30 - 08:30  

Prevention, screening, and treatment: Are we ignoring anal cancer in PLWH?  

Chairs:  
Stefan Esser, Germany  
Boris Revollo, Spain

Meet-the-expert/Clinical cases  
07:30 - 08:30  

Drug resistance in HIV and how to treat?  

Chairs:  
Linos Vandekerckhove, Belgium  
Annemarie Wensing, Netherlands

CC3/1  
Bictegravir virology failure with emergence of a previously unreported mutation in the integrase gene  
Francois Raffi, France

Plenary lecture  
08:30 - 09:00  

PL1, The latent HIV-1 reservoir  
Session interpreted in Russian  

Chairs:  
Marylyn Addo, Germany

The latent HIV-1 reservoir  
Matthieu Perreau, Switzerland

European Hector Research Award in HIV 2019 ceremony - Best basic science, translational paper  
Georg Behrens, Germany
Scientific Programme

Plenary lecture
09:00 - 09:30

**PL2, New drugs - Who would need them?**

Session interpreted in Russian

**Chairs:**
Esteban Martínez, Spain

*New drugs - Who would need them?*
Chloe Orkin, United Kingdom

---

**ePosters**

09:00 - 18:00

**Antiretroviral therapy preclinical**

**PE4/3**  *In vivo dissection of the effects of HIV and antivirals on mitochondrial function in chronic treated HIV*
Theodoros Kelesidis, United States

**PE4/4**  *The main barriers to “Test and Start” in Central Asia from the service providers’ and patients’ point of view*
Yelena Kudussova, Kazakhstan

**PE4/5**  *Preclinical aspects of an anti-HIV molecule targeting vimentin*
Celia Berta Fernandez-Ortega, Cuba

**PE4/6**  *PK/PD modelling of bnAbs for HIV treatments identifying knowledge gaps*
Mark Baker, Switzerland

**PE4/7**  *A new inhibitor of HIV-1 infection exploiting host intracellular signaling to alter viral RNA processing*
Raymond Waiman Wong, Canada

---

**ePosters**

09:00 - 18:00

**HIV drug resistance**

**PE13/1**  *Daranavir resistance among patients exposed to protease inhibitors failing ARV therapy*
Luis Fernando Brigido, Brazil

**PE13/2**  *Prevalence and factors associated to the detection (population and next generation sequencing) of archived 3TC resistance mutations in aviremic HIV-infected adults (GEN-PRO)*
Lourdes Domínguez-Domínguez, Spain

**PE13/4**  *Monitoring the prevalence of transmitted HIV drug resistance in Hungary*
Eva Ay, Hungary

**PE13/5**  *Predominant reverse transcriptase resistance mutations as barriers to achieving elimination of mother-to-child transmission of HIV in South Africa*
Oladele Vincent Adeniyi, South Africa
**Scientific Programme**

**PE13/6**  
*Virologic failure and human immunodeficiency virus drug resistance in adolescents on antiretroviral therapy in Yaounde and Douala*  
Magaly Jeanne Estelle Moukoko Mbonjo, Cameroon

**PE13/7**  
*Selection of integrase inhibitor (INI) resistance mutations in an INI experienced patient treated by Bictegravir*  
Thanes Vanig, United States

**PE13/8**  
*Impact of HIV-1 subtypes and integrase natural polymorphisms on virological response to first-line integrase inhibitors based regimens*  
Daniele Armenia, Italy

**PE13/9**  
*HIV-1 integrase inhibitor resistance associated mutations defined by majority and minority populations among individuals failing therapy*  
Smitha Gudipati, United States

**PE13/10**  
*HIV-1 diversity and antiretroviral resistance among bulgarian citizens infected abroad and foreigners registered with HIV/AIDS in bulgaria from 2012 to 2017 (preliminary analysis)*  
Ivailo Alexiev, Bulgaria

**PE13/11**  
*Analytical treatment interruption and its association with rearrangement of peripheral archived resistance mutations*  
Claudia Alteri, Italy

**PE13/12**  
*A low level of darunavir resistance-associated mutation emergence in patients with virological failure during long term use of darunavir in people living with HIV, the French ANRS CO3 Aquitaine cohort*  
Fabrice Bonnet, France

**PE13/13**  
*Patients infected with multi-class resistant HIV-1 and with viral suppression treated with no more than one active drug: comparison of historical resistance reports and drug resistance in proviral DNA*  
Christian Hoffmann, Germany

**PE13/14**  
*Non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance in people living with HIV-1 (PLWH) subtype non-B from the Swiss HIV Cohort Study (SHCS)*  
Martina L. Reichmuth, Switzerland

**PE13/15**  
*HIV-1 from antiretroviral-naïve and experienced patients lack capsid substitutions associated with GS-6207 in vitro resistance*  
Anne-Geneviève Marcelin, France

**PE13/16**  
*Long-term efficacy, safety and durability of ibalizumab in expanded access study*  
Graeme Moyle, United Kingdom

**PE13/17**  
*Clinical impact of minority mutations in patients failing an integrase inhibitor-based regimen: what do clinicians do?*  
Smitha Gudipati, United States

**PE13/18**  
*Identification of HIV-1 transmission clusters in Croatia, 2014 - 2017: evidence for the forward spread of HIV-1 resistant variants*  
Josip Begovac, Croatia

**PE13/19**  
*High levels of resistance among HIV-1 treatment naive patients in Greece, a nationwide study: evidence for country and regional level transmission networks*  
Dimitris Chatzidimitriou, Greece
Scientific Programme

PE13/20  A phase 3b, open-label, pilot study to evaluate switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) in virologically-suppressed HIV-1 infected adult subjects harboring NRTI resistance mutations M184V/I +/- TAMs (GS-US-292-1824): week 24 results
Ignacio Pérez-Valero, Spain

PE13/21  Sustained viral suppression among participants with pre-existing M184V/I who switched to bictegravir/emtricitabine/tenofovir alafenamide
Kristen Andreatta, United States

PE13/22  Absence of naturally existing resistance against the HIV-1 capsid inhibitor GS-6207 in HIV-1 primary isolates
Christian Callebaut, United States

PE13/23  Impacts assessment of home based care program over adherence to ART among adolescence living with HIV and AIDS in Blantyre Malawi
Lesily Samson Kapile, Malawi

PE13/24  Correlation of results analysis drug resistance of HIV-1 among patients with virological failure by next-generation sequencing and traditional population sequencing
Alina Kirichenko, Russian Federation

PE13/25  Analysis of the latent reservoir of a patient infected with HIV under PrEP by single full-length HIV-1 amplification
Maximilian Damagnez, Germany

PE13/26  Drug resistance profile according to HIV-1 viral load after long-term exposure to antiretroviral treatment in the absence of routine virological monitoring: results from a programmatic cohort in sub-Saharan Africa
Giovanni Villa, United Kingdom

PE13/27  In vitro analysis of replicative capacity and phenotypic susceptibility of integrase mutant HIV-2 viruses
Quentin Le Hingrat, France

PE13/28  Treatment simplification with two-drug regimens: impact of transmitted drug resistance mutations in residents of South-East Austria
Evelyn Stelzl, Austria

PE13/29  Baseline resistance to Doravirine depends on the algorithm used for interpretation
Carlos Guerrero Beltrán, Spain

PE13/30  Baseline resistance to EACS first line recommended antiretroviral regimens in newly diagnosed patients in Spain
Federico García, Spain

PE13/31  A retrospective evaluation of a national home infusion provider’s approach to medication adherence of parenteral ibalizumab-uiyk in the alternate-site and homecare setting
Kathryn Andrusko-Furphy, United States

PE13/32  Prevalence of HIV-1 drug resistance among patients with antiretroviral therapy failure in Moscow region, Russia
Natalya Lebedeva, Russian Federation

PE13/33  HIV-1 drug resistance surveillance among parturient women on anti-retroviral therapy in the Eastern Cape, South Africa: implications for elimination of mother-to-child transmission
Oladele Vincent Adeniyi, South Africa
Scientific Programme

PE13/34  Antiretroviral Resistance patterns in HIV-1 infected patients failing to second-line in Bamako, Mali
Almoustapha Issiaka Maiga, Mali

Human genomics

PE15/1  Genetic characterization of the near full-length genome of an HIV-1 A1/C/D/K/B unique recombinant form from the Eastern Cape, South Africa: a case report
Oladele Vincent Adeniyi, South Africa

PE15/2  Impact of KIR and their ligands (HLA allele) on susceptibility to selected viral opportunistic conditions and HIV plasma viral load in HIV+ patients
Magdalena Leszczyszyn-Pynka, Poland

PE15/3  The identification and causal analysis of aberrant CD4 counts in an HIV cohort in Southern Alberta, Canada
Raynell Lang, Canada

PE15/4  Placental gene expression profiles and pathways in HIV-1 positive Cameroonian women under ART
Forgu Esemu Livo, Cameroon

PE15/5  Functional clustering and association of HLA class I alleles to viral load in HIV-positive and ART-naïve participants from the INSIGHT START study
Adrian Gabriel Zucco, Denmark

PE15/6  miRNA expression profiling in subcutaneous adipose tissue of monozygotic twins discordant for HIV infection: validation of differentially expressed miRNA and bioinformatic analysis
Nicola Squillace, Italy

PE15/7  Factors influencing late presentation into care of HIV disease
Bogusz Aksak-Wąs, Poland

Immunology

PE16/1  Immunological and metabolic effects of dasatinib treatment in IL7-stimulated CD4+ T-cells subpopulations
Humberto Erick De La Torre Tarazona, Spain

PE16/2  New T- and B-lymphocytes production and T-cell receptor diversity in young adults perinatally infected by HIV
Martina Properzi, Italy

PE16/3  In Vivo modelling of mechanisms of HIV-1-related monocyte dysfunction
Theodoros Kelesidis, United States
Scientific Programme

PE16/4 Lectin-like oxidized low-density lipoprotein (LOX-1) is elevated in proinflammatory monocytes in chronic treated HIV
Theodoros Kelesidis, United States

PE16/5 In vivo dissection of the impact of HIV-1 versus antivirals on immune activation in chronic treated HIV
Theodoros Kelesidis, United States

PE16/6 Differential impact of HIV-1 versus antivirals on systemic inflammation in chronic treated HIV
Theodoros Kelesidis, United States

PE16/7 Correlation between blood telomere length and CD4+ CD8+ T-cell subsets in HIV-1-positive individuals with long-term virological suppression on antiretroviral therapy
Javier Rodríguez-Centeno, Spain

PE16/9 Phenotypical recovery of the T-cell pool following switch to dual and triple INSTI-based cART
Camilla Tincati, Italy

PE16/11 Expression of PD-1 in a population of double-negative T cells (CD3+CD4-CD8-) in HIV-infected patients - the preliminary study results
Weronika Rymer, Poland

PE16/12 Targeting inflammation in chronic treated HIV with oral ApoA-I mimetics
Theodoros Kelesidis, United States

PE16/13 Poor recovery of T-cell receptor repertoire despite long-term antiretroviral therapy
James Brown, United Kingdom

Pathogenesis and immunopathogenesis

PE26/2 Colonic microbiota exhibits disparate associations with HIV-infection and sexual practices
Eveline Verheij, Netherlands

PE26/3 Zonulin indicates loss of intestinal integrity and microbial translocation in HIV+ patients
Max Augustin, Germany

PE26/4 Distinct pro-inflammatory and cardio-protective effects of antiretroviral drugs in vascular endothelial cells
Akif A. Khawaja, United Kingdom

PE26/5 Bacterial translocation kinetics in HIV-1 infection: from acute to chronic stages
Paula Aranguren-Rivas, Spain

PE26/6 Mitochondrial antioxidants attenuate In vivo liver fibrosis in chronic treated HIV
Theodoros Kelesidis, United States

PE26/7 Mitochondrial antioxidants attenuate In vivo mitochondrial dysfunction and exhaustion in T cells in chronic treated HIV
Theodoros Kelesidis, United States
**Scientific Programme**

**PE26/8**  Inhibition of caspase 1 reduces viral load, CD4 T cell depletion and immune activation in HIV-1 infected humanized mice  
Philipp Adams, Luxembourg

**PE26/9**  Effect of early initiation of ART on alterations in natural killer cells in HIV infected pediatric patients  
Romsha Kumar, India

**PE26/10**  HIV-DNA levels, HLA-B*27 and HLA-DRB1*13 among LTNPs, ECs and HIV controllers  
Arianna Gabrieli, Italy

**PE26/11**  Macromolecule uptake across intestinal epithelia in HIV infection  
Carolin Grünhagen, Germany

**PE26/12**  Immune cell activation as a risk factor for hypertension in people living with HIV in Sub-Saharan Africa using the recent American Heart Association and American College of Cardiology Guidelines  
Sepiso Masenga, Zambia

**ePosters**  
09:00 - 18:00  
Exhibition hall

**Vaccines and immune based therapies**

**PE36/2**  Development of engineered nanocarrier for controlled delivery of a protease inhibitor  
Saurabh Bhargava, India

**ePosters**  
09:00 - 18:00  
Exhibition hall

**Virology**

**PE38/1**  Identification of an HIV-1 BC intersubtype recombinant form, which is circulating in Spain  
Javier Enrique Cañada García, Spain

**PE38/2**  Viral reservoir dynamics in very early primary HIV infection (PHI) patients receiving an intensified antiretroviral regimen (ART): a pilot clinical trial  
Juan Ambrosioni, Spain

**PE38/3**  Lamivudine-based two-drug regimens are not associated with an increased risk of detectable rectal HIV-RNA  
Alberto Borghetti, Italy

**PE38/4**  Comparison of HIV-1 viral load and drug resistance mutations between cerebrospinal fluid and plasma in patients with HIV and Cryptococcal meningitis co-infection in Botswana  
Nametso Kelentse, Botswana

**PE38/5**  HTLV-II antisense protein Aph-2 negatively regulates HIV-1 transcription  
Rajkumar Londhe, India

**PE38/6**  HIV compartmentalization between plasma and CSF and association with neurocognitive disorders  
Alessandro Lazzaro, Italy
17th European AIDS Conference  
November 6-9, 2019  
Basel, Switzerland

**Scientific Programme**

**PE38/7** Determinants of neurocognitive impairments in a Romanian cohort of young adults with chronic HIV infection  
Simona Ruta, Romania

**PE38/8** Reconstruction of phylogeography for Indian HIV-1 sub-subtype A1  
Ajit Patil, India

**PE38/9** Broad and potent neutralizing antibody responses in HIV-1 infected Angolan patients: implications for vaccine design and efficacy  
Francisco Martin, Portugal

**PE38/10** The XbnAb cohort: a HIV-1 cohort of 304 bnAb inducers and matched controls tailored to study determinants of bnAb induction  
Irene Abela, Switzerland

**PE38/11** Performance of 'Xpert® HIV-1 Qual assay' for diagnosis of HIV-1 infection using Dried Blood Spot specimens  
Swarali Kurle, India

**PE38/12** HIV-1 infections belonging to transmission clusters originating in different countries are frequently detected in Spain among newly diagnosed individuals  
Javier Cañada, Spain

---

**ePosters**  
09:00 - 18:00  
Exhibition hall

### Antiretroviral observational studies

**PE2/1** A study of the effect of antiretroviral therapy on sexual risk behavior in a high-risk cohort of Congolese women  
Samuel Bita, Congo, the Democratic Republic of the

**PE2/2** Coagulation system and HIV infection: a review  
Nnamdi Nwachukwu, Nigeria

**PE2/3** Effectiveness, persistence and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF), F/TAF+3rd agent or rilpivirine/F/TAF (R/F/TAF) in treatment-naive HIV-1 infected patients - 24-month results from the German TAFNES cohort study  
Hans-Jürgen Stellbrink, Germany

**PE2/4** “Attracting men” - extended clinic hours as differentiated model of care in an urban Malawian cohort  
Sam Phiri, Malawi

**PE2/5** HIV care in India: a systematic review of barriers to anti-retroviral therapy adherence  
Charu Kohli, India

**PE2/6** Comparing NRTI-sparing dual regimens using data from the Swiss HIV cohort study  
Jim Young, Switzerland

**PE2/7** Physicians’ opinions on generic antiretroviral drugs and single tablet regimen (STR) desimplification for the treatment of HIV infection: a multicentre survey in Spain  
Inés Suárez-García, Spain
Simplifying salvage regimens with darunavir-based dual therapy in HIV-infected individuals harboring multidrug-resistance
Pilar Vizcarra, Spain

Clinical outcomes among HIV-infected Africans with advanced disease in Spain
Adrià Ramírez-Mena, Switzerland

The Treatment of Primary HIV (TopHIV) cohort: a prospective multicenter cohort in Germany
Melanie Stecher, Germany

No decrease in CD4/CD8 ratio after 36 months therapy in patients who were switched to two dual regimens containing rilpivirine
Cecilia Tortajada, Spain

Clinical experience of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) in real life practice: data from the Turkish HIV-TR cohort
Volkan Korten, Turkey

Real world utilisation of raltegravir 1200mg once daily (The RETRO Study)
Christine Mackay, United Kingdom

Effectiveness, persistence and safety in treatment-naive and treatment-experienced HIV-1 infected patients receiving elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) - 12-month evaluation of the French TARANIS cohort
Jean-Luc Meynard, France

24-month evaluation of the German TAFNES cohort - Effectiveness, persistence and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF), F/TAF + 3rd agent or rilpivirine/F/TAF (R/F/TAF) in treatment-experienced HIV-1 infected patients
Heribert Knechten, Germany

Effectiveness, safety and tolerability of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in HIV-1 infected adult patients in routine clinical practice - 6 months results of the BICSTaR cohort
Stefan Esser, Germany

Short-term increase in Body Mass Index and systolic blood pressure elevation in treatment naive persons starting INSTI-based antiretroviral therapy
Ronald Galdamez, Spain

Baseline characteristics in JUNGLE, a German observational cohort study of Juluca as 2-drug Regimen in virologically suppressed patients, compared to the phase-3 SWORD 1 & 2 study populations
F. Schabaz, Germany

Examining the efficacy in clinical practice of the dual antiretroviral therapy regimen of boosted protease inhibitors with maraviroc
Abhishek Katliyar, United Kingdom

Good efficacy but side effects including hypercholesterolemia and body weight gain after switching to dolutegravir plus booster protease inhibitor regimen among treatment experienced HIV-positive patients
Yu-Lin Lee, Taiwan, Republic of China

Rates of DTG/ABC/3TC discontinuation in a real-life setting: no surprises found in reported adverse events
Ana Gorgulho, Portugal
Low baseline HIV viral loads with a history of PrEP use - how should these patients be managed?
Victoria Tittle, United Kingdom

Lamivudine-based maintenance 2-drugs regimens: an algorithm for the estimation of 2-years risk of virological failure in clinical practice
Alberto Borghetti, Italy

Adding raltegravir to a bPI failing regimen was not associated with higher virologic suppression
Monica Maria Gomes-da-Silva, Brazil

Neuropsychiatric tolerability of bictegravir combined with FTC/TAF in clinical practice
Christian Hoffmann, Germany

Real-world clinical outcomes of patients switched from complex multi-tablet regimens to TAF-based single-tablet regimens plus a boosted protease inhibitor
Charlotte-Paige Rolle, United States

Dual therapy with fixed dose combination of darunavir/ritonavir plus raltegravir in HIV-infected patients in Argentina
Diego Martin Cecchini, Argentina

Detectability of HIV residual viremia despite therapy is highly associated with treatment with protease inhibitor
Gilles Darcis, Belgium

Prediction of virological failure in patients with low level HIV-1 viremia using a joint latent class model
Enrique Bernal, Spain

Comparing effectiveness and tolerability of emtricitabine/tenofovir alafenamide (F/TAF) with emtricitabine/tenofovir disoproxil fumarate (F/TDF) in HIV-1 infected adult patients in routine clinical practice: a cross cohort analysis
Stefan Esser, Germany

Effectiveness of Dolutegravir-based antiretroviral therapy in a real-world setting in a Belgian cohort of 4101 HIV patients
Rakan Nasreddine, Belgium

Characterizations of weight gain following antiretroviral regimen initiation in treatment-naïve individuals living with HIV
Ricky Hsu, United States

How to RESPOND to modern challenges for people living with HIV: a new cohort collaboration
Bastian Neesgaard, Denmark

ART simplification: use of dual therapy for HIV in a public health reference center (CRT-DST/Aids) in São Paulo, Brazil
Roberta Schiavon Nogueira, Brazil

Simplification to dual (2D) antiretroviral therapy (ART) with lamivudine and dolutegravir in HIV-infected patients with solid organ transplantation (SOT): a preliminary single-center experience
Juan Ambrosioni, Spain
Scientific Programme

PE2/36  Comparable effectiveness of Raltegravir-based dual therapy versus other regimens in patients switched for maintenance
Karen Martin, Germany

PE2/37  Comparison of a two-drug regimen (dolutegravir/rilpivirine) to standard three-drug regimens in virologically suppressed, treatment experienced individuals in the real world
Gerald Pierone, United States

PE2/38  Effectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir in treatment-experienced patients: a multicentre cohort study
Inés Suárez-García, Spain

PE2/39  High persistence of dolutegravir-containing 2-drug regimens in routine clinical care
Sebastian Noe, Germany

PE2/40  Virologic, immunologic and clinical outcomes in antiretroviral treatment (ART) naive individuals in the RESPOND cohort collaboration
Amanda Mocroft, United Kingdom

PE2/41  A retrospective analysis of the EuResist data set assessing HIV dual therapy success in a real-life context
Michael Böhm, Germany

PE2/42  The real-world impact of switching to tenofovir-alafenamide (TAF) on metabolic comorbidities in PLWH aged over 60s
Ming Jie Lee, United Kingdom

PE2/43  Effect of simplification to INSTI-based dual therapy on residual inflammation and viral reservoir
Giulia Marchetti, Italy

PE2/44  Changes in LDL after switch from TDF to TAF in the U.S.
Paddy Mallon, Ireland

PE2/45  A retrospective analysis of the EuResist data set assessing if NRTI resistance impairs INSTI based treatment with NRTI backbone
Michael Böhm, Germany

PE2/46  Impact of archived M184V/I mutations on the effectiveness of switching to coformulated elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide among virologically suppressed HIV-positive patients
Chien-Ching Hung, Taiwan, Republic of China

PE2/47  Central nervous system (CNS) side effects and viral blips post cART switch from atazanavir boosted with ritonavir (ATZ/r) to atazanavir boosted with cobicistat (ATZ/c)
Stephanie Tyler, United Kingdom

PE2/48  Quantitation of cellular HIV-1 DNA levels by droplet digital PCR in virologically-suppressed patients switching to dolutegravir plus lamivudine: a prospective study
Francesca Lombardi, Italy

PE2/49  Evaluation of weight gain in incarcerated individuals living with HIV/AIDS after switching to a raltegravir-based regimen
Melissa Badowski, United States
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>PE2/50</td>
<td>Determinants of viral non-suppression among people living with HIV (PLHIV) in rural setting, Neno: a retrospective cohort study</td>
<td>Potiphar Damiano, Malawi</td>
</tr>
<tr>
<td>PE2/51</td>
<td>Risk of developing HIV resistance in patients with low level viraemia in a large London cohort</td>
<td>Naomi Fitzgerald, United Kingdom</td>
</tr>
<tr>
<td>PE2/52</td>
<td>Virological outcomes of first line regimens in women living with HIV from Icona cohort: comparison with clinical trial data</td>
<td>Cristina Mussini, Italy</td>
</tr>
<tr>
<td>PE2/53</td>
<td>Well-being in people living with HIV/AIDS (PLWHA) according to cART exposure: data from IOCONA cohort</td>
<td>Antonella Cingolani, Italy</td>
</tr>
<tr>
<td>PE2/54</td>
<td>Body composition changes in HIV: do INSTI matter?</td>
<td>Giovanni Guaraldi, Italy</td>
</tr>
<tr>
<td>PE2/55</td>
<td>Dolutegravir-based regimens are associated with weight gain over two years following ART-initiation in ART-naive people living with HIV (PLWH)</td>
<td>Heidi Crane, United States</td>
</tr>
<tr>
<td>PE2/56</td>
<td>Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in combination with boosted darunavir (DRV) in treatment experienced patients with HIV</td>
<td>Lucas Hill, United States</td>
</tr>
<tr>
<td>PE2/57</td>
<td>Real world data of using Triumeq (dolutegravir/abacavir/lamivudine; DTG/ABC/3TC): final outcomes of the 3-year German TRIUMPH cohort show good virologic effectiveness and safety in clinical routine</td>
<td>Nils Postel, Germany</td>
</tr>
<tr>
<td>PE2/58</td>
<td>The effectiveness of E/C/F/TAF in treatment-naive (TN) or treatment-experienced (TE) adult HIV-infected patients in a real-world setting, results from southern Turkey</td>
<td>Dilara Inan, Turkey</td>
</tr>
<tr>
<td>PE2/59</td>
<td>Comparison of efficacy and safety of a switch to fixed-dose combination FTC/TDF-TAF/RPV versus fixed-dose combination 3TC/ABC/DTG in HIV-1-infected, treatment experienced and virologically suppressed patients: a cohort study</td>
<td>Gaetana Sterrantino, Italy</td>
</tr>
<tr>
<td>PE2/60</td>
<td>COPEDOL: a 2-year French multicentric, observational, longitudinal retro-prospective study, in pretreated HIV-1-infected patients starting dolutegravir based regimen due to treatment failure</td>
<td>Roland Landman, France</td>
</tr>
<tr>
<td>PE2/61</td>
<td>Drug-drug interactions with recommended first-line antiretroviral therapy in real-world settings</td>
<td>Wang-Huei Sheng, Taiwan, Republic of China</td>
</tr>
<tr>
<td>PE2/62</td>
<td>Determinants of switching to TAF-based cART or dual combinations (DC) from TDF-based regimens in a cohort of HIV-infected individuals with controlled viral load≤50 copies/mL</td>
<td>Alessandra Vergori, Italy</td>
</tr>
<tr>
<td>PE2/63</td>
<td>An early proactive switch to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/T/TAF) is effective in maintaining virologic control and improving quality of life (QoL) in patients with a primary HIV-1 infection (PHI). An interim analysis of a phase IV clinical trial (ESTER study)</td>
<td>Marta Camici, Italy</td>
</tr>
</tbody>
</table>
**Scientific Programme**

**PE2/64** Prevalence of neuropsychiatric conditions in patients living with HIV-1 treated with antiretroviral therapies - a perspective from US Medicaid  
Wing Chow, United States

**PE2/65** Switch to dolutegravir dual regimens and inflammation mediated by annexin  
Claudio Ucciferri, Italy

**PE2/66** Efficacy of dual antiretroviral therapy (ART) as intermittent short cycle regimen in virologically suppressed HIV-infected patients: an observational cohort  
Romain Palich, France

**PE2/67** Modelling time varying viral load and CD4 cell counts response to antiretroviral therapy in a cohort of HIV naive patients  
Margarida Tavares, Portugal

**PE2/68** Impact of switching to E/C/F/TAF on lipid profile and renal function in HIV-infected patients  
Bilgul Mete, Turkey

---

**Antiretroviral randomized clinical trials**

**PE3/1** Genital HIV-1 RNA and DNA shedding in virologically suppressed individuals switching from triple- to dual- or monotherapy: pooled results from two randomized controlled trials  
Laurent Hocqueloux, France

**PE3/2** Comparison of the Ease of Swallowability of B/F/TAF placebo compared to DTG/ABC/3TC placebo  
John Ernest McKinnon, United States

**PE3/3** Evaluation of total HIV-DNA changes in HIV-1 infected patients who continue a 2-drug regimen with dolutegravir plus one reverse transcriptase inhibitor or switch to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide enrolled in the Be-One Study  
Maria Mercedes Santoro, Italy

**PE3/4** Phase-3 trials of new antiretrovirals are not representative of the global HIV epidemic  
Toby Pepperrell, United Kingdom

**PE3/5** Impact of susceptibility scoring on virologic response in heavily treatment-experienced participants with HIV-1 receiving a fostemsavir-based antiretroviral regimen: results through week 96 from the randomized cohort of the Phase 3 BRIGHTE study  
Peter Ackerman, United States

**PE3/6** Reversibility of dolutegravir/lamivudine/abacavir neuropsychiatric toxicity after 24 weeks of switching to elvitegravir/cobicistat/emtricitabine/tenofovir-alafenamide (EVG/c/FTC/TAF). The DREAM Clinical Trial  
Ignacio Pérez-Valero, Spain

**PE3/7** A switch to dolutegravir in combination with boosted darunavir is safe and effective in suppressed patients with HIV - a predefined psychosocial subanalysis of the DUALIS study  
Christoph Spinner, Germany

**PE3/8** Tenofovir alafenamide versus tenofovir disoproxil fumarate - is there a true difference in safety?  
Toby Pepperrell, United Kingdom
Scientific Programme

PE3/9  Biologic sex is not the only difference between men and women: data from the Doravirine phase 2/3 clinical trials
Sharon Walmsley, Canada

PE3/10  No metabolic or renal benefits when switching to an NRTI-free dolutegravir-containing 2 drug regimen (2DR) - a subanalysis of the DUALIS study
Christoph Boesecke, Germany

PE3/11  Sustained viral suppression with dolutegravir monotherapy during 9,899 patient weeks of follow-up in individuals starting combination antiretroviral therapy during primary HIV infection (EARLY SIMPLIFIED): a randomized, controlled, multi-site, non-inferiority trial
Dominique Laurent Braun, Switzerland

PE3/12  Rapid initiation of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in patients with human immunodeficiency virus (HIV)-1 infection: age, race/ethnicity, and gender subgroup analyses from the DIAMOND study
David Anderson, United States

PE3/13  A systematic review and meta-analysis evaluating the risk of central nervous system adverse events in randomised controlled trials of dolutegravir
Khadija Muniath Chowdhury, United Kingdom

PE3/14  Long-term efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in ART-naive adults
Chloe Orkin, United Kingdom

PE3/15  Switching from a 3-drug tenofovir alafenamide (TAF)-based regimen (TBR) to a 2-drug dolutegravir/lamivudine (2DR, DTG/3TC FDC) was not associated with a higher frequency of intermittent viremia in suppressed patients in the TANGO study
Ruolan Wang, United States

PE3/16  Phase 3 randomized, controlled DISCOVER study of daily emtricitabine/tenofovir alafenamide (F/TAF) or emtricitabine/tenofovir disoproxil fumarate (F/TDF) for HIV pre-exposure prophylaxis (PrEP): week 96 results
Peter J Ruane, United States

PE3/17  Single doses of long-acting capsid inhibitor GS-6207 administered by subcutaneous injection are safe and efficacious in people living with HIV
Eric S Daar, United States

PE3/18  Long-term safety and efficacy of rilpivirine plus nucleoside/nucleotide reverse transcriptase inhibitors in HIV-1 infected patients: 7-year roll-over study from phase 2 and 3 clinical studies
Jean-Michel Molina, France

PE3/20  Prevalence of archived HIV-1 DNA resistance-associated mutations (RAMs) and their lack of effect on virologic outcome at week 96 in antiretroviral treatment (ART)-experienced, virologically suppressed patients receiving the once-daily, single-tablet regimen (STR) darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in the EMERALD phase III trial
Erkki Lathouwers, Belgium

PE3/21  Islatravir efficacy and safety for selected demographic and baseline subgroups from a Phase 2 trial in treatment naive adults with HIV-1 infection
Jean-Michel Molina, France
Pharmacology, pharmacogenomics and drug interactions

PE27/1  Efficacy and safety of artemether-lumefantrine as treatment for Plasmodium falciparum uncomplicated malaria in adult patients on efavirenz based antiretroviral therapy in Zambia: an open label non-randomized interventional trial
Mike Chaponda, Zambia

PE27/2  Ritonavir-boosted darunavir plus two nucleoside reverse transcriptase inhibitors versus other regimens for initial antiretroviral therapy for people with HIV infection: a systematic review
Tatevik Balayan, Armenia

PE27/3  Towards individualization of antiretroviral therapy - more cost-effective than dose intensification in patients
Bhavik Dalal, India

PE27/4  The valproic acid - dolutegravir drug-drug interaction is based on displacement of protein binding and unlikely to be clinically relevant
Henrieke Prins, Netherlands

PE27/5  BESIDE - clinical relevance and implications for management of antiretroviral therapy due to recreational drug use in PLWH in Germany
Karen Martin, Germany

PE27/6  Drug-drug interactions between antiretrovirals and carbamazepine or oxcarbazepine: a real-life investigation
Cristina Gervasoni, Italy

PE27/7  Drug-drug interactions between dolutegravir (DTG) and immunosuppressant drugs (IS) in HIV-infected patients with solid organ transplantation (SOT): a single-arm clinical trial (DTG-SOT)
Christian Manzardo, Spain

PE27/8  Abacavir hypersensitivity reaction (HSR), associated to baseline false negative HLAB5701 screening, in antiretroviral treatment naive HIV-1 patient
Salvatore Martini, Italy

PE27/9  Central nervous system penetration of antiretroviral drugs in HIV-positive patients with neurocognitive impairment, assessed from paired plasma-CSF concentrations
Perrine Courlet, Switzerland

Co-morbidities, ageing

PE9/1  Detectable subclinical myocardial abnormalities in people living with HIV: insights from cardiac magnetic resonance imaging (MRI)
Gavin Paul Raphael Manmathan, United Kingdom

PE9/2  Hypertension and ECG alterations in HIV positive patients in DREAM centres in Mozambique
Isotta Triulzi, Italy
### Scientific Programme

| PE9/3 | Cardiovascular events are declining in men with HIV aged 50 years or older in Austria  
Maria Kitchen, Austria |
| PE9/4 | Prevalence of HIV-associated neurocognitive disorder (HAND) in Turkey and assessment of Addenbrooke’s Cognitive Examination Revised (ACE-R) test as a screening tool  
Volkan Korton, Turkey |
| PE9/5 | Pilot study assessing the Rotterdam Healthy Aging Score in a cohort of HIV-positive adults  
Sharon Walmsley, Canada |
| PE9/6 | Obesity and HIV - the overlapping epidemics  
Justyna Kowalska, Poland |
| PE9/7 | Exhaled nitric oxide levels are higher in people living with HIV compared to uninfected controls suggesting increased eosinophilic pulmonary inflammation  
Rebekka Faber Thudium, Denmark |
| PE9/8 | Comparison of changes in bone microarchitecture with abacavir-lamivudine versus tenofovir disoproxil fumarate-emtricitabine in adults living with HIV  
Roger Bedimo, United States |
| PE9/9 | Limitations of FRAX equation for predicting low bone mineral density or bone loss progression among people living with HIV: the role of secondary causes of osteoporosis  
Pilar Vizcarra, Spain |
| PE9/10 | Elevated body mass index during pregnancy and gestational weight gain in HIV-infected women in Cape Town, South Africa: association with adverse birth outcomes  
Hiengi Madlala, South Africa |
| PE9/11 | Facilitating primary care non-antiretroviral drug prescribing in people living with HIV: the Think ARV project  
Jaime Vera, United Kingdom |
| PE9/12 | Characterization of moderate and severe anemia by peripheral blood smear in HIV infected patients in the Kilombero and Ulanga antiretroviral cohort  
Vanesa Anton-Vazquez, United Kingdom |
| PE9/13 | HIV infection and smoking: PET imaging reveals early pulmonary perfusion abnormalities  
Puja Kohli, United States |
| PE9/14 | Bariatric surgery in HIV obese patients: first results of the French ObéVIH ongoing study  
Valérie Pourcher, France |
| PE9/16 | Plasma cotinine cut-off for distinguishing smokers from non-smokers among people living with HIV (PLWH)  
Omid Rezahosseini, Denmark |
| PE9/17 | An analysis of HIV and co-morbidity profiles for adults accessing health care in Khayelitsha, South Africa  
Richard Osei-Yeboah, South Africa |
| PE9/18 | Femoral arteries better indicator than carotid arteries of cardiovascular risk in HIV/AIDS patients  
Gordana Dragovic Lukic, Serbia |
| PE9/19 | Cardiovascular risk assessment in PLWH over 50: agreement between cardiovascular risk predictors and Coronary Artery Calcium CT Scoring (CACS)  
Branca Pereira, United Kingdom |
PE9/20  Safety and tolerance of denosumab in HIV patients
Sara Vela, Spain

PE9/21  Lower incidence of liver steatosis in patients treated with lamivudine plus dolutegravir dual therapy
Davide Moschese, Italy

PE9/22  Correlations between computerised and standard cognitive testing in persons with HIV and controls
Davide De Francesca, United Kingdom

PE9/23  Whole body MRI detects high prevalence of incidental findings in older HIV-1-infected patients participating in a randomised, controlled trial of maraviroc and/or metformin for non-alcoholic fatty liver disease
Sarah Pett, United Kingdom

PE9/24  An analysis of potential drug-drug interactions in an aging HIV cohort
Pádraig Gardiner, Ireland

PE9/25  A standardized comparison of cardiovascular risk factor prevalence between people living with HIV and general population in Spain
Vicente Estrada, Spain

PE9/26  Subclinical atherosclerosis burden by ultrasound in carotid and femoral territories in HIV subjects: relationships with HIV and non-HIV related factors
Vicente Estrada, Spain

PE9/27  Subcutaneous adipose tissue modifications induced by a switch to dual raltegravir-maraviroc therapy in controlled HIV-infected patients: a sub-study of the ANRS-ROCnRAL157 clinical trial
Jacqueline Capeau, France

PE9/28  Results of 10 year experience of a specialist clinic for people living with HIV over 50 at Chelsea and Westminster Hospital
Branca Pereira, United Kingdom

PE9/29  Discordance in diagnosis of osteoporosis in HIV-infected patients: prevalence, characteristics, and impact on FRAX equation
Pilar Vizcarra, Spain

PE9/30  CD4/CD8 ratio is a better indicator of acute phase inflammation than absolute CD4 count during virally-suppressed HIV infection
Rodney Rousseau, Canada

PE9/31  Immune activation and chronic inflammation: is there an additional effect of HIV in a geriatric population?
Clotilde Allavena, France

PE9/32  Trends in cardiovascular risk factors and estimated 10-year cardiovascular risk score in a Spanish cohort of PLWH: 2010-2018
Francisco Fanjul, Spain

PE9/33  Prevalence of depression and associated psychosocial factors among HIV positive patients attending ART clinic at Gulu Regional Referral Hospital
Ronald Kiyemba, Uganda

PE9/34  Potentially inappropriate medications in older adults with HIV in the region of Madrid, Spain
Beatriz López-Centeno, Spain
Scientific Programme

PE9/35 Impact of the reproductive/hormonal status on weight, fat and insulin resistance in HIV-infected women switching from a PI regimen to dual raltegravir-etravirine therapy: results from the ANRS163-ETRAL trial at 48 and 96 weeks
Jacqueline Capeau, France

PE9/37 Age- and sex-related differences in concomitant diseases and use of co-medication in patients with treated HIV-infection in Germany
Karen Martin, Germany

PE9/38 Kidney transplantation in HIV-positive patients in Israel including the first case of HIV-positive living donor to HIV-positive recipient with a 7-year follow-up
Eugene Katchman, Israel

PE9/39 Vitamin D deficiency and frailty phenotype in HIV-infected men
Fiona Bhondoekhan, United States

PE9/40 The UCSD performance-based skills assessment is associated to cognitive performance in HIV positive population with very good immunological condition
Valentina Delle Donne, Italy

PE9/41 Alcohol, smoking and the association with HIV virological non-suppression among people living with HIV on ART
Timothy Peter Wynne Jones, United Kingdom

PE9/42 Decreasing incidence of diabetes mellitus in HIV-positive Taiwanese patients on combination antiretroviral therapy from 2004 to 2011
Pei-Ying Wu, Taiwan, Republic of China

PE9/43 Incidental findings in PLWH over 50 undergoing coronary artery calcium scoring (CACS) for cardiovascular risk assessment
Maria Mazzitelli, United Kingdom

PE9/44 Aging biomarkers, inflammatory cytokines and development of cardiovascular ischemic events or diabetes in HIV-infected persons
Jose I Bernardino, Spain

PE9/45 Falls but not frailty are common in people living with HIV using an mHealth platform: issues of ageing within the EmERGE cohort
Tom Levettt, United Kingdom

PE9/46 A standardized comparison of cardiovascular risk factor treatment in people living with HIV and general population
Vicente Estrada, Spain

PE9/48 Perceptions of ageing and desire for ageing information amongst users of the EmERGE mHealth platform
Tom Levettt, United Kingdom

PE9/49 Switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in adults aged >65 or older: week 48 results from a phase 3b, open-label trial
Franco Maggiolo, Italy

PE9/50 Safety and efficacy of switching from tenofovir disoproxil fumarate to tenofovir alafenamide in people with HIV aged 50 years and older
Hans-Jürgen Stellbrink, Germany
PE9/51  HIV testing in patients diagnosed with community acquired pneumonia or primary lung cancer from 2014 to 2018 in a tertiary reference hospital in Northern Spain
Teresa Rubio Obanos, Spain

PE9/52  Menopause in aging women living with HIV: changes in bone mineral density and trabecular bone score
Giovanni Guaraldi, Italy

PE9/53  Higher anti-CMV IgG concentrations are not associated with longitudinal brain injury in virally suppressed people with HIV
Jonathan Underwood, United Kingdom

PE9/55  Higher Prevalence of CKD in HIV+ individuals compared to the general population
Stefan Esser, Germany

PE9/56  Effect of CMV viraemia on endothelial dysfunction over 42 weeks in Malawian adults initiating ART with advanced immune suppression
Christine Kelly, Ireland

PE9/57  High prevalence of neurocognitive impairment in adults with perinatally acquired HIV infection
Irene Portilla-Tamarit, Spain

PE9/58  Modeling 2018 AHA cholesterol guidelines in HIV
Giacomo Ciusa, Italy

PE9/59  A multi-disciplinary Neuro-HIV Platform in managing patients with neurocognitive impairment
Phanie Bidlingmeyer, Switzerland

PE9/60  Archi-Prevaleat project. A national register of color-Doppler ultrasonography of the epi-aortic vessels in patients living with HIV
Salvatore Martini, Italy

PE9/61  Preliminary results of a diagnostic-therapeutic work-up to early detect cardiovascular disease in HIV positive patients
Giovanni Millotti, Italy

PE9/62  Bone mineral density changes in young African women on tenofovir disoproxil fumarate antiretroviral therapy and non-hormonal contraception
Flavia Kiweewa Matovu, Uganda

PE9/63  Examination of HIV-infected patients regarding weight gain while using integrase inhibitors in Japan
Ryoko Sekiya, Japan

PE9/65  Predictors of sarcopenia and its impact on components of the frailty phenotype in an Asian population living with HIV
Grace Lui, Hong Kong

PE9/66  Failure to restore CD4 cell count with combination antiretroviral therapy is associated with increased systemic inflammation
Rodney Rousseau, Canada

PE9/67  High prevalence of left ventricular systolic dysfunction assessed by speckle tracking in asymptomatic HIV patients
Dimitris Basoulis, Greece
Scientific Programme

PE9/68  Polypharmacy and drug-drug interactions - prevalence in a Portuguese HIV Metabolic Clinic
Joana Fragoso, Portugal

PE9/69  Bone density alterations in the HIV-infected patient - epidemiologic characterization of a Portuguese cohort
Diogo Guerra, Portugal

PE9/70  Cigarette smoking disproportionately impairs nitric oxide signaling in pulmonary artery endothelial cells in HIV: role of viral and host factors
Saurabh Aggarwal, United States

PE9/71  Frailty phenotype in older virologically suppressed PLWHIV is strongly correlated with specific comorbidities and tobacco use
Christina Katerina Psomas, France

PE9/72  HIV-FUNCRAIL study: differences between women and men aging with HIV
Fátima Brañas, Spain

PE9/73  Prevalence, risk factors and outcomes of cardiovascular, metabolic and chronic kidney diseases in HIV-infected vs. uninfected adults in sub-Saharan Africa: a systematic review and meta-analysis
Ajibola Awotiwon, South Africa

PE9/74  People living with HIV are more likely to be screened for cardiovascular disease risk factors than other members of the general population in Botswana - a community based study
Onkabetse Julia Molefe-Baikai, Botswana

PE9/75  APOL1 high risk genotype has an adverse impact on kidney function in African HIV-infected patients with high viral load
Nongodo Firmin Kabore, France

PE9/76  Comparison of 2 frailty scores in PLWHIV aged 50 and over: SOF index and FRIED phenotype
Christina Katerina Psomas, France

PE9/77  Annexin V, Annexin A1 and cardiovascular risk in HIVpopulation
Claudio Ucciferri, Italy

PE9/78  Could we consider the intima-media thickness (c-IMT) > 1mm as a risk factor for cardiovascular diseases in HIV+ subjects chronically treated with antiretrovirals?
Alessio Pampaloni, Italy

PE9/79  Immune reconstitution inflammatory syndrome (IRIS) in HIV-infected hospitalized patients with advanced disease
Alberto Díaz-de Santiago, Spain

PE9/80  Low Body Mass Index (BMI) in ART naïve HIV-positive subjects and risk of virological failure and drug discontinuation: data from the ICONA Foundation Cohort
Roberto Rossotti, Italy

PE9/81  Sistatin C, KIM1 and NGAL as biological markers for detecting early kidney injury in HIV positive patients
Aslıhan Ulu, Turkey

PE9/82  Long-term AIDS survivors: comorbidities and polypharmacy a new challenge
María José Galindo Puerto, Spain
Scientific Programme

PE9/83 Risk Factors associated to immune reconstitution inflammatory syndrome (IRIS) in HIV-infected hospitalized patients with advanced disease
Alberto Díaz-de Santiago, Spain

PE9/84 Sleep disorders and depression through efavirenz to dolutegravir transition in Brazil: what really changed after all
Melissa Medeiros, Brazil

PE9/85 Patterns of inflammation and comorbidity in Human Immunodeficiency Virus (HIV) infection: a clustering analysis from the CARDAMONE study
Sonia Zebachi, France

PE9/86 Cognitive impairment in patients with HIV in a Mexican hospital
Lucia Carrazco Ibarra, Mexico

PE9/87 Clinical management of ageing people living with HIV in Europe: The view of the care providers
Marta Boffito, United Kingdom

PE9/88 Real-world characterization of the Portuguese population living with HIV who initiated Raltegravir based-regimen in the last three years - REALITY Study
Joana Almeida, Portugal

PE9/89 Long-term lipid-lowering-therapy in HIV is clinically effective
Henning Drechsler, United States

ePosters
09:00 - 18:00
Exhibition hall

HIV-associated and non HIV-associated tumours

PE14/1 Prevalence of anal dysplasia among persons living with human immunodeficiency virus (HIV)
Adelaine Lopez, Philippines

PE14/2 HIV infection is associated with reduced survival among hepatocellular carcinoma cases from an urban referral hospital: Kampala, Uganda
Sara Nsibirwa, Uganda

PE14/3 High prevalence of anal and cervical dysplasia in a cohort of HIV-infected women, but low prevalence of concomitant lesions
Ana Gomez, Ecuador

PE14/4 Malignant and benign skin lesions in HIV-1 infected people
Alessandra Latini, Italy

PE14/5 Results of HPV-testing for anal screening in HIV-infected women
Anna Popova, Russian Federation

PE14/6 COHORT SDT (Granada): decrease of the incidence of HSIL+ in the anal mucosa of HIV+ patients MSM after the performance of a screening, diagnostic and therapeutic program (2010-2018)
Carmen Hidalgo-Tenorio, Spain
Scientific Programme

**PE14/7**  Prospective longitudinal study on immunogenicity and safety of vaccination against human papillomavirus (HPV) with the 9valent vaccine in HIV-positive women, the Papillon study: preliminary results on tolerance and safety  Déborah Konopnicki, Belgium

**PE14/8**  Cancer trends and outcomes in a cohort of people living with HIV  Andrea De Vito, Italy

**PE14/9**  Rate of HCC occurrence and associated risk factors in a multicentric cohort of HIV/HCV co-infected patients treated with DAAs  Alice Toschi, Italy

**ePosters**  
09:00 - 18:00  
Exhibition hall

**Other coinfections/Sexually transmitted infections**

**PE24/2**  High rates of ocular and neurosyphilis in a large German, city-based university hospital: lessons learned on ocular syphilis  Laura Franziska Wagner, Germany

**PE24/3**  Decreasing rate of HIV and HBV co-infection in nationwide Korean HIV/AIDS cohort and its meaning  Yoonjung Kim, Korea, Republic of

**PE24/5**  Prevalence of syphilitic hepatitis among HIV-infected patients in Istanbul, Turkey, a region with increasing incidence of syphilis and HIV infection  Ozlem Altuntas Aydin, Turkey

**PE24/6**  Seroconversion rate after yellow fever vaccine in HIV- positive patients  Charlotte Martin, Belgium

**PE24/7**  Low seroprevalence of syphilis infection among key populations in Togo in 2017: a national cross-sectional survey  Fifonsi Gbeasor, Togo

**PE24/8**  Socio demographics, sexual behavior and clinical manifestations of HIV+ and HIV- patients diagnosed with syphilis, Brussels 2017-2019  Agnès Libois, Belgium

**PE24/9**  Risk factors and prevalence of syphilis, gonorrhea and chlamydia infections in the Swiss HIV cohort study  Catrina Mugglin, Switzerland

**PE24/10**  Predictors of serofast state after treatment for syphilis in HIV-infected patients  Gregor Paul, Germany

**PE24/11**  A proactive approach to assess rising STIs among different at-risk groups of MSM in the early era of PrEP: a real-world clinical care setting  Christina Katerina Psomas, France

**PE24/12**  Profiles of multidrug resistant gonorrhea in HIV-infected patients attending an urban hospital in Uganda  Christine Katusiime, Uganda
<table>
<thead>
<tr>
<th>PE24/13</th>
<th>Sexually transmitted diseases clinic in a Portuguese Infectious Diseases unit</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Joana Fragoso, Portugal</td>
</tr>
<tr>
<td>PE24/14</td>
<td>Quantification of DNA human papillomavirus 16 and 18 in anal cells improves the prediction of high grade anal intraepithelial neoplasia in HIV patients</td>
</tr>
<tr>
<td></td>
<td>Marcos Diez, Spain</td>
</tr>
<tr>
<td>PE24/15</td>
<td>Primary prophylaxis against Pneumocystis jirovecii Pneumonia may be effective in preventing severe bacterial pneumonia in HIV-positive patients: findings from a large Italian center</td>
</tr>
<tr>
<td></td>
<td>Alex Dusina, Italy</td>
</tr>
<tr>
<td>PE24/16</td>
<td>HHV-8 salivary shedding in individuals with different HIV status and sexual behaviour</td>
</tr>
<tr>
<td></td>
<td>Elvira Domonova, Russian Federation</td>
</tr>
<tr>
<td>PE24/17</td>
<td>Insights into syphilis reinfection in HIV patients: predictors and role of serofast condition</td>
</tr>
<tr>
<td></td>
<td>Chiara Picarelli, Italy</td>
</tr>
<tr>
<td>PE24/18</td>
<td>Infective endocarditis, a current health problem in Romanian injecting drug users</td>
</tr>
<tr>
<td></td>
<td>Irina Cristiana Ianache, Romania</td>
</tr>
<tr>
<td>PE24/19</td>
<td>Preventable risk factors and predictors of hepatic and non-hepatic co-morbidities among PLHIV</td>
</tr>
<tr>
<td></td>
<td>Oluwakemi Odukoya, Nigeria</td>
</tr>
<tr>
<td>PE24/20</td>
<td>Incidence of asymptomatic HAV infection among MSM living with HIV in South-Western Poland</td>
</tr>
<tr>
<td></td>
<td>Aleksandra Szymczak, Poland</td>
</tr>
<tr>
<td>PE24/21</td>
<td>Behavioural patterns to identify key populations for syphilis prevention</td>
</tr>
<tr>
<td></td>
<td>Sara Andresen, Switzerland</td>
</tr>
<tr>
<td>PE24/22</td>
<td>Evaluation of a systematic sexually transmitted infections screening pilot programme in HIV-positive men who have sex with men (MSM)</td>
</tr>
<tr>
<td></td>
<td>Paula Prieto, Spain</td>
</tr>
<tr>
<td>PE24/23</td>
<td>Chemsex in Barcelona: a descriptive approach about men who have sex with men (MSM) who use recreational drugs in a sexual context</td>
</tr>
<tr>
<td></td>
<td>Lorena De la Mora, Spain</td>
</tr>
<tr>
<td>PE24/24</td>
<td>Analysis of serum metabolite changes in early syphilis patients with or without serologic response after treatment</td>
</tr>
<tr>
<td></td>
<td>Chia-Jui Yang, Taiwan, Republic of China</td>
</tr>
<tr>
<td>PE24/25</td>
<td>Stable transmission of amoebiasis among newly diagnosed HIV-positive patients in Taiwan, 2009-2018</td>
</tr>
<tr>
<td></td>
<td>Sung-Hsi Huang, Taiwan, Republic of China</td>
</tr>
<tr>
<td>PE24/26</td>
<td>Mycoplasma genitalium resistance against macrolide antibiotics in the Berlin MSM cohort tested with the Allplex MG &amp; AzIR Assay (SeeGene)</td>
</tr>
<tr>
<td></td>
<td>Martin Obermeier, Germany</td>
</tr>
<tr>
<td>PE24/27</td>
<td>Predictors of ureaplasma urealyticum urinary colonization in HIV+ pregnant women: a pilot study</td>
</tr>
<tr>
<td></td>
<td>Iacopo Franconi, Italy</td>
</tr>
</tbody>
</table>
No indication of decreased syphilis susceptibility with repeated syphilis episodes in HIV-infected men who have sex with men: a multicentre prospective cohort study on risk factors and the potential role of syphilis immunity
Jan Roth, Switzerland

The prevalence of high-risk anal HPV in HIV-positive MSM in Lebanon
Nesrine Rizk, Lebanon

Toxicities

Sleep and functional characteristics of Central London Outpatient HIV Cohort
Ana Milinkovic, United Kingdom

Osteopenia and osteoporosis in young HIV-infected patients less than age of 40 years: incidence and risk factors
Shu-Ying Chang, Taiwan, Republic of China

Predictors of weight gain in patients treated with dolutegravir
Lucia Taramasso, Italy

Effects of lamivudine plus dolutegravir 2-drug-regimen on bone mineral density in a multicenter Italian cohort
Arturo Ciccullo, Italy

Switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) lowers alanine transaminase (ALT) and aspartate transaminase (AST) in patients with HIV infection with or without viral hepatitis co-infection
Nicola Squillace, Italy

Weight gain in people living with HIV switched to dual therapy with dolutegravir plus rilpivirine: changes in body fat mass
Pilar Vizcarra, Spain

Does switching to tenofovir alafenamide fumarate impair recovery of renal function in individuals newly diagnosed with tenofovir disoproxil fumarate induced renal tubular toxicity?
John Booth, United Kingdom

Weight gain among HIV-positive persons treated with dolutegravir or elvitegravir
Leïla Belkhir, Belgium

NRTI backbone modification impact on weight, lipids and cardiovascular risk
Ana Milinkovic, United Kingdom

Comparative neuropsychiatric toxicity profile of dolutegravir (DTG) versus efavirenz (EFV) versus other antiretroviral third drugs used either in first-line or switch antiretroviral therapies (ART): data from Icona Foundation Study Cohort
Annalisa Mondi, Italy

SWORD 1&2: maintenance or improvement in renal function in PLWH through 148 weeks after switch to the dolutegravir + rilpivirine 2-drug regimen
Josep M Llibre, Spain
Scientific Programme

PE32/12 Neurotoxicity related to efavirenz does not predict neurotoxicity related to dolutegravir
Sara de la Fuente, Spain

PE32/13 Human embryonic stem cells exposed to dolutegravir show decreased cellular proliferation, reduced pluripotency, and increased mitochondrial toxicity, in a dose-dependent manner: preliminary data
Marie-Soleil R. Smith, Canada

PE32/14 Dolutegravir but not raltegravir reduces cell proliferation and increases mitochondrial toxicities in cultured fibroblasts; effects that are not mitigated by telomerase reverse transcriptase
Helene Cote, Canada

ePosters
09:00 - 18:00
Exhibition hall

Tuberculosis and opportunistic infections

PE35/1 Nontuberculous mycobacteria infections in Russian HIV patients: clinical features and outcomes
Mikhail Savchenko, Russian Federation

PE35/2 Human immunodeficiency virus and the outcome of treatment for pulmonary tuberculosis: a retrospective study in Tehran, Iran
Mohammad Bagheri, Iran, Islamic Republic of

PE35/3 Rifampicin pharmacokinetics and pharmacogenetics in Ugandan patients with multi-drug resistant tuberculosis
Jackson K. Mukonzo, Uganda

PE35/4 Mycobacteria-induced immune responses by mucosal-associated invariant T (MAIT) cells are impaired in patients with tuberculosis (TB) and HIV-associated TB
Muki Shey, South Africa

PE35/5 Acute onset of cerebral toxoplasmosis in patients with HIV infection
Tatiana Ermak, Russian Federation

PE35/6 Association between immunological status and TB disease development in HIV-infected individuals with LTBI
Ngai Sze Wong, Hong Kong

PE35/7 Amoeba- a swiss army knife for diagnosis and mechanistic understanding of Legionella infection
Breanne M Head, Canada

PE35/8 Causes and outcomes of hospitalizations among HIV positive persons in Georgia’s referral institution, 2012-2017
Nino Rukhadze, Georgia

PE35/9 Population pharmacokinetic analysis of dolutegravir in HIV/TB co-infected people with and without rifampicin
Rajendra Singh, United States

PE35/10 Lung function and health-related quality of life among patients following pulmonary tuberculosis treatment in urban Uganda: a cross-sectional study
Josephine Zawedde, Uganda
Scientific Programme

PE35/11  Clinical and laboratory characterization of progressive multifocal leukoencephalopathy in HIV-infected patients in the intensive care unit
Anastasia Pokrovskaya, Russian Federation

PE35/13  Cryptococcal and tuberculosis coinfection: case series identified through the implementation of an advanced HIV disease package of care linked to a TB active case finding strategy in rural Mozambique
Alejandro Blanco-Arévalo, Spain

PE35/14  Trends in latent tuberculosis screening in a cohort of HIV-infected patients from a low tuberculosis incidence country
Pedro Palma, Portugal

PE35/15  Drug-induced hepatic injury developed in tuberculosis / HIV co-infection treatment
Sarah Silva, Brazil

ePosters
09:00 - 18:00  Exhibition hall

NASH

PE22/1  Assessment of non alcoholic fatty liver disease in a cohort of HIV mono-infected patients
Paola Columpsi, United Kingdom

PE22/2  Non-alcoholic fatty liver disease (NAFLD) and related metabolic disorders among HIV-infected patients in the country of Georgia
Lali Sharvadze, Georgia

PE22/3  Non-alcoholic fatty liver disease is a significant predictor of cardiovascular risk in HIV-infected patients
Adriana Cervo, Italy

PE22/4  Non alcoholic fatty liver disease diagnosed by non-invasive markers in HIV-infected patients
Carmen Busca, Spain

PE22/5  Global prevalence of liver impairment in HIV population in direct antiviral agents (DAA) era: the role of fatty liver disease
Matilde Sánchez-Conde, Spain

ePosters
09:00 - 18:00  Exhibition hall

Viral hepatitis

PE37/1  Acute hepatitis C infection in HIV-infected patients who achieved viral suppression: incidence and risk factors
Hsin-Yen Ku, Taiwan, Republic of China

PE37/2  HBV infections among HIV infected HAART receiving mothers and their exposed infants in a tertiary hospital in Kenya
James Kangethe, Kenya
Direct-acting antivirals (DAAs) improve liver stiffness measurements but do not improve the Veterans Aging Cohort Study (VACS) Index in HIV/HCV co-infected Egyptian patients: is improved discrimination needed?
Ahmed Cordie, Egypt

HCV/HIV coinfection in the DAA era: which patients have not been treated for HCV?
Fabian Dario Rodriguez-Monaco, Germany

Hepatitis E seroprevalence in HIV-positive patients
Mustafa Altindis, Turkey

Success of unrestricted DAA therapy is limited by HCV reinfections and loss to follow-up in HIV-positive patients
David Chromy, Austria

Efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide as maintenance treatment of patients with HIV and Hepatitis B Virus (HBV) coinfection
Yu-Shan Huang, Taiwan, Republic of China

Effectiveness of hepatitis a vaccination among people living with HIV in Taiwan: is one dose enough?
Chia-Jui Yang, Taiwan, Republic of China

HIV patients remain at high risk for advanced liver fibrosis after curing HCV infection
Natalia Bolokadze, Georgia

HIV/HCV coinfection in Spain: trouble will soon be over
Juan Berenguer, Spain

Care cascade of incident HCV infection among HIV-positive patients in Taiwan
Miao-Hui Huang, Taiwan, Republic of China

Current characteristics of HIV/HBV coinfected patients in a single HIV reference centre of Madrid
Luz Martín-Carbonero, Spain

High HCV reinfection rate in MSM living with HIV in Barcelona: the need to focus on high risk population to achieve HCV elimination
Maria Martínez-Rebollar, Spain

Liver disease in HIV-infected subjects in the post-HCV DAA treatment era
Carmen Busca, Spain

Seroprevalence of hepatitis E in a Portuguese cohort of human immunodeficiency virus infected patients
André Silva-Pinto, Portugal

Loss of seroprotection against hepatitis B virus (HBV) was associated with lower CD4 counts among HIV-positive patients who were born in the era of nationwide neonatal HBV vaccination
Yi-Chia Huang, Taiwan, Republic of China

Improvement of immunity and hepatic fibrosis after HCV treatment with DAA in people living with HIV and HCV
Montserrat Laguno, Spain
PE37/18  DAA treating Hepatitis C in HIV/HCV coinfected patients in two prisons of Rome: results and problems
Sara Lardo, Italy

PE37/19  Progress towards eliminating mother-to-child transmission of HIV in the Macha area in Zambia from 2010-2018
Mutinta Hamahuwa, Zambia

PE37/20  Evaluation of the hepatitis C care cascade in the country of Georgia: monitoring 4 years of progress towards elimination
Tengiz Tsertsvadze, Georgia

PE37/21  Epidemiology of HIV, HBV and HCV co-infection in Israel
Karen Olshtain-Pops, Israel

PE37/22  Hepatitis C treatment outcomes of HIV infected people who inject drugs in a real-world cohort
Dimitris Basoulis, Greece

PE37/23  Treatment of acute HCV infection with direct acting antivirals (DAA) in HIV patients
Cristina Gómez-Ayerbe, Spain

PE37/24  Hepatic fibrosis progression among HIV patients in Israel
Karen Olshtain-Pops, Israel

PE37/25  Acute hepatitis B in persons living with HIV in a low hepatitis B prevalence area during the last two decades
Luz Martín-Carbonero, Spain

PE37/26  Virological response to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in HIV-positive patients with lamivudine-resistant hepatitis B virus coinfection
Yu-Shan Huang, Taiwan, Republic of China

PE37/27  Impact of direct-acting antiviral (DAA) agents on T cell counts and liver stiffness in HIV/HCV-coinfected patients: a multicenter prospective observational cohort study
David Dalmau, Spain

PE37/28  Trends of HCV infection among HCV-seronegative, HIV-positive patients in Taiwan between 2011-2018
Li-Hsin Su, Taiwan, Republic of China

PE37/29  The micro-elimination approach to eliminating Hepatitis C: a Fast Track City project
Franco Maggiolo, Italy

PE37/30  Road to HCV elimination in HV/HCV coinfected patients by screening and universal access to DAA: baseline data from the first screening of NoCo (No-Coinfection) study
Antonella d’Arminio Monforte, Italy

PE37/31  HCV cascade of care for HIV/HCV coinfected individuals in Greece and HCV treatment considerations in clinical practice
Mina Psychogiou, Greece

PE37/32  Hepatitis B core-related antigen and anti-hepatitis B core antibody are not associated with liver fibrosis evolution in HIV-HBV co-infected patients during treatment with tenofovir
Romuald Cruchet, France

PE37/33  Antiretroviral therapy: a possible role in lipid changes after HCV eradication by DAAs
Alessandra Vergori, Italy
Scientific Programme

PE37/34  Treatment of cirrhotic monoinfected and HCV/HIV coinfected patients with direct acting antivirals (DAAs)
Fábio Videira Santos, Portugal

PE37/35  Predictors of vaccine efficacy after hepatitis B vaccination in people with HIV infection
Gerardo Ibarra, Germany

PE37/36  Long term response to mandatory anti-HBV vaccination: risks for disease acquisition and opportunities for re-vaccination within the ICONA cohort
Roberto Rossotti, Italy

PE37/37  The assessment of HbsAg serum concentration during chronic hepatitis B phases' identification among HIV/HBV coinfected patients before antiviral therapy prescription
Tetiana Melnyk, Ukraine

PE37/38  Predictors of liver fibrosis improvement after HCV eradication in HIV+ patients: data from an Italian cohort
Alessandra Vergori, Italy

PE37/39  Long-term follow-up of people who use drugs (PWUD) following HCV infection therapy: drug use patterns among HIV co-infected versus mono-infected patients
Astou Thiam, Canada

PE37/40  Treatment outcome of HCV single vs multi tablet regimen in mono and HIV co-infected people who use drugs (PWUD): a long-term follow-up analysis
Astou Thiam, Canada

ePosters
09:00 - 18:00  Exhibition hall

Gender issues

PE10/1  Patient, clinical and virus genetic characteristics of migrants from Eastern, Central and Western Africa enrolled in the SHCS
Nadine Bachmann, Switzerland

PE10/2  Menopause impacts drug use and mental health in women with HIV in Switzerland
Anna Hachfeld, Switzerland

PE10/3  Gender-specific analysis of a German cohort of HIV-infected patients on Raltegravir-based therapy shows distinctive baseline co-morbidity profiles of women versus men but no impact on treatment outcomes
Karen Martin, Germany

PE10/4  Menopausal symptoms, sleep disorders and anxiety/depression among premenopausal and postmenopausal HIV-infected women: a multicenter cohort study in Spain
Ines Suarez, Spain

PE10/5  An evaluation of the care given to older women attending an HIV clinic in London
Claire Williams, United Kingdom

PE10/6  Anti-Mullerian hormone a plausible indicator of cardiometabolic risk in HIV-infected women
Umbelina Caixas, Portugal

PE10/7  Differences in sexual health among HIV infected and uninfected women of child-bearing age
Raffaella Marocco, Italy
### Scientific Programme

#### ePosters  09:00 - 18:00  
**Exhibition hall**

### Mother-to-child transmission

**PE21/1**  
**HIV infection in pregnant women and children in Switzerland: how effective are measures for preventing mother-to-child transmission?**  
Martin Gebhardt, Switzerland

**PE21/2**  
**No evidence for induced glucuronidation of dolutegravir in HIV-infected pregnant women**  
Vera Bukkems, Netherlands

**PE21/3**  
**Comparative analysis of clinic and laboratory parameters and frequency of mother-to-child transmission of HIV among HIV-positive pregnant women with marked immunodeficiency and normal immunological status**  
Olga Mozaleva, Russian Federation

**PE21/4**  
**Analysis of perinatal HIV transmission cases in St. Petersburg**  
Anna Samarina, Russian Federation

**PE21/5**  
**Geopolitical assessment and relevance for acceptance of vaginal delivery in good controlled HIV-infected pregnant women in Japan**  
Kimikazu Hayashi, Japan

**PE21/6**  
**Pregnancy outcomes in HIV-positive women: a retrospective national cohort study from the “Grigorios AIDS Clinic” in Cyprus**  
Georgios Siakallis, Cyprus

**PE21/7**  
**New-born infants from HIV positive women: five years experience of Infectious Diseases Hospital Iasi**  
Alexandra Largu, Romania

**PE21/8**  
**Risk factors for peripartum virological failure in South African pregnant women on anti-retroviral therapy: East London Prospective Cohort Study**  
Oladele Vincent Adeniyi, South Africa

---

### Paediatric, adolescent

**PE25/1**  
**Effect of cluster of differentiation (CD4) on viral respiratory infection in children, between 0-5 years of age. A study conducted in Kwazulu-Natal, South Africa**  
Temitayo Famoroti, South Africa

**PE25/2**  
**Adolescent HIV and asymptomatic malaria parasitemia (AMP) co-infection**  
David Segun Adeniyi, Nigeria

**PE25/3**  
**Clinical features of viral diarrhea in the children of HIV**  
Marufjon Salokhiddinov, Uzbekistan

**PE25/4**  
**High rate of rubella seronegativity in perinatally-infected HIV women of childbearing age: a case-control study**  
Nicolas Dauby, Belgium
**Health outcomes in adolescents and young adults living with HIV before and after transition to adult care in Barcelona**
By Josep Ferrer Arbaizar, Spain

**Correction of lipid abnormality by integrase inhibitor among children taking ART**
By Anna Samarina, Russian Federation

**Increasing contribution of sexually-transmitted HIV diagnoses in adolescents in Spain**
By Enrique Bernal, Spain

**Factors associated to late presentation of HIV newly diagnosed adolescents in Spain**
By Enrique Bernal, Spain

**Comparison of antiretroviral treatment initiation in HIV newly diagnosed adolescents in Spain**
By Melchor Riera Jaume, Spain

**Oral self-testing for adolescents and young adults absent or declining to test during home-based HIV testing - a mixed-method study embedded in a cluster-randomized trial in Lesotho (ADORE study)**
By Alain Amstutz, Switzerland

**Preterm births in women living with HIV in Switzerland: a 13-year evaluation**
By Christian R Kahlert, Switzerland

**Poor clinical outcomes in HIV-infected children who start antiretroviral therapy at an older age**
By Kevin P. McKenzie, United States

**Prevalence and predictors of unintended pregnancies among HIV positive young adults (14-24 years) attending an urban HIV clinic in Uganda**
By Mackline Hope, Uganda

**Microbiota composition in a cohort of underweight HIV-positive children aged 24-72 months in Cape Town, South Africa**
By Margaret Van Niekerk, South Africa

**Influence of maternal parameters on birth outcome in HIV-exposed newborns - 11 year observation**
By Karolina Nowicka, Poland

---

**Self-reported non-receipt of HIV test results: a silent barrier to HIV epidemic control in Mozambique**
By Didier Mugabe, Mozambique

**Improvement in ART initiation in different regions of Ukraine from 2010 to 2014**
By Tetiana Salyuk, Ukraine

**The HIV treatment cascade in Azerbaijan, 2018**
By Natig Zulfugarov, Azerbaijan
### Scientific Programme

<table>
<thead>
<tr>
<th>PE6/4</th>
<th>Seven years of European Testing Week: impact of a regional awareness campaign on increase in awareness and testing activities in Europe</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Lauren Combs, Denmark</td>
</tr>
<tr>
<td>PE6/5</td>
<td>Impact of integrated family planning and HIV services on early postpartum contraceptive use among women with HIV in the Eastern Cape, South Africa</td>
</tr>
<tr>
<td></td>
<td>Oladele Vincent Adeniyi, South Africa</td>
</tr>
<tr>
<td>PE6/6</td>
<td>The first report of Prevention of Mother-to-Child Transmission (PMTCT) of HIV in Islamic Republic of Iran</td>
</tr>
<tr>
<td></td>
<td>Ebrahim Ghaderi, Iran, Islamic Republic of</td>
</tr>
<tr>
<td>PE6/7</td>
<td>New HIV diagnosis and linkage to care in two outpatient units in South Europe</td>
</tr>
<tr>
<td></td>
<td>Alessio Pampaloni, Italy</td>
</tr>
<tr>
<td>PE6/8</td>
<td>The HIV- and HCV-cascade in Swiss opioid agonist treatment (OAT) patients - the SAMMSU-cohort</td>
</tr>
<tr>
<td></td>
<td>Andrea Bregenzer, Switzerland</td>
</tr>
<tr>
<td>PE6/9</td>
<td>Increased Integrated testing for HIV and HCV in health care facilities: examples from the INTEGRATE activities in Lithuania and Romania</td>
</tr>
<tr>
<td></td>
<td>Raimonda Matulionyte, Lithuania</td>
</tr>
<tr>
<td>PE6/10</td>
<td>AIDS and late presentation follows testing gaps in Poland - data from Test and Keep in care (TAK) Polska project</td>
</tr>
<tr>
<td></td>
<td>Justyna Kowalska, Poland</td>
</tr>
<tr>
<td>PE6/11</td>
<td>Loss to follow-up and re-linkage to care in a single cohort study: who do we re-link to care?</td>
</tr>
<tr>
<td></td>
<td>Laura Magnasco, Italy</td>
</tr>
<tr>
<td>PE6/12</td>
<td>Expanding access to HIV tests in 13 cities in Indonesia: an interrupted time series investigating effect of HIV policy intervention using six years population data</td>
</tr>
<tr>
<td></td>
<td>Yane Tarigan, Australia</td>
</tr>
<tr>
<td>PE6/13</td>
<td>Link HIV-infected injection drug users after the imprisonment to continuum of HIV care program in Taiwan</td>
</tr>
<tr>
<td></td>
<td>Wei-Wei Wu, Taiwan, Republic of China</td>
</tr>
<tr>
<td>PE6/14</td>
<td>HIV continuum of care by sex and mode of transmission in Spain, 2016: use of different sources of information</td>
</tr>
<tr>
<td></td>
<td>Victoria Hernando, Spain</td>
</tr>
<tr>
<td>PE6/15</td>
<td>Temporal trends in time from HIV diagnosis to viral load suppression in CoRIS</td>
</tr>
<tr>
<td></td>
<td>Belén Alejos, Spain</td>
</tr>
<tr>
<td>PE6/16</td>
<td>Navigation of HIV positive clients. Reasons of gaps in HIV cascade among PWID</td>
</tr>
<tr>
<td></td>
<td>Oksana Pashchuk, Ukraine</td>
</tr>
<tr>
<td>PE6/17</td>
<td>Tracing the patterns of HIV-1 transmission among individuals with different time to diagnosis in Greece</td>
</tr>
<tr>
<td></td>
<td>Evangelia-Georgia Kostaki, Greece</td>
</tr>
<tr>
<td>PE6/18</td>
<td>Late diagnosis and delayed presentation in Korean HIV/AIDS cohort</td>
</tr>
<tr>
<td></td>
<td>Shin Woo Kim, Korea, Republic of</td>
</tr>
<tr>
<td>PE6/19</td>
<td>Interruption of HIV care: understanding the predictors and outcomes in the Belgian national HIV cohort</td>
</tr>
<tr>
<td></td>
<td>Dominique Van Beckhoven, Belgium</td>
</tr>
</tbody>
</table>
The HIV continuum of care: current situation and advances. A systematic review  
Georgia Vourli, Greece

The contribution of a partnership with a civil society organization (SCO) to early HIV diagnosis and UNAIDS goals  
Antonio Diniz, Portugal

HIV cascade of care in Turkey: data from the HIV-TR cohort  
Deniz Gökengin, Turkey

Cascade analysis of anonymous voluntary HIV counseling and testing among HIV-infected patients in Taiwan  
Chun-Yuan Lee, Taiwan, Republic of China

Late presentation of HIV in Armenia  
Trdat Grigoryan, Armenia

Oral self-testing for individuals absent or refusing testing during home-based HIV testing - a cluster-randomized trial in Lesotho (HOSENG trial)  
Tracy R Glass, Switzerland

Acceptability of rapid tests for migrants during the medical consultation at the migration point  
Martin Duracinsky, France

Evaluation of the “test and treat” strategy in an high-income setting: data from a multicenter Italian cohort  
Gianmaria Baldin, Italy

Pill box return as a predictor of treatment outcome to antiretroviral therapy in PLHIV: a prospective cohort study  
Robert Ndege, Tanzania, United Republic of

Potentially missed opportunity to diagnose HIV with standard testing algorithm among adult patients with ongoing mononucleosis-like illness  
Anna Vassilenko, Belarus

HIV Continuum of Care Cascade in Cluj County, Romania. Comparative situation of the years 2016, 2017, 2018  
Adriana Topan, Romania

People living with HIV lost to follow up in the Paris region area and actions carried out by HIV care centers  
Nicolas Vignier, France

Far from 90-90-90 goals in Latin America  
Maria Greco, Argentina

Barriers to involving patients in ART as a challenge to the national health system in Ukraine  
Serhii Riabokon, Ukraine

Index testing and intensified case finding for efficiency in HIV testing in Rwanda  
Eric Remera, Switzerland
**Morbidity/mortality in the era of cART**

**PE20/1**  
The association of rare HLA alleles with clinical disease progression in HIV-positive cohorts with varied treatment strategies  
Christina Ekenberg, Denmark

**PE20/2**  
Neutrophil-to-lymphocyte ratio compared to CD4+:CD8+ T-cell ratio as a predictor of non-AIDS events in treated people living with HIV  
Nick Power, Ireland

**PE20/3**  
Factors associated with virologic failure in women with HIV: Condesa specialized clinics, Mexico City  
Teresita De Jesús Cabrera Lòpez, Mexico

**PE20/4**  
Causes of death among a cohort of HIV-infected adults in rural Tanzania  
Fiona Vanobberghen, Switzerland

**PE20/5**  
Predictors of early mortality among adult HIV-infected patients on antiretroviral therapy in a Kenyan pastoralist community: a retrospective cohort study  
Paul Yonga, Kenya

**PE20/6**  
Trends in underlying causes of death in HIV-infected patients from 2016 to 2018 in Ukraine: a cohort study  
Tetiana Kyrychenko, Ukraine

**PE20/7**  
Dynamic of CD4+/CD8+ ratio in late presenters: impact on clinical outcomes  
Marta Rava, Spain

**PE20/8**  
Retrospective investigation into the causes of death in HIV-infected patients from Bonn in the era of combined Anti-Retroviral Therapy  
Lukas Knieps, Germany

**PE20/9**  
Reduced utility of early procalcitonin in HIV febrile patients admitted to the emergency department  
Chiara Picarelli, Italy

**PE20/10**  
Patients with HIV and HCV in intensive care treatment: admission criteria and trends in the intensive care unit (ICU) at the University Hospital of Bonn 2014-2019  
Stefan Schlabe, Germany

**PE20/11**  
Burden of disease in PLWH harboring a 4-class drug resistant virus: data from PRESTIGIO Registry  
Maria Rita Parisi, Italy

**PE20/12**  
Changing pattern of hospital admissions due to medical conditions in HIV-infected subjects in a European public health care system with free access to antiretroviral treatment  
Joan Raga Almudéver, Spain

**PE20/13**  
Association of non-adherence to antiretroviral therapy with cardiovascular outcomes in virologically suppressed persons living with HIV: the Swiss HIV Cohort Study  
Tracy R Glass, Switzerland

**PE20/14**  
Differences in social and mental well-being of long-term survivors among people who inject drugs and other participants in the Swiss HIV Cohort Study: 1980 - 201  
Katharina Kusejko, Switzerland
Scientific Programme

PE20/15  Low pre-ART CD4 count is associated with increased risk of clinical progression or death even after reaching 500 CD4 cells/µL on ART  
Nikos Pantazis, Greece

PE20/16  A comparative analysis on blood pressure in HIV-infected individuals versus uninfected controls residing in Sub-Saharan Africa: a narrative review  
Edith Phalane, South Africa

PE20/17  Causes of death in AIDS/HIV-infected patients at the hospital of infectious diseases in St. Petersburg, Russia  
Olga Sokolova, Russian Federation

PE20/18  Dynamics and structure of mortality of HIV-positive people in Ukraine  
Natalia Bugaienko, Ukraine

ePosters  
09:00 - 18:00  
Exhibition hall

Prevalence, incidence and dynamics of HIV epidemics

PE29/1  Monitoring rates and accessibility of HIV and STI’s testing, HAV and HBV vaccination among men who have sex with men in Slovenia  
Miran Solinc, Slovenia

PE29/2  Data triangulation to re-shape interventions to improve the HIV response: comparng data from estimates, case reporting, and sentinel surveillance in Ukraine  
Tetiana Salyuk, Ukraine

PE29/3  The impact of frequent cannabis use on injection drug use patterns among people who use drugs in a Canadian setting  
Hudson Reddon, Canada

PE29/4  Predicting early loss to follow-up on ART: a retrospective review of clients’ retention on ART in North-western Nigeria  
Johnson Okolie, Nigeria

PE29/5  The increasing number of late HIV diagnosis among men having sex with men and transgender women in a key population-led HIV testing and treatment facility and its societal implication in the Philippines  
Patrick Eustaquio, Philippines

PE29/6  HIV transmission network in a cohort of subjects with primary infection in a single clinical center in Rome  
Lavinia Fabeni, Italy

PE29/7  Evaluation of a multiassay approach for determination recent HIV infection in the Russian Federation  
Anastasia Murzakova, Russian Federation

PE29/8  Ongoing spread of HIV subtype A in Tel Aviv, Israel  
Dan Turner, Israel

PE29/9  Simple clinical and laboratory based score may identify HIV infection recency and subsidize HIV surveillance in low and middle-income countries (LMIC), Santo André/Brazil experience  
Elaine Monteiro Matsuda, Brazil
Scientific Programme

PE29/10  Clinical, epidemiological & virological features of primary HIV-1 infection in an HIV reference center in Brussels: a ten years' review
Arthur Poncelet, Belgium

PE29/11  Current trends in HIV genetic diversity in Russia: increase of the unique recombinants prevalence
Anastasilia Antonova, Russian Federation

PE29/12  Analysis of risk factors in HIV/AIDS patients
Esra Zerdali, Turkey

PE29/13  Tracing the first HIV-1 epidemics in the Milan area
Alessia Lai, Italy

PE29/14  Analysis of the local HIV-1 epidemic in Vologda region, Russia: predominance of CRF03_AB and rapid expansion of URFs
Ekaterina Ozhmegova, Russian Federation

PE29/15  Identification of first near full length recombinant genome of HIV-1 in Korea
Mee-Kyung Kee, Korea, Republic of

PE29/16  Characteristics of HIV infection among children in Georgia, 1989-2018
Natela Chokoshvili, Georgia

PE29/17  HIV infection in older patients
Barbara Belfiori, Italy

PE29/18  Seroincidence of the human herpesvirus 8 (HHV 8) infection among HIV-positive patients in Taiwan, 2016-2019
Yi-Ching Su, Taiwan, Republic of China

PE29/19  Risk factors for late presentation for HIV care in 2019 in Ukraine
Maryna Sukach, Ukraine

PE29/20  Incidence of hepatitis C virus infection among people living with HIV( PLHIV ): an Egyptian Cohort Study
Rahma Mohamed, Egypt

PE29/21  High HIV prevalence following screening of subjects with HIV indicator conditions in a hospital setting
Camilla Tincati, Italy

PE29/22  First decrease in new HIV diagnoses in 2018 among men who have sex with men (MSM), in the East PACA (Provence Alpes Côte-d’Azur) area in France
Philippe Bouvet de la Maisonneuve, France

PE29/23  The collision of public health interventions on HIV-1 spread in Albania by molecular epidemiology
Shkurti Enkelejda, Albania

PE29/24  Two decades of HIV infection late diagnosis: the experience of a Portuguese Hospital
Sofia Jordão, Portugal

PE29/25  Characterization of HIV patients followed in a specialist consultation at a tertiary and universitary centre
Fábio Videira Santos, Portugal
Scientific Programme

PE29/26  Trends in epidemiology and clinical picture of late presentation among patients of the Hospital for Infectious Diseases in Warsaw
Joanna Pula, Poland

PE29/27  An evolutionary insight into a growing HIV subtype A epidemic in Serbia
Marina Siljic, Serbia

PE29/28  Change of prevalence, diseases distribution and factors associated with the risk of AIDS presentation in Italy over last decade (2009-2018)
Andrea Antinori, Italy

PE29/29  The effect of gender on late diagnosis of HIV infection in a high incidence European population
Rita Filipe, Portugal

PE29/30  Two decades surveillance of HIV-1 transmitted drug resistance in Serbia
Valentina Cirkovic, Serbia

PE29/31  3M-BRIHT - Manchester Cohort. Investigation of the feasibility and acceptability of rapid HIV testing in a European Emergency Department setting
Molly M. O’Kane, Ireland

PE29/32  HIV-1 A6 subtype: its challenging identification and Southern Russian molecular epidemiology
Saleta Sierra, Germany

PE29/33  Neurodevelopmental assessments to screen for HIV encephalopathy in newly diagnosed infants not on ART in Mozambique
Jyodi Mohole, United States

ePosters
09:00 - 18:00  Exhibition hall

Prevention of horizontal transmission, cART as prevention

PE30/1  Tolerability and treatment completion of tenofovir alafenamide/emtricitabine/rilpivirine (TAF/FTC/RPV) as HIV postexposure prophylaxis
Marie Chauveau, France

ePosters
09:00 - 18:00  Exhibition hall

Standard of care

PE31/1  Exploring the attitudes of HIV-positive patients on single-tablet antiretroviral regimens towards generic de-simplification
Ciara Levey, Ireland

PE31/2  Comparison of Immunological and virological response to cART between HIV-1/O and HIV-1/M patients followed-up in France: the ANRS ORIVAO and COPANA studies
Guillemette Unal, France

PE31/3  From HIV diagnosis to antiretroviral therapy initiation in Croatia from 2013 to 2018
Nikolina Bogdanić, Croatia
Scientific Programme

**PE31/5** Tetanus seroprotection in HIV-positive subjects living in Belgium: risk factors for seronegativity, evaluation of medical history and a rapid dipstick test
Nicolas Dauby, Belgium

**PE31/6** The prevalence of virologic failure and resistance associated mutations in single and multi-tablet HIV treatment regimens
Chien-Yu Cheng, Taiwan, Republic of China

**PE31/7** Development and validation of a risk score for predicting non-adherence to antiretroviral therapy
Hernando Knobel, Spain

**PE31/8** Measles seroprevalence among HIV infected patients in central part of Poland - vaccination proposal
Ewa Siwak, Poland

**PE31/9** Nurse-led annual health review - one year follow up
Marie-Pierre Klein, United Kingdom

**PE31/11** Viral hepatitis in HIV-positive patients - testing, prophylaxis and treatment in Central and Eastern Europe
Kerstin Kase, Estonia

**PE31/12** Evaluating a national pilot process for reviewing late HIV diagnoses in England and Wales
Ming Jie Lee, United Kingdom

**PE31/13** GESIDA quality of care indicators for PLWH: report from two Spanish hospitals 2009-2017
Francisco Fanjul, Spain

**PE31/14** Late presentation and barriers to the early HIV diagnosis in Central part of Ukraine
Tetiana Koval, Ukraine

**PE31/15** Operational research of barriers and facilitators to harm reduction services for intravenous drug users (including female IDUs)
Tamar Zurashvili, Georgia

**PE31/16** A seven-month prospective review of HIV admissions to a regional infectious disease unit in Manchester, UK
Hamzah Zahid Farooq, United Kingdom

**PE31/17** Annual health review for people living with HIV - an evaluation
Sarah Edwards, United Kingdom

**PE31/18** Analysis of adherence to HIV-positive quality of care indicators and their impact of service quality perceptions in patient: a Spanish cross-sectional study
Alejandra Gimeno García, Spain

**ePosters**
09:00 - 18:00
Exhibition hall

**Behavioural interventions**

**PE5/1** Close group social media network and social gatherings for comprehensive HIV services among adolescent MSM in Lagos Nigeria
Orobosa Enadeghe, Nigeria
Scientific Programme

PE5/2  Good hygiene practices post circumcision: a case for low adverse events in VMMC  
Timothy Kipkosgei, Kenya

PE5/3  Challenges of implementing HIV counselling and testing (HCT) campaigns for higher education distance learning students at University of South Africa  
Nkay Pascal Kiabilua, South Africa

PE5/4  Enhancing effective HIV prevention among girls by fighting child marriage and sexual and gender based violence in Karonga district, Malawi  
Shora Manuel Kauluka, Malawi

PE5/5  Effectiveness of rapid HIV and HCV testing programmes based on mobile units  
Ekaterina Zinger, Russian Federation

PE5/6  It can`t happen to me - tackling cognitive mistakes and HIV using a national campaign  
Arian Diskovic, Croatia

PE5/7  Is mobility still a HIV/STI associated vulnerable factor in the changing sex work dynamics among female sex workers in India? - Emerging evidence  
Priyanka Dixit, India

PE5/8  “Amare con Sapienza”: an Italian digital ambient media prevention campaign in one of the largest European University to increase U=U, PreP, TasP knowledge  
Serena Vita, Italy

PE5/9  Assessing high risky sexual behaviors in vulnerable women in northern Uganda: baseline results of “Pe Atye Kena, no longer alone” study  
Antonella Cingolani, Italy

PE5/10  HIV/AIDS educational program for secondary school female students in Iran: a school-based randomized controlled trial  
Farid Yousefi, Iran, Islamic Republic of

ePosters  
09:00 - 18:00  
Exhibition hall

Clinical trials of vaccines

PE8/1  Seroprevalence of vaccine preventable viral diseases and vaccine response among HIV positive patients  
Fatma Sebnem Erdinc, Turkey

PE8/2  Could we recommend the current herpes zoster vaccine for patients living with HIV (PLHIV)?  
Thomas Huleux, France

ePosters  
09:00 - 18:00  
Exhibition hall

PrEP

PE28/1  Establishment of the service system of HIV pre-exposure prophylaxis/post exposure prophylaxis (PrEP/PEP) in a certain area of Southern Taiwan  
Kuei Ying Wang, Taiwan, Republic of China
Systematic review of post-migration HIV acquisition within Europe: the case for PrEP interventions for migrants
Simran Mann, United Kingdom

Self-reported STI history and associated factors among German PrEP users
Uwe Koppe, Germany

PrEP implementation among MSM in Ukraine: results of pilot project in Kyiv
Roman Marchenko, Ukraine

Emergency post-exposure prophylaxis (PEP) seeking behaviors among men who have sex with men (MSM) with recent HIV risk exposure in Thailand
Tarandeep Anand, Thailand

The back side: Lymphogranuloma venereum in PrEP-users and PLWH
Sven Schellberg, Germany

Awareness and interest in pre-exposure prophylaxis (PrEP) among MSM population in Serbia
Vanja Subotic, Serbia

PrEP reimbursement and access in Europe: 2019 update
Krzysztof Tronczyński, Poland

Users’ perspective of an ideal service model for delivering pre-exposure prophylaxis (PrEP) to men who have sex with men
Shui Shan Lee, Hong Kong

Assessment of the trough concentrations of tenofovir in HIV-negative subjects on pre-exposure prophylaxis: a single center, real-life experience
Dario Cattaneo, Italy

No new HIV infections, but high incidence of syphilis among Pre-exposure Prophylaxis (PrEP) users in Georgia
Ekaterine Karkashadze, Georgia

Feasibility and acceptability of an oral pre-exposure prophylaxis (PrEP) program against HIV targeting female sex workers in Belgium
Florence Deneumoustier, Belgium

First results after 52 weeks of informal PrEP use in a cohort of MSM in Southern Spain
Alejandro Berto Moran, Spain

Clinical outcomes of pre-exposure prophylaxis from clinical center in Warsaw, Poland
Iwona Cielniak, Poland

Where are we with PrEP use in Central and Eastern Europe? - data from the ECEE Network Group
Josip Begovac, Croatia

Sexual risk and HIV preventative behaviours among men who have sex in men in London in the era of HIV pre-exposure prophylaxis, 2019
Fiona Burns, United Kingdom

Chemsex and mood disorders under HIV pre-exposure prophylaxis
Helene Peyriere, France
Scientific Programme

PE28/18  
**Pre-exposure prophylaxis one year after implementation in Portugal - the reality of a central hospital**
Diogo Guerra, Portugal

PE28/19  
**DISCOVER in Europe: a sub-analysis of the phase 3 randomized, controlled trial of daily emtricitabine/tenofovir alafenamide (F/TAF) or emtricitabine/tenofovir disoproxil fumarate (F/TDF) for HIV pre-exposure prophylaxis (PrEP)**
Frank Post, United States

PE28/20  
**The Good and Bad of PrEP: a 14 month follow up on awareness, adherence, efficacy and sexually transmitted diseases at Hospital de Curry Cabral**
Marta Leal dos Santos, Portugal

PE28/21  
**PrEP for life: new challenges and barriers in PrEP uptake among men who have sex with men (MSM) and transgender people (TG) in Kyiv, Ukraine**
Dzmitry Filippau, Ukraine

PE28/22  
**Analysis of the need for pre-exposure prophylaxis of HIV among people that have high risk to be infected**
Vitaliy Andres, Ukraine

PE28/23  
**Lesson learnt from a combined HIV prevention using HIV self-testing and oral pre-exposure prophylaxis (PrEP) demonstration project in the United Republic of Tanzania**
Neema Makyao, Tanzania, United Republic of

ePosters  
09:00 - 18:00  
Exhibition hall

Treatment as prevention

PE33/1  
**HIV-1 viral load quantification using Aptima HIV-1 Quant Dx assay in Kenya: a diagnostic accuracy study**
Geoffrey Kangogo, Kenya

PE33/3  
**Rapid ART start in primary HIV infection: time to viral suppression in a London cohort**
Nico Girometti, United Kingdom

PE33/4  
**Reality check: HIV post-exposure prophylaxis (PEP) in real-life at a tertiary care centre prior to the PrEP era**
Lina Thewes, Germany

Access to and models of care

PE1/1  
**Barriers in TB services for people living with HIV and overcoming them according to the health care workers opinion in the TB facilities in Russia (sociological study)**
Zinaida Zagdyn, Russian Federation

PE1/2  
**Investigating the impact of peer counseling intervention on access and use of sexual and reproductive health services in women Living with HIV in Nepal: a prospective cohort study**
Khem Pokhrel, Nepal
Health care delivery for HIV-positive people with tuberculosis in Europe
Adrian Bentzon, Denmark

A survey of physicians on circumstances and factors influencing testing for HIV in Lithuania
Raimonda Matulionyte, Lithuania

Experiences of forgiveness and unforgiveness of HIV-specific offenses among people living with HIV/AIDS in Ghana
Judith A. Osae-Larbi, Ghana

Time to antiretroviral therapy: service model adaptation during an outbreak of HIV in people who inject drugs (PWIDs)
Harrison Stubbs, United Kingdom

HIV infection hospital-based active case finding in Sardinia, Italy: results from the SHOT project
Maria Sabrina Mameli, Italy

Retention activities based on home visits as a tool of return and keeping in care of low adhered patients. Results of work 2016-2019 Krasnoyarsk AIDS clinic
Konstantin Kandlen, Russian Federation

Pilot project of shared assistance with primary care for patients with HIV infection
Adrián Ferre, Spain

Sexual behaviors and seroprevalence of HIV, HBV, and HCV among hill tribe youths of Northern Thailand
Tawatchai Apidechkul, Thailand

The blind spot: high HIV burden among slum-dwelling school-age girls in Kampala, Uganda
Jude Thaddeus Ssensamba, Uganda

Research of behavioral models of transgender people leading to high rates of HIV prevalence in Ukraine
Igor Medvid, Ukraine

Outreach services for HIV testing and prevention among female transgender commercial sex workers in Milan: different approaches for different populations?
Giuseppe Lapadula, Italy

The impact of unstable housing on HIV treatment outcomes in people living with HIV/AIDS in an urban setting of Southern Europe
Hernando Knobel, Spain

Reflection of sex work criminalization in court judgements targeting to protect health, sanitary and epidemiological well-being
Marina Avramenko, Russian Federation

Caring for the Transgender HIV-positive patient
Chiara Picarelli, Italy

ePosters
09:00 - 18:00 Exhibition hall

HIV and marginalised groups

Sexual behaviors and seroprevalence of HIV, HBV, and HCV among hill tribe youths of Northern Thailand
Tawatchai Apidechkul, Thailand

The blind spot: high HIV burden among slum-dwelling school-age girls in Kampala, Uganda
Jude Thaddeus Ssensamba, Uganda

Research of behavioral models of transgender people leading to high rates of HIV prevalence in Ukraine
Igor Medvid, Ukraine

Outreach services for HIV testing and prevention among female transgender commercial sex workers in Milan: different approaches for different populations?
Giuseppe Lapadula, Italy

The impact of unstable housing on HIV treatment outcomes in people living with HIV/AIDS in an urban setting of Southern Europe
Hernando Knobel, Spain

Reflection of sex work criminalization in court judgements targeting to protect health, sanitary and epidemiological well-being
Marina Avramenko, Russian Federation

Caring for the Transgender HIV-positive patient
Chiara Picarelli, Italy
Scientific Programme

**PE11/9**  
Association of current Estradiol use with carotid intimal media thickness among transgender women: a cross-sectional study  
Rodrigo Moreira, Brazil

**PE11/10**  
HIV and migrants: a demographic and clinical characterization of migrants under follow up at an Infectious Diseases Department in Lisbon, Portugal  
Marta Leal dos Santos, Portugal

---

**ePosters**  
09:00 - 18:00  
Exhibition hall

**Novel consultations, remote care - telemedicine, mobile applications**

**PE23/1**  
Harnessing mobile technology for health worker capacity building to improve quality of care in resource-constrained settings  
Walter Joseph Arinaitwe, Uganda

**PE23/2**  
Feasibility, uptake and acceptability of the EmERGE mHealth app in individuals living with stable HIV in five European countries  
Jenny Whetham, United Kingdom

**PE23/3**  
Attracting people who use drugs to HIV prevention and care programs via darknet and messengers: evidence from St. Petersburg, Russia  
Aleksey Lakhov, Russian Federation

**PE23/4**  
People living with HIV (PLHIV) and their doctors: adopters and sceptics, and those opened to e-health  
Christine Jacomet, France

**PE23/5**  
Fitness tracking wearable devices and a dedicated smart phone app (MySAwH App) to predict quality of life in PLWH: a multi-centre prospective study  
Giovanni Guaraldi, Italy

**PE23/6**  
The efficiency of introducing the EmERGE Pathway of care for stable Croatian PLHIV  
Eduard J. Beck, United Kingdom

**PE23/7**  
‘The 4th 90’: a preliminary assessment of change in quality of life over 1 year of the EmERGE study: PROQOL-HIV and EQ-5D-5L, a descriptive analysis  
Christopher Jones, United Kingdom

**PE23/8**  
Measuring empowerment in EmERGE mHealth platform users: a descriptive analysis of interim data  
Stephen Bremner, United Kingdom

---

**Social and behavioural science**

**PE30/2**  
Priorities for behavioral interventions in a group of long term PLWHA - the experience of the Baylor Clinical Centre of Excellence in Constanta, Romania  
Ana-Maria Schweitzer, Romania
PE30/3  Will HIV-infected patients taking oral ARV switch to long-acting injectable ART when it become available?  
Marie-Aude Khuong-Josses, France

PE30/4  Time perspectives as predictors of depression and suicidal ideation amongst adolescents and young adults with HIV: the moderating role of resilience  
Oluwapelumi Ashamu, Nigeria

PE30/5  Social support and quality of life of people living with AIDS receiving ART at BPKIHS  
Ram Sharan Mehta, Nepal

PE30/7  Knowledge, attitudes, beliefs and HIV-related behaviour in metropolitan France: investigation in a festive place  
Fernanda Medina, France

PE30/9  Injectable long acting antiretrovirals for HIV treatment or prevention: the ANRS CLAPT study  
Laurence Slama, France

PE30/10  Quality of life in people living with HIV: a regional survey in Flanders  
Gert Scheerder, Belgium

PE30/11  Innovative strategies to sustain community participation in HIV vaccine trials, experience of Makerere University Walter Reed Project (MUWRP) in Kampala, Uganda  
Jauhara Nanyondo, Uganda

PE30/12  Stigma among healthcare providers towards people living with HIV/AIDS in India  
Akanksha Rathi, India

PE30/13  “I love my life, I don’t want to miss a thing”: motivators and Barriers to ART adherence among women living with HIV/AIDS in Iran  
Nooshin Amirisani, Iran, Islamic Republic of

PE30/14  Medical students as potential sources of information about HIV/AIDS  
Mykola Haras, Ukraine

PE30/15  Gender violence, intimate partner violence and domestic violence among HIV-positive patients in Alicante (Spain). Preliminary results of the VIHOLETA study  
Jara Llenas-García, Spain

PE30/16  Influence of stigma and discrimination on psychosocial health in children affected by AIDS in Nepal: a cross-sectional study  
Kalpana Gaulee Pokhrel, Nepal

PE30/17  The quality of life among people living with HIV in Taiwan in the era of STR  
Chung-Ching Shih, Taiwan, Republic of China

PE30/18  Experiences of and factors influencing physical activity in people living with HIV: a qualitative systematic review  
Megan Davies, United Kingdom

PE30/20  Perception of condom use in the era of pre-exposure prophylaxis (PrEP): a qualitative analysis  
Shui Shan Lee, Hong Kong

PE30/21  Recommendations for enabling timely pregnancy disclosure to clinical staff of women living with HIV  
Stefania Mihale, Romania
Scientific Programme

PE30/22  Health-related quality of life in a single center cohort of people living with chronic diseases: comparison between HIV and other clinical conditions  
Antonella Cingolani, Italy

PE30/23  Experiences of Dutch obstetric healthcare providers with HIV-positive pregnant women: a qualitative study  
Carlijn Damsté, Netherlands

PE30/24  Evaluation of knowledge, attitudes and practices among HIV positive pregnant women and their partners in four healthcare facilities in Malawi  
Isotta Triulzi, Italy

PE30/25  Towards the 4th 90, measuring multi-dimensional quality of life in people living with HIV in Aquitaine, France: psychometric properties of the French version of the WHOQOL-HIV BREF  
Diana Barger, France

PE30/26  Body size modifies the relationship between internalized HIV stigma and pain in people with HIV in the Southeastern USA  
Kaylee Crockett, United States

Treatment in resource-constrained settings

PE34/2  Optimizing clients linkage into ART using family-centered differentiated approach (FCDA) in Kebbi state, northwestern Nigeria: successes and challenges  
Johnson Okolie, Nigeria

PE34/3  A multi-stakeholder evaluation of the early implementation experiences of differentiated anti-retroviral therapy (ART) delivery roll-out across Uganda: a qualitative analysis  
Henry Zakumumpa, Uganda

PE34/5  Evaluation of the financial cost of treating people living with human immunodeficiency virus in the United Kingdom versus matched HIV-negative controls in 2004, 2010 and 2017  
Scott Francis, United Kingdom

PE34/6  Continuous quality improvement across the viral load testing spectrum at the Infectious Diseases Institute, Uganda  
Harriet Tibakabikoba, Uganda

PE34/7  Pediatric HIV viral load suppression: qualitative insights of barriers and facilitators among caregivers of children on ART in high volume sites in Kisumu County, Kenya  
Nicollate Okoko, Kenya

PE34/8  Boosting economic affordability of HIV medicines while considering safety and effectiveness within transition from donor funding. Enabling access to TAF regime with better safety profile in Ukraine through advocacy campaign of community organization  
Zoia Zamikhovska, Ukraine

Vulnerable groups
### Scientific Programme

<table>
<thead>
<tr>
<th>PE39/1</th>
<th>Boys having sex with boys: CD4 count as parameter to estimate the time of infection among HIV seropositive men having sex with men and its societal implications in the Philippines</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Patrick Eustaquio, Philippines</td>
</tr>
<tr>
<td>PE39/2</td>
<td>Evaluating factors increasing the vulnerability of adolescent girls and young women to HIV/AIDS infection in selected communities, Akwa Ibom State</td>
</tr>
<tr>
<td></td>
<td>Jessie Inyang, Nigeria</td>
</tr>
<tr>
<td>PE39/3</td>
<td>Men’s perspectives on HIV self-testing in sub-Saharan Africa: a systematic review and meta-synthesis</td>
</tr>
<tr>
<td></td>
<td>Mbuzeleni Hlongwa, South Africa</td>
</tr>
<tr>
<td>PE39/4</td>
<td>Molecular-biological methods of diagnostics in the investigation of the case of transmission of HIV-infection</td>
</tr>
<tr>
<td></td>
<td>Diana Valutite, Russian Federation</td>
</tr>
<tr>
<td>PE39/5</td>
<td>Implementation of demedicalized and decentralized HIV testing project in Brussels: action test, project for vulnerable populations at high HIV risk in Brussels, including Subsaharan African Migrants (SAM)</td>
</tr>
<tr>
<td></td>
<td>Tresors Kouadio, Belgium</td>
</tr>
<tr>
<td>PE39/6</td>
<td>HIV prevalence, risk-taking behavior and self-testing potential among men who have sex with men and transgender people</td>
</tr>
<tr>
<td></td>
<td>Evgeniy Pisemskiy, Russian Federation</td>
</tr>
<tr>
<td>PE39/7</td>
<td>Political commitment matters in the elimination of the threat of HIV and HCV and TB among people who use drugs</td>
</tr>
<tr>
<td></td>
<td>Gefra Fulane, Portugal</td>
</tr>
<tr>
<td>PE39/8</td>
<td>Challenges in health and social care for migrant HIV patients in the Czech Republic</td>
</tr>
<tr>
<td></td>
<td>Elena Tulupova, Czech Republic</td>
</tr>
<tr>
<td>PE39/9</td>
<td>Integration of hepatitis C cure in housing facility Soleil Evant: health cost implications</td>
</tr>
<tr>
<td></td>
<td>Erika Castro, Switzerland</td>
</tr>
<tr>
<td>PE39/10</td>
<td>The role of sexual partners of people who inject drugs in better uptake of retention in HIV services</td>
</tr>
<tr>
<td></td>
<td>Marine Gogia, Georgia</td>
</tr>
<tr>
<td>PE39/11</td>
<td>Male sex workers and ICT: anthropological approach of male sex workers and the different practices online: bareback, PrEP and chemsex</td>
</tr>
<tr>
<td></td>
<td>Maxime Maes, Belgium</td>
</tr>
<tr>
<td>PE39/12</td>
<td>Portuguese League Against AIDS - mobile screening unit</td>
</tr>
<tr>
<td></td>
<td>Maria Eugénia Saraiva, Portugal</td>
</tr>
<tr>
<td>PE39/13</td>
<td>Detectable viraemia in the era of successful antiretroviral therapy; engagement with multidisciplinary services</td>
</tr>
<tr>
<td></td>
<td>Shimu Khamlichi, United Kingdom</td>
</tr>
<tr>
<td>PE39/14</td>
<td>Optimal HIV self-testing, potential strategies to increase HIV diagnosis in Tanzania</td>
</tr>
</tbody>
</table>
|         | Neema Makyao, Tanzania, United Republic of}
Scientific Programme

ePosters
09:00 - 18:00
Exhibition hall

Clinical case

PE7/1  Disseminated histoplasmosis in HIV, a key point of interest in Latin America
Nelson Delgado, Ecuador

PE7/2  H-ART to Heart: a 43 year old body builder with HIV on anti-retroviral therapy with recurrent myocardial infarctions (5 heart attacks)
Gavin Paul Raphael Manmathan, United Kingdom

PE7/3  Immune reconstitution inflammatory syndrome presenting as toxoplasma macular retinochoroiditis of eyes
Dombu Guiafaing Reine Charlye, Cameroon

PE7/4  Invasive pulmonary aspergillosis and pulmonary tuberculosis in newly HIV diagnosed patients without prior ART exposure: differential diagnosis difficulties, treatment strategy
Katerina Lytvin, Ukraine

PE7/5  Pseudotumor mimicking lung malignancy as a clinical presentation of Mycobacterium Avium infection in AIDS patient
Luka Jovanovic, Serbia

PE7/6  Use of ibalizumab in a heavily treatment-experienced HIV-1-infected subject harbouring a multidrug-resistant virus
Diana Canetti, Italy

PE7/7  Successful use of long-acting injectable cabotegravir and rilpivirine combination therapy in a patient with HIV-1 infection unable to absorb oral medication
Razan Saman, United Kingdom

PE7/8  Cutaneous malignancy in a Romanian HIV-infected patient: diagnosis and treatment challenges
Irina Cristiana Ianache, Romania

PE7/9  Autoantibodies, drugs and a failing liver
Sonia Raffe, United Kingdom

HIV cure

PE12/1  Comparison of three commercial kits for quantitative analysis of HIV-1 RNA produced in Russia
Ilya Lapovok, Russian Federation

PE12/2  Optimization of genotyping by phenotypic analysis of clinical HIV-1 subtype CRF01_AE isolates from South-East Asia
Nina Marty, Switzerland
PS1, Women, pregnancy and children - Pharmacokinetics, injectables, endocrinology

Chairs:
Mariana Mardarescu, Romania
Sharon Walmsley, Canada

ML1  Are there gender and age differences in ARV PK?  10:00 - 10:20
    Felix Stader, Switzerland

PS1/1  Outcomes for women in phase 3 trials of long-acting cabotegravir + rilpivirine: pooled ATLAS and FLAIR week 48 results  10:20 - 10:35
    Romina Quercia, United Kingdom

PS1/2  Dolutegravir (DTG) use during pregnancy and birth outcomes: data from the Antiretroviral Pregnancy Registry (APR)  10:35 - 10:50
    Vani Vannappagari, United States

PS1/3  Prevalence and outcomes of pregnancies over a 20 year period: the EuroSIDA study  10:50 - 11:05
    Justyna Kowalska, Poland

PS1/4  Does menopause affect treatment response in HIV-infected women? a multicenter cohort in Spain  11:05 - 11:20
    Victoria Hernando, Spain

PS1/5  Discontinuation of neonatal postexposure prophylaxis in infants born to HIV-infected mothers with suppressed plasma viral load: safety and implementation of the new Swiss recommendations  11:20 - 11:35
    Paolo Paioni, Switzerland

ML2  Effects of obesity and hormones on the immune system - Implications for women with HIV  11:35 - 11:55
    Donal O’Shea, Ireland

PS2, Social and implementation science

Session interpreted in Russian

Chairs:
Esther Dixon-Williams, United Kingdom
Niklaus Daniel Labhardt, Switzerland

ML1  Treatment access, optimisation and community monitoring in Russia  10:00 - 10:15
    Sergey Golovin, Russian Federation

PS2/1  Empowering home visiting nurses as leaders in the response to the HIV epidemic in Central Asia  10:15 - 10:30
    Yelena Kudussova, Kazakhstan

ML2  Innovative approaches in improving access to care in Ukraine  10:30 - 10:45
    Valeriia Rachynska, Ukraine
PS2/2  Extension of HIV treatment coverage in Ukraine through advocating access of dolutegravir generics to market
Zoia Zamikhovska, Ukraine
Sergey Dmitriev, Ukraine

ML3  PLWHIV 3.0. - Technology makes life easier
Alex Schneider, Switzerland

ML4  EmERGE: mHealth supported pathways of care for people living with stable HIV
Jenny Whetham, United Kingdom

ML5  Innovations in sub-Saharan Africa - May some of these approaches be transferred to Europe?
Helen Ayles, United Kingdom

Panel discussion

Parallel session
10:00 - 12:00  Sydney

PS3, Weight gain under integrase inhibitors: Is this real?

Chairs:
Rui Sarmento e Castro, Portugal
Laura Waters, United Kingdom

ML1  Are new antiretroviral treatments increasing the risks of clinical obesity?
Andrew Hill, United Kingdom

PS3/1  Antiretroviral therapy and body weight in the START (Strategic Timing of Antiretroviral Treatment) trial
Kasper Sommerlund Moestrup, Denmark

PS3/2  Effect of doravirine on body weight and body mass index in treatment naive adults with HIV-1
Chloe Orkin, United Kingdom

PS3/3  The ADVANCE clinical trial: changes from baseline to week 96 in DXA-assessed body composition in TAF/FTC +DTG compared to TDF/FTC+DTG, and TDF/FTC/EFV
Michelle Moorhouse, South Africa

PS3/4  Integrase inhibitors dolutegravir and raltegravir exert proadipogenic and profibrotic effects and induce insulin resistance in adipose tissue and adipocytes
Jennifer Gorwood, France

PS3/5  Changes in weight after switching to dolutegravir containing antiretroviral therapy in the Swiss HIV cohort study
Catrina Mugglin, Switzerland

PS3/6  Switching to an integrase inhibitor containing antiretroviral regimen is not associated with above-average weight gain in middle-aged people living with HIV on long-term suppressive antiretroviral therapy, the AGEhIV cohort study
Sebastiaan Verboeket, Netherlands
Scientific Programme

Special session  
10:00 - 12:00  
Boston 1-3

Cure symposium   co-organised with the National Agency for AIDS Research (ANRS)

Chairs:  
François Dabis, France  
Annemarie Wensing, Netherlands

ML1  
Mechanisms of HIV persistence  
Maria Jose Buzón, Spain  
10:00 - 10:15

ML2  
Cell metabolism and HIV pathogenesis  
Asier Sáez-Cirión, France  
10:15 - 10:30

ML3  
Antiviral NK cells and HIV-1 immunotherapy  
Marcus Altfeld, Germany  
10:30 - 10:45

PS14/1  
HIV reservoir in gut from PHI treated individuals is stable over time and correlates with blood markers of HIV reservoir and inflammation-findings from the HEATHER gut study  
John Patrick Thornhill, United Kingdom  
10:45 - 11:00

PS14/2  
Effects of long-term ART on integrated and intact HIV-DNA in acutely treated vs chronically infected patients: is there a real advantage of treating early?  
Manuela Ceccarelli, Italy  
11:00 - 11:15

PS14/3  
Increased frequency of cytotoxic CXCR5+ effector memory CD8+ T cells during natural control of HIV-1 infection  
Philipp Adams, Luxembourg  
11:15 - 11:30

PS14/4  
HIV-1 reservoir formation, stability and dynamics during cART  
Fabian Otte, Switzerland  
11:30 - 11:45

Industry sponsored session  
12:15 - 13:45  
San Francisco

Industry sponsored session
(For more details, please visit the <a href="https://eacs-conference2019.com/index.php?article_id=166" target="_blank">conference website</a>)

Industry sponsored session  
12:15 - 13:45  
Sydney

Industry sponsored session
(For more details, please visit the <a href="https://eacs-conference2019.com/index.php?article_id=166" target="_blank">conference website</a>)
Scientific Programme

Workshop/Symposium
12:15 - 13:15
Shanghai 3

Migration and HIV  Session convened by EATG
Convener: EATG

Chairs:
Tristan Barber, United Kingdom
Esther Dixon-Williams, United Kingdom

Introduction
Tristan Barber, United Kingdom
Esther Dixon-Williams, United Kingdom
12:15 - 12:19

Migrant access to HIV treatment in 15 countries across WHO Europe and in closed settings/refugee camps
Ferenc Bagyinszky, Germany
12:19 - 12:28

Migration and religion: The intersection between Religion, Migration and treatment and care for Black MSM?
Jide Macaulay, United Kingdom
12:28 - 12:37

Migration and Women
Maryan Said, Norway
12:37 - 12:46

Migration during war in Ukraine
Valeriia Rachynska, Ukraine
12:46 - 12:55

Panel discussion
Dennis Onyango, United Kingdom
Tristan Barber, United Kingdom
Maryan Said, Norway
Jide Macaulay, United Kingdom
Ferenc Bagyinszky, Germany
Valeriia Rachynska, Ukraine
12:55 - 13:10

Summary
Tristan Barber, United Kingdom
Esther Dixon-Williams, United Kingdom
13:10 - 13:15

ePosters
12:30 - 13:15
ePosters area

Moderated ePosters II: Clinical science

Chairs:
Giovanni Guaraldi, Italy
Annette Haberl, Germany

PE18/1  Are women living with HIV in increased risk of complications to birth when planning elective caesarean section? A Danish nation wide population based study
Mathilde Ørbaek, Denmark

PE18/2  Cesarean section is still the most common mode of delivery among HIV-positive women in Central Poland
Justyna Kowalska, Poland
**Scientific Programme**

**PE18/3** The Swiss Mother and Child HIV Cohort Study (MoCHiV), a unique opportunity to monitor and adapt measures to prevent HIV mother to child transmission  
Christian R Kahlert, Switzerland

**PE18/4** Influence of HCV co-infection and hepatitis C treatment on risk of chronic kidney disease in HIV positive persons  
Lars Peters, Denmark

**PE18/5** The hepatitis C continuum of care among HIV-infected individuals in Austria  
David Chromy, Austria

---

**ePosters**  
12:30 - 13:15

**ePosters area**

**Moderated ePosters I: Basic science**

**Chairs:**  
Hendrik Streeck, Germany

**PE17/1** Abdominal adipose tissue is associated with alterations in tryptophan-kynurenine metabolism and markers of systemic inflammation in people living with HIV  
Marco Gelpi, Denmark

**PE17/2** Integrase inhibitor negatively affects CD8 T-cell function  
Enrico Richter, Germany

**PE17/3** The evolution of HIV-1 drug resistance during the 3-month WHO-recommended enhanced adherence counselling period  
Jennifer Anne Brown, Switzerland

**PE17/4** Replication-competent HIV-1 reservoirs form in mucosal tissue macrophages of patients under antiretroviral therapy  
Morgane Bomsel, France

**PE17/5** Skin tissue resident memory T cells (TRMs) are depleted in HIV infection and reconstituted by an early begin of ART  
Simona Saluzzo, Austria

**PE17/6** Baseline and emergent genotypic and phenotypic results in HIV-1-infected, heavily treatment-experienced (HTE) participants meeting protocol-defined virologic failure (PDVF) criteria through week 96 in the fostemsavir (FTR) phase 3 BRIGHTTE study  
Peter Ackerman, United States

---

**ePosters**  
12:30 - 13:15

**ePosters area**

**Moderated ePosters III: Social and implementation sciences**

**Chairs:**  
Niklaus Daniel Labhardt, Switzerland

**PE19/1** Untreated HCV in HIV/HCV-coinfected US population remains common despite the availability of curative therapies  
Rick Elion, United States
**Scientific Programme**

**PE19/2**  
**HepCare Europe - a model of integrated care in Romanian HCV/HIV co-infected patients from key populations**  
Cristiana Oprea, Romania

**PE19/3**  
**Prélub: evaluating a newly launched Canadian provider of innovative internet-based services for self-directed HIV and STI screening**  
Khadija Benomar, Canada

**PE19/4**  
**Employment of people living with HIV approaching that of the HIV-negative population irrespective of migrant status and sexual orientation**  
Christina Carlander, Sweden

**PE19/5**  
**Retention in care and virological suppression in naïve HIV-infected transgender women initiating treatment in Argentina: 48-week results (TRANSViiV study)**  
Claudia Frola, Argentina

**PE19/6**  
**Addressing the needs of female sex workers in Switzerland: model of care beyond STI testing**  
Karoline Aebi-Popp, Switzerland

---

**Parallel session**  
**14:00 - 16:00**  
**Event Hall**

**PS4, More than the sum of its parts? Multimorbidity in PLWH**

**Session interpreted in Russian**

**Chairs:**  
Stefan Mauss, Germany  
Peter Reiss, Netherlands

**ML1**  
**Neighbours visiting: Update from the 2019 co-morbidity workshop**  
Judith Currier, United States  
**14:00 - 14:15**

**PS4/1**  
**AIDS defining and non-defining cancers in persons living with HIV in a single center cohort followed since 1986**  
Rocio Montejano Sanchez, Spain  
**14:15 - 14:30**

**PS4/2**  
**Incidence of CKD with TDF and non-TDF containing antiretroviral regimens by baseline D:A:D CKD risk in people living with HIV (PLWH)**  
Ricky Hsu, United States  
**14:30 - 14:45**

**PS4/3**  
**The ADVANCE trial: the impact of DXA-assessed bone mineral density of TDF/FTC/EFV and TDF/FTC+DTG versus TAF/FTC+DTG**  
Michelle Moorhouse, South Africa  
**14:45 - 15:00**

**PS4/4**  
**Pericardial adipose tissue volume is independently associated with HIV status**  
Andreas Dehlbæk Knudsen, Denmark  
**15:00 - 15:15**

**PS4/6**  
**Comparing a risk score against physiological markers for predicting diabetes incidence in HIV+ individuals**  
Karla I Galaviz, United States  
**15:15 - 15:30**
## PS5, Basic and translational HIV biology

**Chairs:**
Huldrych Günthard, Switzerland
Michaela Müller-Trutwin, France

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Speaker(s)</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>PS5/1</td>
<td>Stem-cell-like CD4+ memory T cells expand during the acute HIV-1 infection accelerating disease progression</td>
<td>Jernej Pušnik, Germany</td>
<td>14:30 - 14:45</td>
</tr>
<tr>
<td>PS5/2</td>
<td>Correlation between cerebrospinal fluid (CSF) and plasma concentrations of neurofilament light protein (NFL) in treated HIV infection in the COmOrBidity in Relation to AIDS (COBRA) study</td>
<td>Jasmini Alagaratnam, United Kingdom</td>
<td>14:45 - 15:00</td>
</tr>
<tr>
<td>PS5/3</td>
<td>TET2 genetic variation affects HIV viral load in ART-naïve persons</td>
<td>Daniel D. Murray, Denmark</td>
<td>15:00 - 15:15</td>
</tr>
<tr>
<td>PS5/4</td>
<td>Temporal evolution of a unique N332 supersite directed bnAb lineage in slow progressing HIV-1 infection</td>
<td>Merle Schanz, Switzerland</td>
<td>15:15 - 15:30</td>
</tr>
<tr>
<td>PS5/5</td>
<td>Prevalence of InSTI resistance and effectiveness of InSTI-based regimens in HIV-infected patients: results from a European cohort study</td>
<td>Barbara Rossetti, Italy</td>
<td>15:30 - 15:45</td>
</tr>
<tr>
<td>PS5/6</td>
<td>In vitro analysis of doravirine activity on HIV-1 clones harboring multiple NNRTI resistance mutations</td>
<td>Francesco Saladini, Italy</td>
<td>15:45 - 16:00</td>
</tr>
</tbody>
</table>
Parallel session
14:00 - 16:00
Sydney

**PS6, Addressing the HIV and STI syndemics** co-organised with the International AIDS Society (IAS)

**Chairs:**
Ken Mayer, United States
Fiona Mulcahy, Ireland

**ML1** Global epidemiology of HIV and STI
Teodora Elvira Wi, Switzerland
14:00 - 14:15

**ML2** Framing the clinical issues
Henry de Vries, Netherlands
14:15 - 14:30

**ML3** STI in the era of PrEP and U=U
Jean-Michel Molina, France
14:30 - 14:45

**ML4** New and emerging STI concerns
Nicola Low, Switzerland
14:45 - 15:00

**ML5** Considerations for key populations
Ken Mayer, United States
15:00 - 15:15

**PS6/1** The natural history of anal high grade squamous intraepithelial lesions in HIV positive and HIV negative gay and bisexual men
David James Templeton, Australia
15:15 - 15:30

**PS6/2** The role of E6/7 mRNA for anal cancer screening in HIV-infected men who have sex with men
Ana Silva-Klug, Spain
15:30 - 15:45

**PS6/3** Modelling the syphilis epidemic among HIV-positive and negative MSM in Switzerland
Suraj Balakrishna, Switzerland
15:45 - 16:00

Parallel session
14:00 - 16:00
Boston 1-3

**PS7, Antiretroviral therapy in special populations**

**Chairs:**
Carlo Federico Perno, Italy
Caroline Sabin, United Kingdom

**PS7/1** RPV+DRV/cobi as 2DR option in HIV-infected subjects on virologic suppression
Franco Maggiolo, Italy
14:00 - 14:20

**PS7/2** Switching to DTG/3TC fixed dose combination (FDC) is non-inferior to continuing a TAF-based regimen (TBR) through 48 weeks: subgroup analyses from the TANGO study
Jean van Wyk, United Kingdom
14:20 - 14:40
PS7/3  Safety and efficacy of triple therapy with Dolutegravir plus 2 NRTIs, in treatment-naïve HIV-2 infected patients - 48 weeks results from a phase II study
Patricia Pacheco, Portugal

PS7/4  HIV-1-RNA kinetics in blood plasma and in seminal plasma of men starting a dolutegravir-based regimen at the time of primary HIV-1 infection
Jade Ghosn, France

PS7/5  Dolutegravir and lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a pilot clinical trial (ART-PRO)
Rosa De Miguel Buckley, Spain

PS7/6  Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide vs comparators in cis-women and girls (living with HIV): an analysis of 5 clinical trials
Chloe Orkin, United Kingdom

Special session
16:30 - 17:30  Event Hall
EACS Guidelines session
Session interpreted in Russian

Chairs:
Andri Rauch, Switzerland
Lene Ryom, Denmark

Welcome
Andri Rauch, Switzerland
Lene Ryom, Denmark

Introduction
Manuel Battegay, Switzerland

ART panel
Jose Arribas, Spain

Drug-drug interaction panel
Catia Marzolini, Switzerland

Paddy Mallon, Ireland

Charles Béguelin, Switzerland

Ole Kirk, Denmark

Simon Collins, United Kingdom
Scientific Programme

Closing
Andri Rauch, Switzerland
Lene Ryom, Denmark

Special session
17:30 - 18:30
San Francisco

EuroSIDA 25 years: What have we learned from cohort studies?

Chairs:
Amanda Mocroft, United Kingdom
Jürgen Rockstroh, Germany
Gilles Wandeler, Switzerland

17:30 - 17:35
Welcome
Amanda Mocroft, United Kingdom
Jürgen Rockstroh, Germany
Gilles Wandeler, Switzerland

17:35 - 17:45
Major achievements in EuroSIDA : Perspective from invited expert
Alison Rodger, United Kingdom

17:45 - 17:55
The role of EuroSIDA in HIV, HCV and TB research in Central East and Eastern Europe
Daria Podlekareva, Denmark

17:55 - 18:10
What HIV observational cohorts have brought to the field
Bruno Ledergerber, Switzerland

18:10 - 18:25
Adapting HIV cohorts to future challenges in HIV research
Jens D. Lundgren, Denmark

18:25 - 18:30
Questions/Wrap-up
Gilles Wandeler, Switzerland

Workshop/Symposium
17:30 - 18:30
Boston 1-3

EACS Regional Representatives

Chairs:
Cristiana Oprea, Romania
Ann Sullivan, United Kingdom

17:30 - 17:35
Welcome and introduction
Cristiana Oprea, Romania

17:35 - 17:45
Update on new structure of EACS - Regional Representatives and Governing Board, Q&A on EACS activities
Sanjay Bhagani, United Kingdom

17:45 - 17:55
Feedback on the Standard of Care meeting in Bucharest
Cristiana Oprea, Romania
Scientific Programme

**Euroguidelines in Central and Eastern Europe network update**
Andrzej Horban, Poland
17:55 - 18:05

**To be announced**
Cristina Mussini, Italy
18:05 - 18:15

**Roundtable**
18:15 - 18:25

Industry sponsored session
17:45 - 18:45
Sydney

(For more details, please visit the [conference website](https://eacs-conference2019.com/index.php?article_id=166))

Industry sponsored session
17:45 - 19:15
Samarkand + Osaka

(For more details, please visit the [conference website](https://eacs-conference2019.com/index.php?article_id=166))
Scientific Programme

Friday, 08 November 2019

Meet-the-expert/Clinical cases
07:30 - 08:30

Clinical cases I

Chairs:
Sanjay Bhagani, United Kingdom
Yvonne Gilleece, United Kingdom

CC1/1  
**Cutaneous and asymptomatic visceral leishmaniasis in late-stage HIV infection**
Daniela Lages, Portugal
07:30 - 07:50

CC1/2  
**An unusual neurologic manifestation**
Luba Tau, Israel
07:50 - 08:10

CC1/3  
**Treatment with DAA HIV-HCV coinfected patient with XDR-tuberculosis**
Narina Sargsyants, Armenia
08:10 - 08:30

Meet-the-expert/Clinical cases
07:30 - 08:30

HIV-associated neurocognitive disorders and neurological complications – An update

Chairs:
Andrea Calcagno, Italy
Matthias Cavassini, Switzerland

Special session
07:30 - 08:30

Ageing with HIV

Chairs:
Tristan Barber, United Kingdom
Jaime Vera, United Kingdom

**Introduction**
Tristan Barber, United Kingdom
Jaime Vera, United Kingdom
07:30 - 07:32

**Do we need models of care for older people with HIV?**
Jaime Vera, United Kingdom
07:32 - 07:40

**Examples of models of care for older people with HIV in Europe**

**Italy**
Giovanni Guaraldi, Italy
07:40 - 07:48
### Scientific Programme

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:48 - 07:56</td>
<td>Poland</td>
<td></td>
</tr>
<tr>
<td>07:56 - 08:04</td>
<td>Norway</td>
<td></td>
</tr>
<tr>
<td>08:04 - 08:12</td>
<td>Community perspective</td>
<td></td>
</tr>
<tr>
<td>08:12 - 08:22</td>
<td>Panel discussion and audience questions</td>
<td></td>
</tr>
<tr>
<td>08:22 - 08:27</td>
<td>Closing</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:30 - 08:30</td>
<td>Workshop/Symposium</td>
<td>Boston 1-3</td>
</tr>
</tbody>
</table>

### Euroguidelines in Central and Eastern Europe Symposium

**Chairs:**
Josip Begovac, Croatia  
Andrzej Horban, Poland  
Vadim Pokrovsky, Russian Federation

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:30 - 07:35</td>
<td>Who we are and what we do?</td>
<td></td>
</tr>
<tr>
<td>07:35 - 07:50</td>
<td>ECEE Workshop in Lviv - clinicians' perspective on HIV care in Ukraine</td>
<td></td>
</tr>
<tr>
<td>07:50 - 08:05</td>
<td>Access to new cART components, new treatment strategies and clinical trials in CEE</td>
<td></td>
</tr>
<tr>
<td>08:05 - 08:20</td>
<td>HIV care in CEE - what is changing, what is not</td>
<td></td>
</tr>
<tr>
<td>08:20 - 08:30</td>
<td>Discussion on future perspectives and action points</td>
<td></td>
</tr>
</tbody>
</table>

### Meet-the-expert/Clinical cases

07:30 - 08:30  
**Darwin**

### HIV and the liver

**Chairs:**
Christoph Boesecke, Germany  
Marina Klein, Canada

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:30 - 07:50</td>
<td>Hepatitis B reactivation after tenofovir cessation in an HIV-infected patient with poor immunological status</td>
<td></td>
</tr>
</tbody>
</table>

Page 110 / 167
Scientific Programme

Meet-the-expert/Clinical cases
07:30 - 08:30
Kairo 2

Vaccination in HIV: Which vaccine for whom?

Chairs:
Christoph Fux, Switzerland
Carolynne Schwarze-Zander, Germany

Plenary lecture
08:30 - 09:00
Event Hall

PL3, Precision medicine in HIV

Session interpreted in Russian

Chairs:
Cristina Mussini, Italy

- Precision medicine in HIV
  Amalio Telenti, United States
- European Hector Research Award in HIV 2019 ceremony - Best clinical science and/or epidemiological paper
  Esteban Martínez, Spain

Plenary lecture
09:00 - 09:30
Event Hall

PL4, Whole genome sequencing for tuberculosis treatment and control: A game changer?

Session interpreted in Russian

Chairs:
Paddy Mallon, Ireland

- Whole genome sequencing for tuberculosis treatment and control: A game changer?
  Iñaki Comas, Spain

ePosters
09:00 - 16:00
Exhibition hall

HIV cure

PE12/1  Comparison of three commercial kits for quantitative analysis of HIV-1 RNA produced in Russia
Ilya Lapovok, Russian Federation

PE12/2  Optimization of genotyping by phenotypic analysis of clinical HIV-1 subtype CRF01_AE isolates from South-East Asia
Nina Marty, Switzerland
**Scientific Programme**

**ePosters**
09:00 - 16:00

**Exhibition hall**

**Antiretroviral therapy preclinical**

PE4/3  
*In vivo dissection of the effects of HIV and antivirals on mitochondrial function in chronic treated HIV*
Theodoros Kelesidis, United States

PE4/4  
*The main barriers to “Test and Start” in Central Asia from the service providers’ and patients' point of view*
Yelena Kudussova, Kazakhstan

PE4/5  
*Preclinical aspects of an anti-HIV molecule targeting vimentin*
Celia Berta Fernandez-Ortega, Cuba

PE4/6  
*PK/PD modelling of bnAbs for HIV treatments identifying knowledge gaps*
Mark Baker, Switzerland

PE4/7  
*A new inhibitor of HIV-1 infection exploiting host intracellular signaling to alter viral RNA processing*
Raymond Waiman Wong, Canada

**HIV drug resistance**

PE13/1  
*Darunavir resistance among patients exposed to protease inhibitors failing ARV therapy*
Luís Fernando Brigido, Brazil

PE13/2  
*Prevalence and factors associated to the detection (population and next generation sequencing) of archived 3TC resistance mutations in aviremic HIV-infected adults (GEN-PRO)*
Lourdes Domínguez-Domínguez, Spain

PE13/4  
*Monitoring the prevalence of transmitted HIV drug resistance in Hungary*
Eva Ay, Hungary

PE13/5  
*Predominant reverse transcriptase resistance mutations as barriers to achieving elimination of mother-to-child transmission of HIV in South Africa*
Oladele Vincent Adeniyi, South Africa

PE13/6  
*Virologic failure and human immunodeficiency virus drug resistance in adolescents on antiretroviral therapy in Yaounde and Douala*
Magaly Jeanne Estelle Moukoko Mbonjo, Cameroon

PE13/7  
*Selection of integrase inhibitor (INI) resistance mutations in an INI experienced patient treated by Bictegravir*
Thanes Vanig, United States

PE13/8  
*Impact of HIV-1 subtypes and integrase natural polymorphisms on virological response to first-line integrase inhibitors based regimens*
Daniele Armenia, Italy
Scientific Programme

PE13/9  HIV-1 integrase inhibitor resistance associated mutations defined by majority and minority populations among individuals failing therapy  
Smitha Gudipati, United States

PE13/10 HIV-1 diversity and antiretroviral resistance among bulgarian citizens infected abroad and foreigners registered with HIV/AIDS in bulgaria from 2012 to 2017 (preliminary analysis)  
Ivailo Alexiev, Bulgaria

PE13/11 Analytical treatment interruption and its association with rearrangement of peripheral archived resistance mutations  
Claudia Alteri, Italy

PE13/12 A low level of darunavir resistance-associated mutation emergence in patients with virological failure during long term use of darunavir in people living with HIV, the French ANRS CO3 Aquitaine cohort  
Fabrice Bonnet, France

PE13/13 Patients infected with multi-class resistant HIV-1 and with viral suppression treated with no more than one active drug: comparison of historical resistance reports and drug resistance in proviral DNA  
Christian Hoffmann, Germany

PE13/14 Non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance in people living with HIV-1 (PLWH) subtype non-B from the Swiss HIV Cohort Study (SHCS)  
Martina L. Reichmuth, Switzerland

PE13/15 HIV-1 from antiretroviral-naïve and experienced patients lack capsid substitutions associated with GS-6207 in vitro resistance  
Anne-Geneviève Marcelin, France

PE13/16 Long-term efficacy, safety and durability of ibalizumab in expanded access study  
Graeme Moyle, United Kingdom

PE13/17 Clinical impact of minority mutations in patients failing an integrase inhibitor-based regimen: what do clinicians do?  
Smitha Gudipati, United States

PE13/18 Identification of HIV-1 transmission clusters in Croatia, 2014 - 2017: evidence for the forward spread of HIV-1 resistant variants  
Josip Begovac, Croatia

PE13/19 High levels of resistance among HIV-1 treatment naive patients in Greece, a nationwide study: evidence for country and regional level transmission networks  
Dimitris Chatzidimitriou, Greece

PE13/20 A phase 3b, open-label, pilot study to evaluate switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) in virologically-suppressed HIV-1 infected adult subjects harboring NRTI resistance mutations M184V/I +/- TAMs (GS-US-292-1824): week 24 results  
Ignacio Pérez-Valero, Spain

PE13/21 Sustained viral suppression among participants with pre-existing M184V/I who switched to bictegravir/emtricitabine/tenofovir alafenamide  
Kristen Andreatta, United States

PE13/22 Absence of naturally existing resistance against the HIV-1 capsid inhibitor GS-6207 in HIV-1 primary isolates  
Christian Callebaut, United States
PE13/23  Impacts assessment of home based care program over adherence to ART among adolescence living with HIV and AIDS in Blantyre Malawi
Lesily Samson Kapile, Malawi

PE13/24  Correlation of results analysis drug resistance of HIV-1 among patients with virological failure by next-generation sequencing and traditional population sequencing
Alina Kirichenko, Russian Federation

PE13/25  Analysis of the latent reservoir of a patient infected with HIV under PrEP by single full-length HIV-1 amplification
Maximilian Damagnez, Germany

PE13/26  Drug resistance profile according to HIV-1 viral load after long-term exposure to antiretroviral treatment in the absence of routine virological monitoring: results from a programmatic cohort in sub-Saharan Africa
Giovanni Villa, United Kingdom

PE13/27  In vitro analysis of replicative capacity and phenotypic susceptibility of integrase mutant HIV-2 viruses
Quentin Le Hingrat, France

PE13/28  Treatment simplification with two-drug regimens: impact of transmitted drug resistance mutations in residents of South-East Austria
Evelyn Stelzl, Austria

PE13/29  Baseline resistance to Doravirine depends on the algorithm used for interpretation
Carlos Guerrero Beltrán, Spain

PE13/30  Baseline resistance to EACS first line recommended antiretroviral regimens in newly diagnosed patients in Spain
Federico García, Spain

PE13/31  A retrospective evaluation of a national home infusion provider’s approach to medication adherence of parenteral ibalizumab-uiyk in the alternate-site and homecare setting
Kathryn Andrusko-Furphy, United States

PE13/32  Prevalence of HIV-1 drug resistance among patients with antiretroviral therapy failure in Moscow region, Russia
Natalya Lebedeva, Russian Federation

PE13/33  HIV-1 drug resistance surveillance among parturient women on anti-retroviral therapy in the Eastern Cape, South Africa: implications for elimination of mother-to-child transmission
Oladele Vincent Adeniyi, South Africa

PE13/34  Antiretroviral Resistance patterns in HIV-1 infected patients failing to second-line in Bamako, Mali
Almoustapha Issiaka Maiga, Mali

Human genomics

PE15/1  Genetic characterization of the near full-length genome of an HIV-1 A1/C/D/K/B unique recombinant form from the Eastern Cape, South Africa: a case report
Oladele Vincent Adeniyi, South Africa
Scientific Programme

PE15/2  **Impact of KIR and their ligands (HLA allele) on susceptibility to selected viral opportunistic conditions and HIV plasma viral load in HIV+ patients**
Magdalena Leszczyszyn-Pynka, Poland

PE15/3  **The identification and causal analysis of aberrant CD4 counts in an HIV cohort in Southern Alberta, Canada**
Raynell Lang, Canada

PE15/4  **Placental gene expression profiles and pathways in HIV-1 positive Cameroonian women under ART**
Forgu Esemu Livo, Cameroon

PE15/5  **Functional clustering and association of HLA class I alleles to viral load in HIV-positive and ART-naïve participants from the INSIGHT START study**
Adrian Gabriel Zucco, Denmark

PE15/6  **miRNA expression profiling in subcutaneous adipose tissue of monozygotic twins discordant for HIV infection: validation of differentially expressed miRNA and bioinformatic analysis**
Nicola Squillace, Italy

PE15/7  **Factors influencing late presentation into care of HIV disease**
Bogusz Aksak-Waś, Poland

**ePosters**
09:00 - 16:00  
Exhibition hall

**Immunology**

PE16/1  **Immunological and metabolic effects of dasatinib treatment in IL7-stimulated CD4+ T-cells subpopulations**
Humberto Erick De La Torre Tarazona, Spain

PE16/2  **New T- and B-lymphocytes production and T-cell receptor diversity in young adults perinatally infected by HIV**
Martina Properzi, Italy

PE16/3  **In Vivo modelling of mechanisms of HIV-1-related monocyte dysfunction**
Theodoros Kelesidis, United States

PE16/4  **Lectin-like oxidized low-density lipoprotein (LOX-1) is elevated in proinflammatory monocytes in chronic treated HIV**
Theodoros Kelesidis, United States

PE16/5  **In vivo dissection of the impact of HIV-1 versus antivirals on immune activation in chronic treated HIV**
Theodoros Kelesidis, United States

PE16/6  **Differential impact of HIV-1 versus antivirals on systemic inflammation in chronic treated HIV**
Theodoros Kelesidis, United States

PE16/7  **Correlation between blood telomere length and CD4+ CD8+ T-cell subsets in HIV-1-positive individuals with long-term virological suppression on antiretroviral therapy**
Javier Rodríguez-Centeno, Spain
Phenotypical recovery of the T-cell pool following switch to dual and triple INSTI-based cART
Camilla Tincati, Italy

Expression of PD-1 in a population of double-negative T cells (CD3+CD4-CD8-) in HIV-infected patients - the preliminary study results
Weronika Rymer, Poland

Targeting inflammation in chronic treated HIV with oral ApoA-I mimetics
Theodoros Kelesidis, United States

Poor recovery of T-cell receptor repertoire despite long-term antiretroviral therapy
James Brown, United Kingdom

Colonic microbiota exhibits disparate associations with HIV-infection and sexual practices
Eveline Verheij, Netherlands

Zonulin indicates loss of intestinal integrity and microbial translocation in HIV+ patients
Max Augustin, Germany

Distinct pro-inflammatory and cardio-protective effects of antiretroviral drugs in vascular endothelial cells
Akif A. Khawaja, United Kingdom

Bacterial translocation kinetics in HIV-1 infection: from acute to chronic stages
Paula Aranguren-Rivas, Spain

Mitochondrial antioxidants attenuate In vivo liver fibrosis in chronic treated HIV
Theodoros Kelesidis, United States

Mitochondrial antioxidants attenuate In vivo mitochondrial dysfunction and exhaustion in T cells in chronic treated HIV
Theodoros Kelesidis, United States

Inhibition of caspase 1 reduces viral load, CD4 T cell depletion and immune activation in HIV-1 infected humanized mice
Philipp Adams, Luxembourg

Effect of early initiation of ART on alterations in natural killer cells in HIV infected pediatric patients
Romsha Kumar, India

HIV-DNA levels, HLA-B*27 and HLA-DRB1*13 among LTNPs, ECs and HIV controllers
Arianna Gabrieli, Italy

Macromolecule uptake across intestinal epithelia in HIV infection
Carolin Grünhagen, Germany
Scientific Programme

PE26/12  Immune cell activation as a risk factor for hypertension in people living with HIV in Sub-Saharan Africa using the recent American Heart Association and American College of Cardiology Guidelines
Sepiso Masenga, Zambia

Vaccines and immune based therapies

PE36/2  Development of engineered nanocarrier for controlled delivery of a protease inhibitor
Saurabh Bhargava, India

Virology

PE38/1  Identification of an HIV-1 BC intersubtype recombinant form, which is circulating in Spain
Javier Enrique Cañada García, Spain

PE38/2  Viral reservoir dynamics in very early primary HIV infection (PHI) patients receiving an intensified antiretroviral regimen (ART): a pilot clinical trial
Juan Ambrosioni, Spain

PE38/3  Lamivudine-based two-drug regimens are not associated with an increased risk of detectable rectal HIV-RNA
Alberto Borghetti, Italy

PE38/4  Comparison of HIV-1 viral load and drug resistance mutations between cerebrospinal fluid and plasma in patients with HIV and Cryptococcal meningitis co-infection in Botswana
Nametso Kelentse, Botswana

PE38/5  HTLV-II antisense protein Aph-2 negatively regulates HIV-1 transcription
Rajkumar Londhe, India

PE38/6  HIV compartmentalization between plasma and CSF and association with neurocognitive disorders
Alessandro Lazzaro, Italy

PE38/7  Determinants of neurocognitive impairments in a Romanian cohort of young adults with chronic HIV infection
Simona Ruta, Romania

PE38/8  Reconstruction of phylogeography for Indian HIV-1 sub-subtype A1
Ajit Patil, India

PE38/9  Broad and potent neutralizing antibody responses in HIV-1 infected Angolan patients: implications for vaccine design and efficacy
Francisco Martin, Portugal

PE38/10  The XbnAb cohort: a HIV-1 cohort of 304 bnAb inducers and matched controls tailored to study determinants of bnAb induction
Irene Abela, Switzerland
Scientific Programme

**PE38/11**  
**Performance of ‘Xpert® HIV-1 Qual assay’ for diagnosis of HIV-1 infection using Dried Blood Spot specimens**  
Swarali Kurle, India

**PE38/12**  
**HIV-1 infections belonging to transmission clusters originating in different countries are frequently detected in Spain among newly diagnosed individuals**  
Javier Cañada, Spain

**ePosters**  
09:00 - 16:00  
Exhibition hall

### Antiretroviral observational studies

**PE2/1**  
**A study of the effect of antiretroviral therapy on sexual risk behavior in a high-risk cohort of Congolese women**  
Samuel Bita, Congo, the Democratic Republic of the

**PE2/2**  
**Coagulation system and HIV infection: a review**  
Nnamdi Nwachukwu, Nigeria

**PE2/3**  
**Effectiveness, persistence and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF), F/TAF+3rd agent or rilpivirine/F/TAF (R/F/TAF) in treatment-naïve HIV-1 infected patients - 24-month results from the German TAFNES cohort study**  
Hans-Jürgen Stellbrink, Germany

**PE2/4**  
**“Attracting men” - extended clinic hours as differentiated model of care in an urban Malawian cohort**  
Sam Phiri, Malawi

**PE2/5**  
**HIV care in India: a systematic review of barriers to anti-retroviral therapy adherence**  
Charu Kohli, India

**PE2/6**  
**Comparing NRTI-sparing dual regimens using data from the Swiss HIV cohort study**  
Jim Young, Switzerland

**PE2/7**  
**Physicians’ opinions on generic antiretroviral drugs and single tablet regimen (STR) desimplification for the treatment of HIV infection: a multicentre survey in Spain**  
Inés Suárez-García, Spain

**PE2/8**  
**Simplifying salvage regimens with darunavir-based dual therapy in HIV-infected individuals harboring multidrug-resistance**  
Pilar Vizcarra, Spain

**PE2/9**  
**Clinical outcomes among HIV-infected Africans with advanced disease in Spain**  
Adrià Ramírez-Mena, Switzerland

**PE2/10**  
**The Treatment of Primary HIV (TopHIV) cohort: a prospective multicenter cohort in Germany**  
Melanie Stecher, Germany

**PE2/11**  
**No decrease in CD4/CD8 ratio after 36 months therapy in patients who were switched to two dual regimens containing rilpivirine**  
Cecilia Tortajada, Spain

**PE2/12**  
**Clinical experience of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) in real life practice: data from the Turkish HIV-TR cohort**  
Volkan Korten, Turkey
**Scientific Programme**

**PE2/13**  
Real world utilisation of raltegravir 1200mg once daily (The RETRO Study)  
Christine Mackay, United Kingdom

**PE2/14**  
Effectiveness, persistence and safety in treatment-naive and treatment-experienced HIV-1 infected patients receiving elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) - 12-month evaluation of the French TARANIS cohort  
Jean-Luc Meynard, France

**PE2/15**  
24-month evaluation of the German TAFNES cohort - Effectiveness, persistence and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF), F/TAF + 3rd agent or rilpivirine/F/TAF (R/F/TAF) in treatment-experienced HIV-1 infected patients  
Heribert Knechten, Germany

**PE2/16**  
Effectiveness, safety and tolerability of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in HIV-1 infected adult patients in routine clinical practice - 6 months results of the BICSTaR cohort  
Stefan Esser, Germany

**PE2/17**  
Short-term increase in Body Mass Index and systolic blood pressure elevation in treatment naive persons starting INSTI-based antiretroviral therapy  
Ronald Galdamez, Spain

**PE2/18**  
Baseline characteristics in JUNGLE, a German observational cohort study of Juluca as 2-drug Regimen in virologically suppressed patients, compared to the phase-3 SWORD 1 & 2 study populations  
F. Schabaz, Germany

**PE2/19**  
Examining the efficacy in clinical practice of the dual antiretroviral therapy regimen of boosted protease inhibitors with maraviroc  
Abhishek Katiyar, United Kingdom

**PE2/20**  
Good efficacy but side effects including hypercholesterolemia and body weight gain after switching to dolutegravir plus booster protease inhibitor regimen among treatment experienced HIV-positive patients  
Yu-Lin Lee, Taiwan, Republic of China

**PE2/21**  
Rates of DTG/ABC/3TC discontinuation in a real-life setting: no surprises found in reported adverse events  
Ana Gorgulho, Portugal

**PE2/22**  
Low baseline HIV viral loads with a history of PrEP use - how should these patients be managed?  
Victoria Tittle, United Kingdom

**PE2/23**  
Lamivudine-based maintenance 2-drugs regimens: an algorithm for the estimation of 2-years risk of virological failure in clinical practice  
Alberto Borghetti, Italy

**PE2/24**  
Adding raltegravir to a bPI failing regimen was not associated with higher virologic suppression  
Monica Maria Gomes-da-Silva, Brazil

**PE2/25**  
Neuropsychiatric tolerability of bictegravir combined with FTC/TAF in clinical practice  
Christian Hoffmann, Germany

**PE2/26**  
Real-world clinical outcomes of patients switched from complex multi-tablet regimens to TAF-based single-tablet regimens plus a boosted protease inhibitor  
Charlotte-Paige Rolle, United States
Dual therapy with fixed dose combination of darunavir/ritonavir plus raltegravir in HIV-infected patients in Argentina  
Diego Martin Cecchini, Argentina

Detectability of HIV residual viremia despite therapy is highly associated with treatment with protease inhibitor  
Gilles Darcis, Belgium

Prediction of virological failure in patients with low level HIV-1 viremia using a joint latent class model  
Enrique Bernal, Spain

Comparing effectiveness and tolerability of emtricitabine/tenofovir alafenamide (F/TAF) with emtricitabine/tenofovir disoproxil fumarate (F/TDF) in HIV-1 infected adult patients in routine clinical practice: a cross cohort analysis  
Stefan Esser, Germany

Effectiveness of Dolutegravir-based antiretroviral therapy in a real-world setting in a Belgian cohort of 4101 HIV patients  
Rakan Nasreddine, Belgium

Characterizations of weight gain following antiretroviral regimen initiation in treatment-naive individuals living with HIV  
Ricky Hsu, United States

How to RESPOND to modern challenges for people living with HIV: a new cohort collaboration  
Bastian Neesgaard, Denmark

ART simplification: use of dual therapy for HIV in a public health reference center (CRT-DST/Aids) in São Paulo, Brazil  
Roberta Schiavon Nogueira, Brazil

Simplification to dual (2D) antiretroviral therapy (ART) with lamivudine and dolutegravir in HIV-infected patients with solid organ transplantation (SOT): a preliminary single-center experience  
Juan Ambrosioni, Spain

Comparable effectiveness of Raltegravir-based dual therapy versus other regimens in patients switched for maintenance  
Karen Martin, Germany

Comparison of a two-drug regimen (dolutegravir/rilpivirine) to standard three-drug regimens in virologically suppressed, treatment experienced individuals in the real world  
Gerald Pierone, United States

Effectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir in treatment-experienced patients: a multicentre cohort study  
Inés Suárez-García, Spain

High persistence of dolutegravir-containing 2-drug regimens in routine clinical care  
Sebastian Noe, Germany

Virologic, immunologic and clinical outcomes in antiretroviral treatment (ART) naïve individuals in the RESPOND cohort collaboration  
Amanda Mocroft, United Kingdom
PE2/41  A retrospective analysis of the EuResist data set assessing HIV dual therapy success in a real-life context  
Michael Böhm, Germany

PE2/42  The real-world impact of switching to tenofovir-alafenamide (TAF) on metabolic co-morbidities in PLWH aged over 60s  
Ming Jie Lee, United Kingdom

PE2/43  Effect of simplification to INSTI-based dual therapy on residual inflammation and viral reservoir  
Giulia Marchetti, Italy

PE2/44  Changes in LDL after switch from TDF to TAF in the U.S.  
Paddy Mallon, Ireland

PE2/45  A retrospective analysis of the EuResist data set assessing if NRTI resistance impairs INSTI based treatment with NRTI backbone  
Michael Böhm, Germany

PE2/46  Impact of archived M184V/I mutations on the effectiveness of switching to coformulated elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide among virologically suppressed HIV-positive patients  
Chien-Ching Hung, Taiwan, Republic of China

PE2/47  Central nervous system (CNS) side effects and viral blips post cART switch from atazanavir boosted with ritonavir (ATZ/r) to atazanavir boosted with cobicistat (ATZ/c)  
Stephanie Tyler, United Kingdom

PE2/48  Quantitation of cellular HIV-1 DNA levels by droplet digital PCR in virologically-suppressed patients switching to dolutegravir plus lamivudine: a prospective study  
Francesca Lombardi, Italy

PE2/49  Evaluation of weight gain in incarcerated individuals living with HIV/AIDS after switching to a raltegravir-based regimen  
Melissa Badowski, United States

PE2/50  Determinants of viral non-suppression among people living with HIV (PLHIV) in rural setting, Neno: a retrospective cohort study  
Potiphar Damiano, Malawi

PE2/51  Risk of developing HIV resistance in patients with low level viraemia in a large London cohort  
Naomi Fitzgerald, United Kingdom

PE2/52  Virological outcomes of first line regimens in women living with HIV from Icona cohort: comparison with clinical trial data  
Cristina Mussini, Italy

PE2/53  Well-being in people living with HIV/AIDS (PLWHA) according to cART exposure: data from IOCONA cohort  
Antonella Cingolani, Italy

PE2/54  Body composition changes in HIV: do INSTI matter?  
Giovanni Guaraldi, Italy

PE2/55  Dolutegravir-based regimens are associated with weight gain over two years following ART-initiation in ART-naive people living with HIV (PLWH)  
Heidi Crane, United States
Scientific Programme

PE2/56  **Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in combination with boosted darunavir (DRV) in treatment experienced patients with HIV**
Lucas Hill, United States

PE2/57  **Real world data of using Triumeq (dolutegravir/abacavir/lamivudine; DTG/ABC/3TC): final outcomes of the 3-year German TRIUMPH cohort show good virologic effectiveness and safety in clinical routine**
Nils Postel, Germany

PE2/58  **The effectiveness of E/C/F/TAF in treatment-naive (TN) or treatment-experienced (TE) adult HIV-infected patients in a real-world setting, results from southern Turkey**
Dilara Inan, Turkey

PE2/59  **Comparison of efficacy and safety of a switch to fixed-dose combination FTC/TDF-TAF/RPV versus fixed-dose combination 3TC/ABC/DTG in HIV-1-infected, treatment experienced and virologically suppressed patients: a cohort study**
Gaetana Sterrantino, Italy

PE2/60  **COPEDOL: a 2-year French multicentric, observational, longitudinal retro-prospective study, in pretreated HIV-1-infected patients starting dolutegravir based regimen due to treatment failure**
Roland Landman, France

PE2/61  **Drug-drug interactions with recommended first-line antiretroviral therapy in real-world settings**
Wang-Huei Sheng, Taiwan, Republic of China

PE2/62  **Determinants of switching to TAF-based cART or dual combinations (DC) from TDF-based regimens in a cohort of HIV-infected individuals with controlled viral load≤50 copies/mL**
Alessandra Vergori, Italy

PE2/63  **An early proactive switch to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/T/TAF) is effective in maintaining virologic control and improving quality of life (QoL) in patients with a primary HIV-1 infection (PHI). An interim analysis of a phase IV clinical trial (ESTER study)**
Marta Camici, Italy

PE2/64  **Prevalence of neuropsychiatric conditions in patients living with HIV-1 treated with antiretroviral therapies - a perspective from US Medicaid**
Wing Chow, United States

PE2/65  **Switch to dolutegravir dual regimens and inflammation mediated by annexin**
Claudio Ucciferri, Italy

PE2/66  **Efficacy of dual antiretroviral therapy (ART) as intermittent short cycle regimen in virologically suppressed HIV-infected patients: an observational cohort**
Romain Palich, France

PE2/67  **Modelling time varying viral load and CD4 cell counts response to antiretroviral therapy in a cohort of HIV naïve patients**
Margarida Tavares, Portugal

PE2/68  **Impact of switching to E/C/F/TAF on lipid profile and renal function in HIV-infected patients**
Bilgul Mete, Turkey
Antiretroviral randomized clinical trials

**PE3/1**  Genital HIV-1 RNA and DNA shedding in virologically suppressed individuals switching from triple- to dual- or monotherapy: pooled results from two randomized controlled trials
Laurent Hocqueloux, France

**PE3/2**  Comparison of the Ease of Swallowability of B/F/TAF placebo compared to DTG/ABC/3TC placebo
John Ernest McKinnon, United States

**PE3/3**  Evaluation of total HIV-DNA changes in HIV-1 infected patients who continue a 2-drug regimen with dolutegravir plus one reverse transcriptase inhibitor or switch to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide enrolled in the Be-One Study
Maria Mercedes Santoro, Italy

**PE3/4**  Phase-3 trials of new antiretrovirals are not representative of the global HIV epidemic
Toby Pepperrell, United Kingdom

**PE3/5**  Impact of susceptibility scoring on virologic response in heavily treatment-experienced participants with HIV-1 receiving a fostemsavir-based antiretroviral regimen: results through week 96 from the randomized cohort of the Phase 3 BRIGHTe study
Peter Ackerman, United States

**PE3/6**  Reversibility of dolutegravir/lamivudine/abacavir neuropsychiatric toxicity after 24 weeks of switching to elvitegravir/cobicistat/emtricitabine/tenofovir-alafenamide (EVG/c/FTC/TAF).
The DREAM Clinical Trial
Ignacio Pérez-Valero, Spain

**PE3/7**  A switch to dolutegravir in combination with boosted darunavir is safe and effective in suppressed patients with HIV - a predefined psychosocial subanalysis of the DUALIS study
Christoph Spinner, Germany

**PE3/8**  Tenofovir alafenamide versus tenofovir disoproxil fumarate - is there a true difference in safety?
Toby Pepperrell, United Kingdom

**PE3/9**  Biologic sex is not the only difference between men and women: data from the Doravirine phase 2/3 clinical trials
Sharon Walmsley, Canada

**PE3/10**  No metabolic or renal benefits when switching to an NRTI-free dolutegravir-containing 2 drug regimen (2DR) - a subanalysis of the DUALIS study
Christoph Boesecke, Germany

**PE3/11**  Sustained viral suppression with dolutegravir monotherapy during 9,899 patient weeks of follow-up in individuals starting combination antiretroviral therapy during primary HIV infection (EARLY SIMPLIFIED): a randomized, controlled, multi-site, non-inferiority trial
Dominique Laurent Braun, Switzerland

**PE3/12**  Rapid initiation of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in patients with human immunodeficiency virus (HIV)-1 infection: age, race/ethnicity, and gender subgroup analyses from the DIAMOND study
David Anderson, United States

**PE3/13**  A systematic review and meta-analysis evaluating the risk of central nervous system adverse events in randomised controlled trials of dolutegravir
Khadija Muniath Chowdhury, United Kingdom
### Scientific Programme

<table>
<thead>
<tr>
<th>PE3/14</th>
<th>Long-term efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in ART-naïve adults</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Chloe Orkin, United Kingdom</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PE3/15</th>
<th>Switching from a 3-drug tenofovir alafenamide (TAF)-based regimen (TBR) to a 2-drug dolutegravir/lamivudine (2DR, DTG/3TC FDC) was not associated with a higher frequency of intermittent viremia in suppressed patients in the TANGO study</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Ruolan Wang, United States</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PE3/16</th>
<th>Phase 3 randomized, controlled DISCOVER study of daily emtricitabine/tenofovir alafenamide (F/TAF) or emtricitabine/tenofovir disoproxil fumarate (F/TDF) for HIV pre-exposure prophylaxis (PrEP): week 96 results</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Peter J Ruane, United States</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PE3/17</th>
<th>Single doses of long-acting capsid inhibitor GS-6207 administered by subcutaneous injection are safe and efficacious in people living with HIV</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Eric S Daar, United States</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PE3/18</th>
<th>Long-term safety and efficacy of rilpivirine plus nucleoside/nucleotide reverse transcriptase inhibitors in HIV-1 infected patients: 7-year roll-over study from phase 2 and 3 clinical studies</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Jean-Michel Molina, France</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PE3/20</th>
<th>Prevalence of archived HIV-1 DNA resistance-associated mutations (RAMs) and their lack of effect on virologic outcome at week 96 in antiretroviral treatment (ART)-experienced, virologically suppressed patients receiving the once-daily, single-tablet regimen (STR) darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in the EMERALD phase III trial</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Erkki Lathouwers, Belgium</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PE3/21</th>
<th>Islatravir efficacy and safety for selected demographic and baseline subgroups from a Phase 2 trial in treatment naive adults with HIV-1 infection</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Jean-Michel Molina, France</td>
</tr>
</tbody>
</table>

### ePosters

**09:00 - 16:00**

**Exhibition hall**

**Pharmacology, pharmacogenomics and drug interactions**

<table>
<thead>
<tr>
<th>PE27/1</th>
<th>Efficacy and safety of artemether-lumefantrine as treatment for Plasmodium falciparum uncomplicated malaria in adult patients on efavirenz based antiretroviral therapy in Zambia: an open label non-randomized interventional trial</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mike Chaponda, Zambia</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PE27/2</th>
<th>Ritonavir-boosted darunavir plus two nucleoside reverse transcriptase inhibitors versus other regimens for initial antiretroviral therapy for people with HIV infection: a systematic review</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Tatevik Balayan, Armenia</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PE27/3</th>
<th>Towards individualization of antiretroviral therapy - more cost-effective than dose intensification in patients</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Bhavik Dalal, India</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PE27/4</th>
<th>The valproic acid - dolutegravir drug-drug interaction is based on displacement of protein binding and unlikely to be clinically relevant</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Henrieke Prins, Netherlands</td>
</tr>
</tbody>
</table>
Scientific Programme

PE27/5  BESIDE - clinical relevance and implications for management of antiretroviral therapy due to recreational drug use in PLWH in Germany
Karen Martin, Germany

PE27/6  Drug-drug interactions between antiretrovirals and carbamazepine or oxcarbazepine: a real-life investigation
Cristina Gervasoni, Italy

PE27/7  Drug-drug interactions between dolutegravir (DTG) and immunosuppressant drugs (IS) in HIV-infected patients with solid organ transplantation (SOT): a single-arm clinical trial (DTGSOT)
Christian Manzardo, Spain

PE27/8  Abacavir hypersensitivity reaction (HSR), associated to baseline false negative HLAB5701 screening, in antiretroviral treatment naive HIV-1 patient
Salvatore Martini, Italy

PE27/9  Central nervous system penetration of antiretroviral drugs in HIV-positive patients with neurocognitive impairment, assessed from paired plasma-CSF concentrations
Perrine Courlet, Switzerland

ePosters
09:00 - 16:00
Exhibition hall

Co-morbidities, ageing

PE9/1  Detectable subclinical myocardial abnormalities in people living with HIV: insights from cardiac magnetic resonance imaging (MRI)
Gavin Paul Raphael Manmathan, United Kingdom

PE9/2  Hypertension and ECG alterations in HIV positive patients in DREAM centres in Mozambique
Isotta Triulzi, Italy

PE9/3  Cardiovascular events are declining in men with HIV aged 50 years or older in Austria
Maria Kitchen, Austria

PE9/4  Prevalence of HIV-associated neurocognitive disorder (HAND) in Turkey and assessment of Addenbrooke's Cognitive Examination Revised (ACE-R) test as a screening tool
Volkan Korten, Turkey

PE9/5  Pilot study assessing the Rotterdam Healthy Aging Score in a cohort of HIV-positive adults
Sharon Walmsley, Canada

PE9/6  Obesity and HIV - the overlapping epidemics
Justyna Kowalska, Poland

PE9/7  Exhaled nitric oxide levels are higher in people living with HIV compared to uninfected controls suggesting increased eosinophilic pulmonary inflammation
Rebekka Faber Thudium, Denmark

PE9/8  Comparison of changes in bone microarchitecture with abacavir-lamivudine versus tenofovir disoproxil fumarate-emtricitabine in adults living with HIV
Roger Bedimo, United States
Limitations of FRAX equation for predicting low bone mineral density or bone loss progression among people living with HIV: the role of secondary causes of osteoporosis
Pilar Vizcarra, Spain

Elevated body mass index during pregnancy and gestational weight gain in HIV-infected women in Cape Town, South Africa: association with adverse birth outcomes
Hlengi Madlala, South Africa

Facilitating primary care non-antiretroviral drug prescribing in people living with HIV: the Think ARV project
Jaime Vera, United Kingdom

Characterization of moderate and severe anemia by peripheral blood smear in HIV infected patients in the Kilombero and Ulanga antiretroviral cohort
Vanessa Anton-Vazquez, United Kingdom

HIV infection and smoking: PET imaging reveals early pulmonary perfusion abnormalities
Puja Kohli, United States

Bariatric surgery in HIV obese patients: first results of the French ObéVIH ongoing study
Valérie Pourcher, France

Plasma cotinine cut-off for distinguishing smokers from non-smokers among people living with HIV (PLWH)
Omid Rezahosseini, Denmark

An analysis of HIV and co-morbidity profiles for adults accessing health care in Khayelitsha, South Africa
Richard Osei-Yeboah, South Africa

Femoral arteries better indicator than carotid arteries of cardiovascular risk in HIV/AIDS patients
Gordana Dragovic Lukic, Serbia

Cardiovascular risk assessment in PLWH over 50: agreement between cardiovascular risk predictors and Coronary Artery Calcium CT Scoring (CACS)
Branca Pereira, United Kingdom

Safety and tolerance of denosumab in HIV patients
Sara Vela, Spain

Lower incidence of liver steatosis in patients treated with lamivudine plus dolutegravir dual therapy
Davide Moschese, Italy

Correlations between computerised and standard cognitive testing in persons with HIV and controls
Davide De Francesco, United Kingdom

Whole body MRI detects high prevalence of incidental findings in older HIV-1-infected patients participating in a randomised, controlled trial of maraviroc and/or metformin for non-alcoholic fatty liver disease
Sarah Pett, United Kingdom

An analysis of potential drug-drug interactions in an aging HIV cohort
Pádraig Gardiner, Ireland
PE9/25  A standardized comparison of cardiovascular risk factor prevalence between people living with HIV and general population in Spain  
Vicente Estrada, Spain  

PE9/26  Subclinical atherosclerosis burden by ultrasound in carotid and femoral territories in HIV subjects: relationships with HIV and non-HIV related factors  
Vicente Estrada, Spain  

PE9/27  Subcutaneous adipose tissue modifications induced by a switch to dual raltegravir-maraviroc therapy in controlled HIV-infected patients: a sub-study of the ANRS-ROCnRAL157 clinical trial  
Jacqueline Capeau, France  

PE9/28  Results of 10 year experience of a specialist clinic for people living with HIV over 50 at Chelsea and Westminster Hospital  
Branca Pereira, United Kingdom  

PE9/29  Discordance in diagnosis of osteoporosis in HIV-infected patients: prevalence, characteristics, and impact on FRAX equation  
Pilar Vizcarra, Spain  

PE9/30  CD4/CD8 ratio is a better indicator of acute phase inflammation than absolute CD4 count during virally-suppressed HIV infection  
Rodney Rousseau, Canada  

PE9/31  Immune activation and chronic inflammation: is there an additional effect of HIV in a geriatric population?  
Clotilde Allavena, France  

PE9/32  Trends in cardiovascular risk factors and estimated 10-year cardiovascular risk score in a spanish cohort of PLWH: 2010-2018  
Francisco Fanjul, Spain  

PE9/33  Prevalence of depression and associated psychosocial factors among HIV positive patients attending ART clinic at Gulu Regional Referral Hospital  
Ronald Kiyemba, Uganda  

PE9/34  Potentially inappropriate medications in older adults with HIV in the region of Madrid, Spain  
Beatriz López-Centeno, Spain  

PE9/35  Impact of the reproductive/hormonal status on weight, fat and insulin resistance in HIV-infected women switching from a PI regimen to dual raltegravir-etravirine therapy: results from the ANRS163-ETRAL trial at 48 and 96 weeks  
Jacqueline Capeau, France  

PE9/37  Age- and sex-related differences in concomitant diseases and use of co-medications in patients with treated HIV-infection in Germany  
Karen Martin, Germany  

PE9/38  Kidney transplantation in HIV-positive patients in Israel including the first case of HIV-positive living donor to HIV-positive recipient with a 7-year follow-up  
Eugene Katchman, Israel  

PE9/39  Vitamin D deficiency and frailty phenotype in HIV-infected men  
Fiona Bhondoekhan, United States
**PE9/40**
The UCSD performance-based skills assessment is associated to cognitive performance in HIV positive population with very good immunological condition
Valentina Delle Donne, Italy

**PE9/41**
Alcohol, smoking and the association with HIV virological non-suppression among people living with HIV on ART
Timothy Peter Wynne Jones, United Kingdom

**PE9/42**
Decreasing incidence of diabetes mellitus in HIV-positive Taiwanese patients on combination antiretroviral therapy from 2004 to 2011
Pei-Ying Wu, Taiwan, Republic of China

**PE9/43**
Incidental findings in PLWH over 50 undergoing coronary artery calcium scoring (CACS) for cardiovascular risk assessment
Maria Mazzitelli, United Kingdom

**PE9/44**
Aging biomarkers, inflammatory cytokines and development of cardiovascular ischemic events or diabetes in HIV-infected persons
Jose I Bernardino, Spain

**PE9/45**
Falls but not frailty are common in people living with HIV using an mHealth platform: issues of ageing within the EmERGE cohort
Tom Levett, United Kingdom

**PE9/46**
A standardized comparison of cardiovascular risk factor treatment in people living with HIV and general population
Vicente Estrada, Spain

**PE9/48**
Perceptions of ageing and desire for ageing information amongst users of the EmERGE mHealth platform
Tom Levett, United Kingdom

**PE9/49**
Switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in adults aged >65 or older: week 48 results from a phase 3b, open-label trial
Franco Maggiolo, Italy

**PE9/50**
Safety and efficacy of switching from tenofovir disoproxil fumarate to tenofovir alafenamide in people with HIV aged 50 years and older
Hans-Jürgen Stellbrink, Germany

**PE9/51**
HIV testing in patients diagnosed with community acquired pneumonia or primary lung cancer from 2014 to 2018 in a tertiary reference hospital in Northern Spain
Teresa Rubio Obanos, Spain

**PE9/52**
Menopause in aging women living with HIV: changes in bone mineral density and trabecular bone score
Giovanni Guaraldi, Italy

**PE9/53**
Higher anti-CMV IgG concentrations are not associated with longitudinal brain injury in virally suppressed people with HIV
Jonathan Underwood, United Kingdom

**PE9/55**
Higher Prevalence of CKD in HIV+ individuals compared to the general population
Stefan Esser, Germany

**PE9/56**
Effect of CMV viraemia on endothelial dysfunction over 42 weeks in Malawian adults initiating ART with advanced immune suppression
Christine Kelly, Ireland
High prevalence of neurocognitive impairment in adults with perinatally acquired HIV infection
Irene Portilla-Tamarit, Spain

Modeling 2018 AHA cholesterol guidelines in HIV
Giacomo Ciusa, Italy

A multi-disciplinary Neuro-HIV Platform in managing patients with neurocognitive impairment
Phanie Bidlingmeyer, Switzerland

Archipevaleat project. A national register of color-Doppler ultrasonography of the epicardic vessels in patients living with HIV
Salvatore Martini, Italy

Preliminary results of a diagnostic-therapeutic work-up to early detect cardiovascular disease in HIV positive patients
Giovanni Millotti, Italy

Bone mineral density changes in young African women on tenofovir disoproxil fumarate antiretroviral therapy and non-hormonal contraception
Flavia Kiweewa Matovu, Uganda

Examination of HIV-infected patients regarding weight gain while using integrase inhibitors in Japan
Ryoko Sekiya, Japan

Predictors of sarcopenia and its impact on components of the frailty phenotype in an Asian population living with HIV
Grace Lui, Hong Kong

Failure to restore CD4 cell count with combination antiretroviral therapy is associated with increased systemic inflammation
Rodney Rousseau, Canada

High prevalence of left ventricular systolic dysfunction assessed by speckle tracking in asymptomatic HIV patients
Dimitris Basoulis, Greece

Polypharmacy and drug-drug interactions - prevalence in a Portuguese HIV Metabolic Clinic
Joana Fragoso, Portugal

Bone density alterations in the HIV-infected patient - epidemiologic characterization of a Portuguese cohort
Diogo Guerra, Portugal

Cigarette smoking disproportionately impairs nitric oxide signaling in pulmonary artery endothelial cells in HIV: role of viral and host factors
Saurabh Aggarwal, United States

Frailty phenotype in older virologically suppressed PLWHIV is strongly correlated with specific comorbidities and tobacco use
Christina Katerina Psomas, France

HIV-FUNCRAIL study: differences between women and men aging with HIV
Fátima Brañas, Spain
Scientific Programme

PE9/73  Prevalence, risk factors and outcomes of cardiovascular, metabolic and chronic kidney diseases in HIV-infected vs. uninfected adults in sub-Saharan Africa: a systematic review and meta-analysis
Ajibola Awotiwon, South Africa

PE9/74  People living with HIV are more likely to be screened for cardiovascular disease risk factors than other members of the general population in Botswana - a community based study
Onkabetse Julia Molefe-Baikai, Botswana

PE9/75  APOL1 high risk genotype has an adverse impact on kidney function in African HIV-infected patients with high viral load
Nongodo Firmin Kabore, France

PE9/76  Comparison of 2 frailty scores in PLWHIV aged 50 and over: SOF index and FRIED phenotype
Christina Katerina Psomas, France

PE9/77  Annexin V, Annexin A1 and cardiovascular risk in HIV population
Claudio Ucciferri, Italy

PE9/78  Could we consider the intima-media thickness (c-IMT) > 1mm as a risk factor for cardiovascular diseases in HIV+ subjects chronically treated with antiretrovirals?
Alessio Pampaloni, Italy

PE9/79  Immune reconstitution inflammatory syndrome (IRIS) in HIV-infected hospitalized patients with advanced disease
Alberto Díaz-de Santiago, Spain

PE9/80  Low Body Mass Index (BMI) in ART naive HIV-positive subjects and risk of virological failure and drug discontinuation: data from the ICONA Foundation Cohort
Roberto Rossotti, Italy

PE9/81  Sistatin C, KIM1 and NGAL as biological markers for detecting early kidney injury in HIV positive patients
Aslıhan Ulu, Turkey

PE9/82  Long-term AIDS survivors: comorbidities and polypharmacy a new challenge
María José Galindo Puerto, Spain

PE9/83  Risk Factors associated to immune reconstitution inflammatory syndrome (IRIS) in HIV-infected hospitalized patients with advanced disease
Alberto Díaz-de Santiago, Spain

PE9/84  Sleep disorders and depression through efavirenz to dolutegravir transition in Brazil: what really changed after all
Melissa Medeiros, Brazil

PE9/85  Patterns of inflammation and comorbidity in Human Immunodeficiency Virus (HIV) infection: a clustering analysis from the CARDAMONE study
Sonia Zebachi, France

PE9/86  Cognitive impairment in patients with HIV in a Mexican hospital
Lucía Carrazco Ibarra, Mexico

PE9/87  Clinical management of ageing people living with HIV in Europe: The view of the care providers
Marta Boffito, United Kingdom
### Scientific Programme

#### PE9/88
Real-word characterization of the Portuguese population living with HIV who initiated Raltegravir based-regimen in the last three years - REALITY Study
Joana Almeida, Portugal

#### PE9/89
Long-term lipid-lowering-therapy in HIV is clinically effective
Henning Drechsler, United States

---

<table>
<thead>
<tr>
<th>ePosters</th>
<th>09:00 - 16:00</th>
<th>Exhibition hall</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIV-associated and non HIV-associated tumours</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>PE14/1</strong></td>
<td>Prevalence of anal dysplasia among persons living with human immunodeficiency virus (HIV)</td>
<td>Adelaine Lopez, Philippines</td>
</tr>
<tr>
<td><strong>PE14/2</strong></td>
<td>HIV infection is associated with reduced survival among hepatocellular carcinoma cases from an urban referral hospital: Kampala, Uganda</td>
<td>Sara Nsibirwa, Uganda</td>
</tr>
<tr>
<td><strong>PE14/3</strong></td>
<td>High prevalence of anal and cervical dysplasia in a cohort of HIV-infected women, but low prevalence of concomitant lesions</td>
<td>Ana Gomez, Ecuador</td>
</tr>
<tr>
<td><strong>PE14/4</strong></td>
<td>Malignant and benign skin lesions in HIV-1 infected people</td>
<td>Alessandra Latini, Italy</td>
</tr>
<tr>
<td><strong>PE14/5</strong></td>
<td>Results of HPV-testing for anal screening in HIV-infected women</td>
<td>Anna Popova, Russian Federation</td>
</tr>
<tr>
<td><strong>PE14/6</strong></td>
<td>COHORT SDT (Granada): decrease of the incidence of HSIL+ in the anal mucosa of HIV+ patients MSM after the performance of a screening, diagnostic and therapeutic program (2010-2018)</td>
<td>Carmen Hidalgo-Tenorio, Spain</td>
</tr>
<tr>
<td><strong>PE14/7</strong></td>
<td>Prospective longitudinal study on immunogenicity and safety of vaccination against human papillomavirus (HPV) with the 9valent vaccine in HIV-positive women, the Papillon study: preliminary results on tolerance and safety</td>
<td>Déborah Konopnicki, Belgium</td>
</tr>
<tr>
<td><strong>PE14/8</strong></td>
<td>Cancer trends and outcomes in a cohort of people living with HIV</td>
<td>Andrea De Vito, Italy</td>
</tr>
<tr>
<td><strong>PE14/9</strong></td>
<td>Rate of HCC occurrence and associated risk factors in a multicentric cohort of HIV/HCV co-infected patients treated with DAAs</td>
<td>Alice Toschi, Italy</td>
</tr>
</tbody>
</table>

---

<table>
<thead>
<tr>
<th>ePosters</th>
<th>09:00 - 16:00</th>
<th>Exhibition hall</th>
</tr>
</thead>
<tbody>
<tr>
<td>Other coinfections/Sexually transmitted infections</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---
| PE24/2 | High rates of ocular and neurosyphilis in a large German, city-based university hospital: lessons learned on ocular syphilis |
|        | Laura Franziska Wagner, Germany |
| PE24/3 | Decreasing rate of HIV and HBV co-infection in nationwide Korean HIV/AIDS cohort and its meaning |
|        | Yoonjung Kim, Korea, Republic of |
| PE24/5 | Prevalence of syphilitic hepatitis among HIV-infected patients in Istanbul, Turkey, a region with increasing incidence of syphilis and HIV infection |
|        | Ozlem Altuntas Aydin, Turkey |
| PE24/6 | Seroconversion rate after yellow fever vaccine in HIV-positive patients |
|        | Charlotte Martin, Belgium |
| PE24/7 | Low seroprevalence of syphilis infection among key populations in Togo in 2017: a national cross-sectional survey |
|        | Fifonsi Gbeasor, Togo |
| PE24/8 | Socio demographics, sexual behavior and clinical manifestations of HIV+ and HIV- patients diagnosed with syphilis, Brussels 2017-2019 |
|        | Agnès Libois, Belgium |
| PE24/9 | Risk factors and prevalence of syphilis, gonorrhoea and chlamydia infections in the Swiss HIV cohort study |
|        | Catrina Mugglin, Switzerland |
| PE24/10 | Predictors of serofast state after treatment for syphilis in HIV-infected patients |
|        | Gregor Paul, Germany |
| PE24/11 | A proactive approach to assess rising STIs among different at-risk groups of MSM in the early era of PrEP: a real-world clinical care setting |
|        | Christina Katerina Psomas, France |
| PE24/12 | Profiles of multidrug resistant gonorrhoea in HIV-infected patients attending an urban hospital in Uganda |
|        | Christine Katusiime, Uganda |
| PE24/13 | Sexually transmitted diseases clinic in a Portuguese Infectious Diseases unit |
|        | Joana Fragoso, Portugal |
| PE24/14 | Quantification of DNA human papillomavirus 16 and 18 in anal cells improves the prediction of high grade anal intraepithelial neoplasia in HIV patients |
|        | Marcos Diez, Spain |
| PE24/15 | Primary prophylaxis against Pneumocystis jirovecii Pneumonia may be effective in preventing severe bacterial pneumonia in HIV-positive patients: findings from a large Italian center |
|        | Alex Dusina, Italy |
| PE24/16 | HHV-8 salivary shedding in individuals with different HIV status and sexual behaviour |
|        | Elvira Domonova, Russian Federation |
| PE24/17 | Insights into syphilis reinfection in HIV patients: predictors and role of serofast condition |
|        | Chiara Picarelli, Italy |
| PE24/18 | Infective endocarditis, a current health problem in Romanian injecting drug users |
|        | Irina Cristiana Ianache, Romania |
Preventable risk factors and predictors of hepatic and non-hepatic co-morbidities among PLHIV
Oluwakemi Odukoya, Nigeria

Incidence of asymptomatic HAV infection among MSM living with HIV in South-Western Poland
Aleksandra Szymczak, Poland

Behavioural patterns to identify key populations for syphilis prevention
Sara Andresen, Switzerland

Evaluation of a systematic sexually transmitted infections screening pilot programme in HIV-positive men who have sex with men (MSM)
Paula Prieto, Spain

Chemsex in Barcelona: a descriptive approach about men who have sex with men (MSM) who use recreational drugs in a sexual context
Lorena De la Mora, Spain

Analysis of serum metabolite changes in early syphilis patients with or without serologic response after treatment
Chia-Jui Yang, Taiwan, Republic of China

Stable transmission of amoebiasis among newly diagnosed HIV-positive patients in Taiwan, 2009-2018
Sung-Hsi Huang, Taiwan, Republic of China

Mycoplasma genitalium resistance against macrolide antibiotics in the Berlin MSM cohort tested with the Allplex MG & AziR Assay (SeeGene)
Martin Obermeier, Germany

Predictors of ureaplasma urealyticum urinary colonization in HIV+ pregnant women: a pilot study
Iacopo Franconi, Italy

No indication of decreased syphilis susceptibility with repeated syphilis episodes in HIV-infected men who have sex with men: a multicentre prospective cohort study on risk factors and the potential role of syphilis immunity
Jan Roth, Switzerland

The prevalence of high-risk anal HPV in HIV-positive MSM in Lebanon
Nesrine Rizk, Lebanon

Sleep and functional characteristics of Central London Outpatient HIV Cohort
Ana Milinkovic, United Kingdom

Osteopenia and osteoporosis in young HIV-infected patients less than age of 40 years: incidence and risk factors
Shu-Ying Chang, Taiwan, Republic of China


Scientific Programme

PE32/3  Predictors of weight gain in patients treated with dolutegravir
Lucia Taramasso, Italy

PE32/4  Effects of lamivudine plus dolutegravir 2-drug-regimen on bone mineral density in a multicenter Italian cohort
Arturo Ciccullo, Italy

PE32/5  Switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) lowers alanine transaminase (ALT) and aspartate transaminase (AST) in patients with HIV infection with or without viral hepatitis co-infection
Nicola Squillace, Italy

PE32/6  Weight gain in people living with HIV switched to dual therapy with dolutegravir plus rilpivirine: changes in body fat mass
Pilar Vizcarra, Spain

PE32/7  Does switching to tenofovir alafenamide fumarate impair recovery of renal function in individuals newly diagnosed with tenofovir disoproxil fumarate induced renal tubular toxicity?
John Booth, United Kingdom

PE32/8  Weight gain among HIV-positive persons treated with dolutegravir or elvitegravir
Leila Belkhir, Belgium

PE32/9  NRTI backbone modification impact on weight, lipids and cardiovascular risk
Ana Milinkovic, United Kingdom

PE32/10  Comparative neuropsychiatric toxicity profile of dolutegravir (DTG) versus efavirenz (EFV) versus other antiretroviral third drugs used either in first-line or switch antiretroviral therapies (ART): data from Icona Foundation Study Cohort
Annalisa Mondi, Italy

PE32/11  SWORD 1&2: maintenance or improvement in renal function in PLWH through 148 weeks after switch to the dolutegravir + rilpivirine 2-drug regimen
Josep M Llibre, Spain

PE32/12  Neurotoxicity related to efavirenz does not predict neurotoxicity related to dolutegravir
Sara de la Fuente, Spain

PE32/13  Human embryonic stem cells exposed to dolutegravir show decreased cellular proliferation, reduced pluripotency, and increased mitochondrial toxicity, in a dose-dependent manner: preliminary data
Marie-Soleil R. Smith, Canada

PE32/14  Dolutegravir but not raltegravir reduces cell proliferation and increases mitochondrial toxicities in cultured fibroblasts; effects that are not mitigated by telomerase reverse transcriptase
Helene Cote, Canada

ePosters
09:00 - 16:00
Exhibition hall

Tuberculosis and opportunistic infections
PE35/1  Nontuberculous mycobacteria infections in Russian HIV patients: clinical features and outcomes
Mikhail Savchenko, Russian Federation

PE35/2  Human immunodeficiency virus and the outcome of treatment for pulmonary tuberculosis: a retrospective study in Tehran, Iran
Mohammad Bagheri, Iran, Islamic Republic of

PE35/3  Rifampicin pharmacokinetics and pharmacogenetics in Ugandan patients with multi-drug resistant tuberculosis
Jackson K. Mukonzo, Uganda

PE35/4  Mycobacteria-induced immune responses by mucosal-associated invariant T (MAIT) cells are impaired in patients with tuberculosis (TB) and HIV-associated TB
Muki Shey, South Africa

PE35/5  Acute onset of cerebral toxoplasmosis in patients with HIV infection
Tatiana Ermak, Russian Federation

PE35/6  Association between immunological status and TB disease development in HIV-infected individuals with LTBI
Ngai Sze Wong, Hong Kong

PE35/7  Amoeba- a swiss army knife for diagnosis and mechanistic understanding of Legionella infection
Breanne M Head, Canada

PE35/8  Causes and outcomes of hospitalizations among HIV positive persons in Georgia’s referral institution, 2012-2017
Nino Rukhadze, Georgia

PE35/9  Population pharmacokinetic analysis of dolutegravir in HIV/TB co-infected people with and without rifampicin
Rajendra Singh, United States

PE35/10 Lung function and health-related quality of life among patients following pulmonary tuberculosis treatment in urban Uganda: a cross-sectional study
Josephine Zawedde, Uganda

PE35/11 Clinical and laboratory characterization of progressive multifocal leukoencephalopathy in HIV-infected patients in the intensive care unit
Anastasia Pokrovskaya, Russian Federation

PE35/13 Cryptococcal and tuberculosis coinfection: case series identified through the implementation of an advanced HIV disease package of care linked to a TB active case finding strategy in rural Mozambique
Alejandro Blanco-Árêvalo, Spain

PE35/14 Trends in latent tuberculosis screening in a cohort of HIV-infected patients from a low tuberculosis incidence country
Pedro Palma, Portugal

PE35/15 Drug-induced hepatic injury developed in tuberculosis / HIV co-infection treatment
Sarah Silva, Brazil
Scientific Programme

ePosters
09:00 - 16:00
Exhibition hall

NASH

PE22/1 Assessment of non alcoholic fatty liver disease in a cohort of HIV mono-infected patients
Paola Columpsi, United Kingdom

PE22/2 Non-alcoholic fatty liver disease (NAFLD) and related metabolic disorders among HIV-infected patients in the country of Georgia
Lali Sharvadze, Georgia

PE22/3 Non-alcoholic fatty liver disease is a significant predictor of cardiovascular risk in HIV-infected patients
Adriana Cervo, Italy

PE22/4 Non alcoholic fatty liver disease diagnosed by non-invasive markers in HIV-infected patients
Carmen Busca, Spain

PE22/5 Global prevalence of liver impairment in HIV population in direct antiviral agents (DAA) era: the role of fatty liver disease
Matilde Sánchez-Conde, Spain

Viral hepatitis

PE37/1 Acute hepatitis C infection in HIV-infected patients who achieved viral suppression: incidence and risk factors
Hsin-Yen Ku, Taiwan, Republic of China

PE37/2 HBV infections among HIV infected HAART receiving mothers and their exposed infants in a tertiary hospital in Kenya
James Kangethe, Kenya

PE37/3 Direct-acting antivirals (DAAs) improve liver stiffness measurements but do not improve the Veterans Aging Cohort Study (VACS) Index in HIV/HCV co-infected Egyptian patients: is improved discrimination needed?
Ahmed Cordie, Egypt

PE37/4 HCV/HIV coinfection in the DAA era: which patients have not been treated for HCV?
Fabian Dario Rodriguez-Monaco, Germany

PE37/5 Hepatitis E seroprevalence in HIV-positive patients
Mustafa Altindis, Turkey

PE37/6 Success of unrestricted DAA therapy is limited by HCV reinfections and loss to follow-up in HIV-positive patients
David Chromy, Austria

PE37/7 Efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide as maintenance treatment of patients with HIV and Hepatitis B Virus (HBV) coinfection
Yu-Shan Huang, Taiwan, Republic of China
Effectiveness of hepatitis a vaccination among people living with HIV in Taiwan: is one dose enough?
Chia-Jui Yang, Taiwan, Republic of China

HIV patients remain at high risk for advanced liver fibrosis after curing HCV infection
Natalia Bolokadze, Georgia

HIV/HCV co-infection in Spain: trouble will soon be over
Juan Berenguer, Spain

Care cascade of incident HCV infection among HIV-positive patients in Taiwan
Miao-Hui Huang, Taiwan, Republic of China

Current characteristics of HIV/HBV coinfected patients in a single HIV reference centre of Madrid
Luz Martín-Carbonero, Spain

High HCV reinfection rate in MSM living with HIV in Barcelona: the need to focus on high risk population to achieve HCV elimination
Maria Martínez-Rebollar, Spain

Liver disease in HIV-infected subjects in the post-HCV DAA treatment era
Carmen Busca, Spain

Seroprevalence of hepatitis E in a Portuguese cohort of human immunodeficiency virus infected patients
André Silva-Pinto, Portugal

Loss of seroprotection against hepatitis B virus (HBV) was associated with lower CD4 counts among HIV-positive patients who were born in the era of nationwide neonatal HBV vaccination
Yi-Chia Huang, Taiwan, Republic of China

Improvement of immunity and hepatic fibrosis after HCV treatment with DAA in people living with HIV and HCV
Montserrat Laguno, Spain

DAA treating Hepatitis C in HIV/HCV coinfected patients in two prisons of Rome: results and problems
Sara Lardo, Italy

Progress towards eliminating mother-to-child transmission of HIV in the Macha area in Zambia from 2010-2018
Mutinta Hamahuwa, Zambia

Evaluation of the hepatitis C care cascade in the country of Georgia: monitoring 4 years of progress towards elimination
Tengiz Tsertsvadze, Georgia

Epidemiology of HIV, HBV and HCV co-infection in Israel
Karen Olshtain-Pops, Israel

Hepatitis C treatment outcomes of HIV infected people who inject drugs in a real-world cohort
Dimitris Basoulis, Greece

Treatment of acute HCV infection with direct acting antivirals (DAA) in HIV patients
Cristina Gómez-Ayerbe, Spain
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>PE37/24</td>
<td>Hepatic fibrosis progression among HIV patients in Israel</td>
<td>Karen Olshtain-Pops, Israel</td>
</tr>
<tr>
<td>PE37/25</td>
<td>Acute hepatitis B in persons living with HIV in a low hepatitis B prevalence area during the last two decades</td>
<td>Luz Martín-Carbonero, Spain</td>
</tr>
<tr>
<td>PE37/26</td>
<td>Virological response to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in HIV-positive patients with lamivudine-resistant hepatitis B virus coinfection</td>
<td>Yu-Shan Huang, Taiwan, Republic of China</td>
</tr>
<tr>
<td>PE37/27</td>
<td>Impact of direct-acting antiviral (DAA) agents on T cell counts and liver stiffness in HIV/HCV-coinfected patients: a multicenter prospective observational cohort study</td>
<td>David Dalmau, Spain</td>
</tr>
<tr>
<td>PE37/28</td>
<td>Trends of HCV infection among HCV-seronegative, HIV-positive patients in Taiwan between 2011-2018</td>
<td>Li-Hsin Su, Taiwan, Republic of China</td>
</tr>
<tr>
<td>PE37/29</td>
<td>The micro-elimination approach to eliminating Hepatitis C: a Fast Track City project</td>
<td>Franco Maggiolo, Italy</td>
</tr>
<tr>
<td>PE37/30</td>
<td>Road to HCV elimination in HV/HCV coinfected patients by screening and universal access to DAA: baseline data from the first screening of NoCo (No-Coinfection) study</td>
<td>Antonella d’Arminio Monforte, Italy</td>
</tr>
<tr>
<td>PE37/31</td>
<td>HCV cascade of care for HIV/HCV coinfected individuals in Greece and HCV treatment considerations in clinical practice</td>
<td>Mina Psichogiou, Greece</td>
</tr>
<tr>
<td>PE37/32</td>
<td>Hepatitis B core-related antigen and anti-hepatitis B core antibody are not associated with liver fibrosis evolution in HIV-HBV co-infected patients during treatment with tenofovir</td>
<td>Romuald Cruchet, France</td>
</tr>
<tr>
<td>PE37/33</td>
<td>Antiretroviral therapy: a possible role in lipid changes after HCV eradication by DAAs</td>
<td>Alessandra Vergori, Italy</td>
</tr>
<tr>
<td>PE37/34</td>
<td>Treatment of cirrhotic monoinfected and HCV/HIV coinfected patients with direct acting antivirals (DAAs)</td>
<td>Fábio Videira Santos, Portugal</td>
</tr>
<tr>
<td>PE37/35</td>
<td>Predictors of vaccine efficacy after hepatitis B vaccination in people with HIV infection</td>
<td>Gerardo Ibarra, Germany</td>
</tr>
<tr>
<td>PE37/36</td>
<td>Long term response to mandatory anti-HBV vaccination: risks for disease acquisition and opportunities for re-vaccination within the ICONA cohort</td>
<td>Roberto Rossotti, Italy</td>
</tr>
<tr>
<td>PE37/37</td>
<td>The assessment of HBsAg serum concentration during chronic hepatitis B phases’ identification among HIV/HBV coinfected patients before antiviral therapy prescription</td>
<td>Tetiana Melnyk, Ukraine</td>
</tr>
<tr>
<td>PE37/38</td>
<td>Predictors of liver fibrosis improvement after HCV eradication in HIV+ patients: data from an Italian cohort</td>
<td>Alessandra Vergori, Italy</td>
</tr>
</tbody>
</table>
**Scientific Programme**

**PE37/39**  
**Long-term follow-up of people who use drugs (PWUD) following HCV infection therapy: drug use patterns among HIV co-infected versus mono-infected patients**  
Astou Thiam, Canada

**PE37/40**  
**Treatment outcome of HCV single vs multi tablet regimen in mono and HIV co-infected people who use drugs (PWUD): a long-term follow-up analysis**  
Astou Thiam, Canada

**Gender issues**

**PE10/1**  
**Patient, clinical and virus genetic characteristics of migrants from Eastern, Central and Western Africa enrolled in the SHCS**  
Nadine Bachmann, Switzerland

**PE10/2**  
**Menopause impacts drug use and mental health in women with HIV in Switzerland**  
Anna Hachfeld, Switzerland

**PE10/3**  
**Gender-specific analysis of a German cohort of HIV-infected patients on Raltegravir-based therapy shows distinctive baseline co-morbidity profiles of women versus men but no impact on treatment outcomes**  
Karen Martin, Germany

**PE10/4**  
**Menopausal symptoms, sleep disorders and anxiety/depression among premenopausal and postmenopausal HIV-infected women: a multicenter cohort study in Spain**  
Ines Suarez, Spain

**PE10/5**  
**An evaluation of the care given to older women attending an HIV clinic in London**  
Claire Williams, United Kingdom

**PE10/6**  
**Anti-Mullerian hormone a plausible indicator of cardiometabolic risk in HIV-infected women**  
Umbelina Caixas, Portugal

**PE10/7**  
**Differences in sexual health among HIV infected and uninfected women of child-bearing age**  
Raffaella Marocco, Italy

**Mother-to-child transmission**

**PE21/1**  
**HIV infection in pregnant women and children in Switzerland: how effective are measures for preventing mother-to-child transmission?**  
Martin Gebhardt, Switzerland

**PE21/2**  
**No evidence for induced glucuronidation of dolutegravir in HIV-infected pregnant women**  
Vera Bukkems, Netherlands

**PE21/3**  
**Comparative analysis of clinic and laboratory parameters and frequency of mother-to-child transmission of HIV among HIV-positive pregnant women with marked immunodeficiency and normal immunological status**  
Olga Mozaleva, Russian Federation
Scientific Programme

PE21/4  Analysis of perinatal HIV transmission cases in St. Petersburg
         Anna Samarina, Russian Federation

PE21/5  Geopolitical assessment and relevance for acceptance of vaginal delivery in good controlled
         HIV-infected pregnant women in Japan
         Kimikazu Hayashi, Japan

PE21/6  Pregnancy outcomes in HIV-positive women: a retrospective national cohort study from the
         “Grigoris AIDS Clinic” in Cyprus
         Georgios Siakallis, Cyprus

PE21/7  New-born infants from HIV positive women: five years experience of Infectious Diseases
         Hospital Iasi
         Alexandra Largu, Romania

PE21/8  Risk factors for peripartum virological failure in South African pregnant women on anti-
         retroviral therapy: East London Prospective Cohort Study
         Oladele Vincent Adeniyi, South Africa

EPosters
09:00 - 16:00  Exhibition hall

Paediatric, adolescent

PE25/1  Effect of cluster of differentiation (CD4) on viral respiratory infection in children, between
         0-5 years of age. A study conducted in Kwazulu-Natal, South Africa
         Temitayo Famoroti, South Africa

PE25/2  Adolescent HIV and asymptomatic malaria parasitemia (AMP) co-infection
         David Segun Adeniyi, Nigeria

PE25/3  Clinical features of viral diarrhea in the children of HIV
         Marufjon Salokhiddinov, Uzbekistan

PE25/4  High rate of rubella seronegativity in perinatally-infected HIV women of childbearing age: a
         case-control study
         Nicolas Dauby, Belgium

PE25/5  Health outcomes in adolescents and young adults living with HIV before and after transition
         to adult care in Barcelona
         Josep Ferrer Arbaizar, Spain

PE25/6  Correction of lipid abnormality by integrase inhibitor among children taking ART
         Anna Samarina, Russian Federation

PE25/7  Increasing contribution of sexually-transmitted HIV diagnoses in adolescents in Spain
         Enrique Bernal, Spain

PE25/8  Factors associated to late presentation of HIV newly diagnosed adolescents in Spain
         Enrique Bernal, Spain

PE25/9  Comparison of antiretroviral treatment initiation in HIV newly diagnosed adolescents in Spain
         Melchor Riera Jaume, Spain
**Scientific Programme**

**PE25/10**  
Oral self-testing for adolescents and young adults absent or declining to test during home-based HIV testing - a mixed-method study embedded in a cluster-randomized trial in Lesotho (ADORE study)  
Alain Amstutz, Switzerland

**PE25/11**  
Preterm births in women living with HIV in Switzerland: a 13-year evaluation  
Christian R Kahlert, Switzerland

**PE25/12**  
Poor clinical outcomes in HIV-infected children who start antiretroviral therapy at an older age  
Kevin P. McKenzie, United States

**PE25/13**  
Prevalence and predictors of unintended pregnancies among HIV positive young adults (14-24 years) attending an urban HIV clinic in Uganda  
Mackline Hope, Uganda

**PE25/14**  
Microbiota composition in a cohort of underweight HIV-positive children aged 24-72 months in Cape Town, South Africa  
Margaret Van Niekerk, South Africa

**PE25/15**  
Influence of maternal parameters on birth outcome in HIV-exposed newborns - 11 year observation  
Karolina Nowicka, Poland

**ePosters**  
09:00 - 16:00  
Exhibition hall

**Cascade of care**

**PE6/1**  
Self-reported non-receipt of HIV test results: a silent barrier to HIV epidemic control in Mozambique  
Didier Mugabe, Mozambique

**PE6/2**  
Improvement in ART initiation in different regions of Ukraine from 2010 to 2014  
Tetiana Salyuk, Ukraine

**PE6/3**  
The HIV treatment cascade in Azerbaijan, 2018  
Natig Zulfugarov, Azerbaijan

**PE6/4**  
Seven years of European Testing Week: impact of a regional awareness campaign on increase in awareness and testing activities in Europe  
Lauren Combs, Denmark

**PE6/5**  
Impact of integrated family planning and HIV services on early postpartum contraceptive use among women with HIV in the Eastern Cape, South Africa  
Oladele Vincent Adeniyi, South Africa

**PE6/6**  
The first report of Prevention of Mother-to-Child Transmission (PMTCT) of HIV in Islamic Republic of Iran  
Ebrahim Ghaderi, Iran, Islamic Republic of

**PE6/7**  
New HIV diagnosis and linkage to care in two outpatient units in South Europe  
Alessio Pampaloni, Italy
The HIV- and HCV-cascade in Swiss opioid agonist treatment (OAT) patients - the SAMMSU-cohort
Andrea Bregenzer, Switzerland

Increased Integrated testing for HIV and HCV in health care facilities: examples from the INTEGRATE activities in Lithuania and Romania
Raimonda Matulionyte, Lithuania

AIDS and late presentation follows testing gaps in Poland - data from Test and Keep in care (TAK) Polska project
Justyna Kowalska, Poland

Loss to follow-up and re-linkage to care in a single cohort study: who do we re-link to care?
Laura Magnasco, Italy

Expanding access to HIV tests in 13 cities in Indonesia: an interrupted time series investigating effect of HIV policy intervention using six years population data
Yane Tarigan, Australia

Link HIV-infected injection drug users after the imprisonment to continuum of HIV care program in Taiwan
Wei-Wei Wu, Taiwan, Republic of China

HIV continuum of care by sex and mode of transmission in Spain, 2016: use of different sources of information
Victoria Hernando, Spain

Temporal trends in time from HIV diagnosis to viral load suppression in CoRIS
Belén Alejos, Spain

Navigation of HIV positive clients. Reasons of gaps in HIV cascade among PWID
Oksana Pashchuk, Ukraine

Tracing the patterns of HIV-1 transmission among individuals with different time to diagnosis in Greece
Evangelia-Georgia Kostaki, Greece

Late diagnosis and delayed presentation in Korean HIV/AIDS cohort
Shin Woo Kim, Korea, Republic of

Interruption of HIV care: understanding the predictors and outcomes in the Belgian national HIV cohort
Dominique Van Beckhoven, Belgium

The HIV continuum of care: current situation and advances. A systematic review
Georgia Vourli, Greece

The contribution of a partnership with a civil society organization (SCO) to early HIV diagnosis and UNAIDS goals
Antonio Diniz, Portugal

HIV cascade of care in Turkey: data from the HIV-TR cohort
Deniz Gökengin, Turkey

Cascade analysis of anonymous voluntary HIV counseling and testing among HIV-infected patients in Taiwan
Chun-Yuan Lee, Taiwan, Republic of China
PE6/24  Late presentation of HIV in Armenia  
Trdat Grigoryan, Armenia

PE6/25  Oral self-testing for individuals absent or refusing testing during home-based HIV testing - a cluster-randomized trial in Lesotho (HOSENG trial)  
Tracy R Glass, Switzerland

PE6/26  Acceptability of rapid tests for migrants during the medical consultation at the migration point  
Martin Duracinsky, France

PE6/27  Evaluation of the “test and treat” strategy in an high-income setting: data from a multicenter Italian cohort  
Gianmaria Baldin, Italy

PE6/28  Pill box return as a predictor of treatment outcome to antiretroviral therapy in PLHIV: a prospective cohort study  
Robert Ndege, Tanzania, United Republic of

PE6/29  Potentially missed opportunity to diagnose HIV with standard testing algorithm among adult patients with ongoing mononucleosis-like illness  
Anna Vassilenko, Belarus

PE6/30  HIV Continuum of Care Cascade in Cluj County, Romania. Comparative situation of the years 2016, 2017, 2018  
Adriana Topan, Romania

PE6/31  People living with HIV lost to follow up in the Paris region area and actions carried out by HIV care centers  
Nicolas Vignier, France

PE6/32  Far from 90-90-90 goals in Latin America  
Maria Greco, Argentina

PE6/33  Barriers to involving patients in ART as a challenge to the national health system in Ukraine  
Serhii Riabokon, Ukraine

PE6/34  Index testing and intensified case finding for efficiency in HIV testing in Rwanda  
Eric Remera, Switzerland

ePosters  
09:00 - 16:00  
Exhibition hall

Morbidity/mortality in the era of cART

PE20/1  The association of rare HLA alleles with clinical disease progression in HIV-positive cohorts with varied treatment strategies  
Christina Ekenberg, Denmark

PE20/2  Neutrophil-to-lymphocyte ratio compared to CD4+:CD8+ T-cell ratio as a predictor of non-AIDS events in treated people living with HIV  
Nick Power, Ireland

PE20/3  Factors associated with virologic failure in women with HIV: Condesa specialized clinics, Mexico City  
Teresita De Jesús Cabrera Lópe, Mexico
PE20/4  Causes of death among a cohort of HIV-infected adults in rural Tanzania  
  Fiona Vanobberghen, Switzerland

PE20/5  Predictors of early mortality among adult HIV-infected patients on antiretroviral therapy in 
  a Kenyan pastoralist community: a retrospective cohort study  
  Paul Yonga, Kenya

PE20/6  Trends in underlying causes of death in HIV-infected patients from 2016 to 2018 in 
  Ukraine: a cohort study  
  Tetiana Kyrychenko, Ukraine

PE20/7  Dynamic of CD4+/CD8+ ratio in late presenters: impact on clinical outcomes  
  Marta Rava, Spain

PE20/8  Retrospective investigation into the causes of death in HIV-infected patients from Bonn in 
  the era of combined Anti-Retroviral Therapy  
  Lukas Knieps, Germany

PE20/9  Reduced utility of early procalcitonin in HIV febrile patients admitted to the emergency 
  department  
  Chiara Picarelli, Italy

PE20/10  Patients with HIV and HCV in intensive care treatment: admission criteria and trends in the 
  intensive care unit (ICU) at the University Hospital of Bonn 2014-2019  
  Stefan Schlabe, Germany

PE20/11  Burden of disease in PLWH harboring a 4-class drug resistant virus: data from PRESTIGIO 
  Registry  
  Maria Rita Parisi, Italy

PE20/12  Changing pattern of hospital admissions due to medical conditions in HIV-infected subjects 
  in a European public health care system with free access to antiretroviral treatment  
  Joan Raga Almudéver, Spain

PE20/13  Association of non-adherence to antiretroviral therapy with cardiovascular outcomes in 
  virologically suppressed persons living with HIV: the Swiss HIV Cohort Study  
  Tracy R Glass, Switzerland

PE20/14  Differences in social and mental well-being of long-term survivors among people who inject 
  drugs and other participants in the Swiss HIV Cohort Study: 1980 - 2011  
  Katharina Kusejko, Switzerland

PE20/15  Low pre-ART CD4 count is associated with increased risk of clinical progression or death 
  even after reaching 500 CD4 cells/µL on ART  
  Nikos Pantazis, Greece

PE20/16  A comparative analysis on blood pressure in HIV-infected individuals versus uninfected 
  controls residing in Sub-Saharan Africa: a narrative review  
  Edith Phalane, South Africa

PE20/17  Causes of death in AIDS/HIV-infected patients at the hospital of infectious diseases in St. 
  Petersburg, Russia  
  Olga Sokolova, Russian Federation

PE20/18  Dynamics and structure of mortality of HIV-positive people in Ukraine  
  Natalia Bugaienko, Ukraine
Prevalence, incidence and dynamics of HIV epidemics

PE29/1 Monitoring rates and accessibility of HIV and STI’s testing, HAV and HBV vaccination among men who have sex with men in Slovenia
Miran Solinc, Slovenia

PE29/2 Data triangulation to re-shape interventions to improve the HIV response: comparing data from estimates, case reporting, and sentinel surveillance in Ukraine
Tetiana Salyuk, Ukraine

PE29/3 The impact of frequent cannabis use on injection drug use patterns among people who use drugs in a Canadian setting
Hudson Reddon, Canada

PE29/4 Predicting early loss to follow-up on ART: a retrospective review of clients’ retention on ART in North-western Nigeria
Johnson Okolie, Nigeria

PE29/5 The increasing number of late HIV diagnosis among men having sex with men and transgender women in a key population-led HIV testing and treatment facility and its societal implication in the Philippines
Patrick Eustaquio, Philippines

PE29/6 HIV transmission network in a cohort of subjects with primary infection in a single clinical center in Rome
Lavinia Fabeni, Italy

PE29/7 Evaluation of a multiassay approach for determination recent HIV infection in the Russian Federation
Anastasia Murzakova, Russian Federation

PE29/8 Ongoing spread of HIV subtype A in Tel Aviv, Israel
Dan Turner, Israel

PE29/9 Simple clinical and laboratory based score may identify HIV infection recency and subsidize HIV surveillance in low and middle-income countries (LMIC), Santo André/Brazil experience
Elaine Monteiro Matsuda, Brazil

PE29/10 Clinical, epidemiological & virological features of primary HIV-1 infection in an HIV reference center in Brussels: a ten years’ review
Arthur Poncelet, Belgium

PE29/11 Current trends in HIV genetic diversity in Russia: increase of the unique recombinants prevalence
Anastasiia Antonova, Russian Federation

PE29/12 Analysis of risk factors in HIV/AIDS patients
Esra Zerdali, Turkey

PE29/13 Tracing the first HIV-1 epidemics in the Milan area
Alessia Lai, Italy

PE29/14 Analysis of the local HIV-1 epidemic in Vologda region, Russia: predominance of CRF03_AB and rapid expansion of URFs
Ekaterina Ozhmegova, Russian Federation
Scientific Programme

PE29/15  Identification of first near full length recombinant genome of HIV-1 in Korea
Mee-Kyung Kee, Korea, Republic of

PE29/16  Characteristics of HIV infection among children in Georgia, 1989-2018
Natela Chokoshvili, Georgia

PE29/17  HIV infection in older patients
Barbara Belfiori, Italy

PE29/18  Seroincidence of the human herpesvirus 8 (HHV 8) infection among HIV-positive patients in Taiwan, 2016-2019
Yi-Ching Su, Taiwan, Republic of China

PE29/19  Risk factors for late presentation for HIV care in 2019 in Ukraine
Maryna Sukach, Ukraine

PE29/20  Incidence of hepatitis C virus infection among people living with HIV( PLHIV ): an Egyptian Cohort Study
Rahma Mohamed, Egypt

PE29/21  High HIV prevalence following screening of subjects with HIV indicator conditions in a hospital setting
Camilla Tincati, Italy

PE29/22  First decrease in new HIV diagnoses in 2018 among men who have sex with men (MSM), in the East PACA (Provence Alpes Côte-d’Azur) area in France
Philippe Bouvet de la Maisonneuve, France

PE29/23  The collision of public health interventions on HIV-1 spread in Albania by molecular epidemiology
Shkurti Enkelejda, Albania

PE29/24  Two decades of HIV infection late diagnosis: the experience of a Portuguese Hospital
Sofia Jordão, Portugal

PE29/25  Characterization of HIV patients followed in a specialist consultation at a tertiary and university centre
Fábio Videira Santos, Portugal

PE29/26  Trends in epidemiology and clinical picture of late presentation among patients of the Hospital for Infectious Diseases in Warsaw
Joanna Pula, Poland

PE29/27  An evolutionary insight into a growing HIV subtype A epidemic in Serbia
Marina Siljic, Serbia

PE29/28  Change of prevalence, diseases distribution and factors associated with the risk of AIDS presentation in Italy over last decade (2009-2018)
Andrea Antinori, Italy

PE29/29  The effect of gender on late diagnosis of HIV infection in a high incidence European population
Rita Filipe, Portugal

PE29/30  Two decades surveillance of HIV-1 transmitted drug resistance in Serbia
Valentina Cirkovic, Serbia
Scientific Programme

PE29/31 3M-BriHT - Manchester Cohort. Investigation of the feasibility and acceptability of rapid HIV testing in a European Emergency Department setting
Molly M. O’Kane, Ireland

PE29/32 HIV-1 A6 subtype: its challenging identification and Southern Russian molecular epidemiology
Saleta Sierra, Germany

PE29/33 Neurodevelopmental assessments to screen for HIV encephalopathy in newly diagnosed infants not on ART in Mozambique
Jyodi Mohole, United States

ePosters 09:00 - 16:00 Exhibition hall
Prevention of horizontal transmission, cART as prevention
PE30/1 Tolerability and treatment completion of tenofovir alafenamide/emtricitabine/rilpivirine (TAF/FTC/RPV) as HIV postexposure prophylaxis
Marie Chauveau, France

PE31/1 Exploring the attitudes of HIV-positive patients on single-tablet antiretroviral regimens towards generic de-simplification
Clara Levey, Ireland

PE31/2 Comparison of Immunological and virological response to cART between HIV-1/O and HIV-1/M patients followed-up in France: the ANRS ORIVAO and COPANA studies
Guillemette Unal, France

PE31/3 From HIV diagnosis to antiretroviral therapy initiation in Croatia from 2013 to 2018
Nikolina Bogdanić, Croatia

PE31/5 Tetanus seroprotection in HIV-positive subjects living in Belgium: risk factors for seronegativity, evaluation of medical history and a rapid dipstick test
Nicolas Dauby, Belgium

PE31/6 The prevalence of virologic failure and resistance associated mutations in single and multi-tablet HIV treatment regimens
Chien-Yu Cheng, Taiwan, Republic of China

PE31/7 Development and validation of a risk score for predicting non-adherence to antiretroviral therapy
Hernando Knobel, Spain

PE31/8 Measles seroprevalence among HIV infected patients in central part of Poland - vaccination proposal
Ewa Siwak, Poland
**Scientific Programme**

**PE31/9** Nurse-led annual health review - one year follow up  
Marie-Pierre Klein, United Kingdom

**PE31/11** Viral hepatitis in HIV-positive patients - testing, prophylaxis and treatment in Central and Eastern Europe  
Kerstin Kase, Estonia

**PE31/12** Evaluating a national pilot process for reviewing late HIV diagnoses in England and Wales  
Ming Jie Lee, United Kingdom

**PE31/13** GESIDA quality of care indicators for PLWH: report from two Spanish hospitals 2009-2017  
Francisco Fanjul, Spain

**PE31/14** Late presentation and barriers to the early HIV diagnosis in Central part of Ukraine  
Tetiana Koval, Ukraine

**PE31/15** Operational research of barriers and facilitators to harm reduction services for intravenous drug users (including female IDUs)  
Tamar Zurashvili, Georgia

**PE31/16** A seven-month prospective review of HIV admissions to a regional infectious disease unit in Manchester, UK  
Hamzah Zahid Farooq, United Kingdom

**PE31/17** Annual health review for people living with HIV - an evaluation  
Sarah Edwards, United Kingdom

**PE31/18** Analysis of adherence to HIV-positive quality of care indicators and their impact of service quality perceptions in patient: a Spanish cross-sectional study  
Alejandra Gimeno García, Spain

**ePosters**  
09:00 - 16:00  
Exhibition hall

**Behavioural interventions**

**PE5/1** Close group social media network and social gatherings for comprehensive HIV services among adolescent MSM in Lagos Nigeria  
Orobosa Enadeghe, Nigeria

**PE5/2** Good hygiene practices post circumcision: a case for low adverse events in VMMC  
Timothy Kipkosgei, Kenya

**PE5/3** Challenges of implementing HIV counselling and testing (HCT) campaigns for higher education distance learning students at University of South Africa  
Nkay Pascal Kiabilua, South Africa

**PE5/4** Enhancing effective HIV prevention among girls by fighting child marriage and sexual and gender based violence in Karonga district, Malawi  
Shora Manuel Kauluka, Malawi

**PE5/5** Effectiveness of rapid HIV and HCV testing programmes based on mobile units  
Ekaterina Zinger, Russian Federation

**PE5/6** It can’t happen to me - tackling cognitive mistakes and HIV using a national campaign  
Arian Diskovic, Croatia
Scientific Programme

PE5/7 Is mobility still a HIV/STI associated vulnerable factor in the changing sex work dynamics among female sex workers in India? - Emerging evidence
Priyanka Dixit, India

PE5/8 “Amare con Sapienza”: an Italian digital ambient media prevention campaign in one of the largest European University to increase U=U, PreP, TasP knowledge
Serena Vita, Italy

PE5/9 Assessing high risky sexual behaviors in vulnerable women in northern Uganda: baseline results of “Pe Atye Kena, no longer alone” study
Antonella Cingolani, Italy

PE5/10 HIV/AIDS educational program for secondary school female students in Iran: a school-based randomized controlled trial
Farid Yousefi, Iran, Islamic Republic of

ePosters
09:00 - 16:00
Exhibition hall

Clinical trials of vaccines

PE8/1 Seroprevalance of vaccine preventable viral diseases and vaccine response among HIV positive patients
Fatma Sebnem Erdinc, Turkey

PE8/2 Could we recommend the current herpes zoster vaccine for patients living with HIV (PLHIV)?
Thomas Huleux, France

ePosters
09:00 - 16:00
Exhibition hall

Treatment as prevention

PE33/1 HIV-1 viral load quantification using Aptima HIV-1 Quant Dx assay in Kenya: a diagnostic accuracy study
Geoffrey Kangogo, Kenya

PE33/3 Rapid ART start in primary HIV infection: time to viral suppression in a London cohort
Nicolo Girometti, United Kingdom

PE33/4 Reality check: HIV post-exposure prophylaxis (PEP) in real-life at a tertiary care centre prior to the PrEP era
Lina Thewes, Germany

ePosters
09:00 - 16:00
Exhibition hall

Access to and models of care
Scientific Programme

PE1/1  Barriers in TB services for people living with HIV and overcoming them according to the health care workers' opinion in the TB facilities in Russia (sociological study)
   Zinaida Zagdyn, Russian Federation

PE1/2  Investigating the impact of peer counseling intervention on access and use of sexual and reproductive health services in women Living with HIV in Nepal: a prospective cohort study
   Khem Pokhrel, Nepal

PE1/3  Health care delivery for HIV-positive people with tuberculosis in Europe
   Adrian Bentzon, Denmark

PE1/4  A survey of physicians on circumstances and factors influencing testing for HIV in Lithuania
   Raimonda Matulionyte, Lithuania

PE1/5  Experiences of forgiveness and unforgiveness of HIV-specific offenses among people living with HIV/AIDS in Ghana
   Judith A. Osae-Larbi, Ghana

PE1/6  Time to antiretroviral therapy: service model adaptation during an outbreak of HIV in people who inject drugs (PWIDs)
   Harrison Stubbs, United Kingdom

PE1/7  HIV infection hospital-based active case finding in Sardinia, Italy: results from the SHOT project
   Maria Sabrina Mameli, Italy

PE1/8  Retention activities based on home visits as a tool of return and keeping in care of low adhered patients. Results of work 2016-2019 Krasnoyarsk AIDS clinic
   Konstantin Kandlen, Russian Federation

PE1/9  Pilot project of shared assistance with primary care for patients with HIV infection
   Adrián Ferre, Spain

ePosters
09:00 - 16:00  Exhibition hall

HIV and marginalised groups

PE11/1  Sexual behaviors and seroprevalence of HIV, HBV, and HCV among hill tribe youths of Northern Thailand
   Tawatchai Apidechkul, Thailand

PE11/3  The blind spot: high HIV burden among slum-dwelling school-age girls in Kampala, Uganda
   Jude Thaddeus Ssensamba, Uganda

PE11/4  Research of behavioral models of transgender people leading to high rates of HIV prevalence in Ukraine
   Igor Medvid, Ukraine

PE11/5  Outreach services for HIV testing and prevention among female transgender commercial sex workers in Milan: different approaches for different populations?
   Giuseppe Lapadula, Italy

PE11/6  The impact of unstable housing on HIV treatment outcomes in people living with HIV/AIDS in an urban setting of Southern Europe
   Hernando Knobel, Spain
Scientific Programme

PE11/7  Reflection of sex work criminalization in court judgements targeting to protect health, sanitary and epidemiological well-being
Marina Avramenko, Russian Federation

PE11/8  Caring for the Transgender HIV-positive patient
Chiara Picarelli, Italy

PE11/9  Association of current Estradiol use with carotid intimal media thickness among transgender women: a cross-sectional study
Rodrigo Moreira, Brazil

PE11/10 HIV and migrants: a demographic and clinical characterization of migrants under follow up at an Infectious Diseases Department in Lisbon, Portugal
Marta Leal dos Santos, Portugal

Social and behavioural science

PE30/2  Priorities for behavioral interventions in a group of long term PLWHA - the experience of the Baylor Clinical Centre of Excellence in Constanta, Romania
Ana-Maria Schweitzer, Romania

PE30/3  Will HIV-infected patients taking oral ARV switch to long-acting injectable ART when it become available?
Marie-Aude Khuong-Josses, France

PE30/4  Time perspectives as predictors of depression and suicidal ideation amongst adolescents and young adults with HIV: the moderating role of resilience
Oluwapelumi Ashamu, Nigeria

PE30/5  Social support and quality of life of people living with AIDS receiving ART at BPKIHS
Ram Sharan Mehta, Nepal

PE30/7  Knowledge, attitudes, beliefs and HIV-related behaviour in metropolitan France: investigation in a festive place
Fernanda Medina, France

PE30/9  Injectable long acting antiretrovirals for HIV treatment or prevention: the ANRS CLAPT study
Laurence Slama, France

PE30/10 Quality of life in people living with HIV: a regional survey in Flanders
Gert Scheerder, Belgium

PE30/11 Innovative strategies to sustain community participation in HIV vaccine trials, experience of Makerere University Walter Reed Project (MUWRP) in Kampala, Uganda
Jauhara Nanyondo, Uganda

PE30/12 Stigma among healthcare providers towards people living with HIV/AIDS in India
Akanksha Rathi, India

PE30/13 “I love my life, I don’t want to miss a thing”: motivators and Barriers to ART adherence among women living with HIV/AIDS in Iran
Nooshin Amirisani, Iran, Islamic Republic of
Scientific Programme

PE30/14  Medical students as potential sources of information about HIV/AIDS
Mykola Haras, Ukraine

PE30/15  Gender violence, intimate partner violence and domestic violence among HIV-positive patients in Alicante (Spain). Preliminary results of the VIHOLETA study
Jara Llenas-García, Spain

PE30/16  Influence of stigma and discrimination on psychosocial health in children affected by AIDS in Nepal: a cross-sectional study
Kalpana Gaulee Pokhrel, Nepal

PE30/17  The quality of life among people living with HIV in Taiwan in the era of STR
Chung-Ching Shih, Taiwan, Republic of China

PE30/18  Experiences of and factors influencing physical activity in people living with HIV: a qualitative systematic review
Megan Davies, United Kingdom

PE30/19  Perception of condom use in the era of pre-exposure prophylaxis (PrEP): a qualitative analysis
Shui Shan Lee, Hong Kong

PE30/20  Recommendations for enabling timely pregnancy disclosure to clinical staff of women living with HIV
Stefania Mihale, Romania

PE30/21  Health-related quality of life in a single center cohort of people living with chronic diseases: comparison between HIV and other clinical conditions
Antonella Cingolani, Italy

PE30/22  Experiences of Dutch obstetric healthcare providers with HIV-positive pregnant women: a qualitative study
Carlijn Damsté, Netherlands

PE30/23  Evaluation of knowledge, attitudes and practices among HIV positive pregnant women and their partners in four healthcare facilities in Malawi
Isotta Triulzi, Italy

PE30/24  Towards the 4th 90, measuring multi-dimensional quality of life in people living with HIV in Aquitaine, France: psychometric properties of the French version of the WHOQOL-HIV BREF
Diana Barger, France

PE30/25  Body size modifies the relationship between internalized HIV stigma and pain in people with HIV in the Southeastern USA
Kaylee Crockett, United States

ePosters
09:00 - 16:00  Exhibition hall

Treatment in resource-constrained settings

PE34/2  Optimizing clients linkage into ART using family-centered differentiated approach (FCDA) in Kebbi state, northwestern Nigeria: successes and challenges
Johnson Okolie, Nigeria
Scientific Programme

PE34/3  A multi-stakeholder evaluation of the early implementation experiences of differentiated anti-retroviral therapy (ART) delivery roll-out across Uganda: a qualitative analysis
Henry Zakumumpa, Uganda

PE34/5  Evaluation of the financial cost of treating people living with human immunodeficiency virus in the United Kingdom versus matched HIV-negative controls in 2004, 2010 and 2017
Scott Francis, United Kingdom

PE34/6  Continuous quality improvement across the viral load testing spectrum at the Infectious Diseases Institute, Uganda
Harriet Tibakabikoba, Uganda

PE34/7  Pediatric HIV viral load suppression: qualitative insights of barriers and facilitators among caregivers of children on ART in high volume sites in Kisumu County, Kenya
Nicollate Okoko, Kenya

PE34/8  Boosting economic affordability of HIV medicines while considering safety and effectiveness within transition from donor funding. Enabling access to TAF regime with better safety profile in Ukraine through advocacy campaign of community organization
Zoia Zamikhovska, Ukraine

ePosters
09:00 - 16:00  Exhibition hall

Vulnerable groups

PE39/1  Boys having sex with boys: CD4 count as parameter to estimate the time of infection among HIV seropositive men having sex with men and its societal implications in the Philippines
Patrick Eustaquio, Philippines

PE39/2  Evaluating factors increasing the vulnerability of adolescent girls and young women to HIV/AIDS infection in selected communities, Akwa Ibom State
Jessie Inyang, Nigeria

PE39/3  Men’s perspectives on HIV self-testing in sub-Saharan Africa: a systematic review and meta-synthesis
Mbuzeleni Hlongwa, South Africa

PE39/4  Molecular-biological methods of diagnostics in the investigation of the case of transmission of HIV-infection
Diana Valutite, Russian Federation

PE39/5  Implementation of demedicalized and decentralized HIV testing project in Brussels: action test, project for vulnerable populations at high HIV risk in Brussels, including Subsaharan African Migrants (SAM)
Tresors Kouadio, Belgium

PE39/6  HIV prevalence, risk-taking behavior and self-testing potential among men who have sex with men and transgender people
Evgeniy Pisemskiy, Russian Federation

PE39/7  Political commitment matters in the elimination of the threat of HIV and HCV and TB among people who use drugs
Gefra Fulane, Portugal
Scientific Programme

PE39/8  Challenges in health and social care for migrant HIV patients in the Czech Republic
        Elena Tulupova, Czech Republic

PE39/9  Integration of hepatitis C cure in housing facility Soleil Evant: health cost implications
        Erika Castro, Switzerland

PE39/10 The role of sexual partners of people who inject drugs in better uptake of retention in HIV services
       Marine Gogia, Georgia

PE39/11 Male sex workers and ICT: anthropological approach of male sex workers and the different practices online: bareback, PrEP and chemsex
       Maxime Maes, Belgium

PE39/12 Portuguese League Against AIDS - mobile screening unit
       Maria Eugénia Saraiva, Portugal

PE39/13 Detectable viraemia in the era of successful antiretroviral therapy; engagement with multidisciplinary services
       Shimu Khamlichi, United Kingdom

PE39/14 Optimal HIV self-testing, potential strategies to increase HIV diagnosis in Tanzania
       Neema Makyao, Tanzania, United Republic of

Clinical case

PE7/1  Disseminated histoplasmosis in HIV, a key point of interest in Latin America
       Nelson Delgado, Ecuador

PE7/2  H-ART to Heart: a 43 year old body builder with HIV on anti-retroviral therapy with recurrent myocardial infractions (5 heart attacks)
       Gavin Paul Raphael Mannathan, United Kingdom

PE7/3  Immune reconstitution inflammatory syndrome presenting as toxoplasma macular retinochoroiditis of eyes
       Dombu Guiafaing Reine Charlye, Cameroon

PE7/4  Invasive pulmonary aspergillosis and pulmonary tuberculosis in newly HIV diagnosed patients without prior ART exposure: differential diagnosis difficulties, treatment strategy
       Katerina Lytvin, Ukraine

PE7/5  Pseudotumor mimicking lung malignancy as a clinical presentation of Mycobacterium Avium infection in AIDS patient
       Luka Jovanovic, Serbia

PE7/6  Use of ibalizumab in a heavily treatment-experienced HIV-1-infected subject harbouring a multidrug-resistant virus
       Diana Canetti, Italy

PE7/7  Successful use of long-acting injectable cabotegravir and rilpivirine combination therapy in a patient with HIV-1 infection unable to absorb oral medication
       Razan Saman, United Kingdom
Scientific Programme

PE7/8  Cutaneous malignancy in a Romanian HIV-infected patient: diagnosis and treatment challenges
Irina Cristiana Ianache, Romania

PE7/9  Autoantibodies, drugs and a failing liver
Sonia Raffe, United Kingdom

ePosters
09:00 - 16:00  Exhibition hall

Novel consultations, remote care - telemedicine, mobile applications

PE23/1  Harnessing mobile technology for health worker capacity building to improve quality of care in resource-constrained settings
Walter Joseph Arinaitwe, Uganda

PE23/2  Feasibility, uptake and acceptability of the EmERGE mHealth app in individuals living with stable HIV in five European countries
Jenny Whetham, United Kingdom

PE23/3  Attracting people who use drugs to HIV prevention and care programs via darknet and messengers: evidence from St. Petersburg, Russia
Aleksey Lakhov, Russian Federation

PE23/4  People living with HIV (PLHIV) and their doctors: adopters and sceptics, and those opened to e-health
Christine Jacomet, France

PE23/5  Fitness tracking wearable devices and a dedicated smart phone app (MySAwH App) to predict quality of life in PLWH: a multi-centre prospective study
Giovanni Guaraldi, Italy

PE23/6  The efficiency of introducing the EmERGE Pathway of care for stable Croatian PLHIV
Eduard J. Beck, United Kingdom

PE23/7  ‘The 4th 90’: a preliminary assessment of change in quality of life over 1 year of the EmERGE study: PROQOL-HIV and EQ-5D-5L, a descriptive analysis
Christopher Jones, United Kingdom

PE23/8  Measuring empowerment in EmERGE mHealth platform users: a descriptive analysis of interim data
Stephen Bremner, United Kingdom

ePosters
09:00 - 16:00  Exhibition hall

PrEP

PE28/1  Establishment of the service system of HIV pre-exposure prophylaxis/post exposure prophylaxis (PrEP/PEP) in a certain area of Southern Taiwan
Kuei Ying Wang, Taiwan, Republic of China
PE28/2  Systematic review of post-migration HIV acquisition within Europe: the case for PrEP interventions for migrants
Simran Mann, United Kingdom

PE28/3  Self-reported STI history and associated factors among German PrEP users
Uwe Koppe, Germany

PE28/4  PrEP implementation among MSM in Ukraine: results of pilot project in Kyiv
Roman Marchenko, Ukraine

PE28/5  Emergency post-exposure prophylaxis (PEP) seeking behaviors among men who have sex with men (MSM) with recent HIV risk exposure in Thailand
Tarandeep Anand, Thailand

PE28/6  The back side: Lymphogranuloma venereum in PrEP-users and PLWH
Sven Schellberg, Germany

PE28/7  Awareness and interest in pre-exposure prophylaxis (PrEP) among MSM population in Serbia
Vanja Subotic, Serbia

PE28/8  PrEP reimbursement and access in Europe: 2019 update
Krzysztof Tronczyński, Poland

PE28/9  Users’ perspective of an ideal service model for delivering pre-exposure prophylaxis (PrEP) to men who have sex with men
Shui Shan Lee, Hong Kong

PE28/10  Assessment of the trough concentrations of tenofovir in HIV-negative subjects on pre-exposure prophylaxis: a single center, real-life experience
Dario Cattaneo, Italy

PE28/11  No new HIV infections, but high incidence of syphilis among Pre-exposure Prophylaxis (PrEP) users in Georgia
Ekaterine Karkashadze, Georgia

PE28/12  Feasibility and acceptability of an oral pre-exposure prophylaxis (PrEP) program against HIV targeting female sex workers in Belgium
Florence Deneumoustier, Belgium

PE28/13  First results after 52 weeks of informal PrEP use in a cohort of MSM in Southern Spain
Alejandro Berto Moran, Spain

PE28/14  Clinical outcomes of pre-exposure prophylaxis from clinical center in Warsaw, Poland
Iwona Cielnia, Poland

PE28/15  Where are we with PrEP use in Central and Eastern Europe? - data from the ECEE Network Group
Josip Begovac, Croatia

PE28/16  Sexual risk and HIV preventative behaviours among men who have sex in men in London in the era of HIV pre-exposure prophylaxis, 2019
Fiona Burns, United Kingdom

PE28/17  Chemsex and mood disorders under HIV pre-exposure prophylaxis
Helene Peyriere, France
17th European AIDS Conference  
November 6-9, 2019  
Basel, Switzerland

Scientific Programme

PE28/18  
**Pre-exposure prophylaxis one year after implementation in Portugal - the reality of a central hospital**  
Diogo Guerra, Portugal

PE28/19  
**DISCOVER in Europe: a sub-analysis of the phase 3 randomized, controlled trial of daily emtricitabine/tenofovir alafenamide (F/TAF) or emtricitabine/tenofovir disoproxil fumarate (F/TDF) for HIV pre-exposure prophylaxis (PrEP)**  
Frank Post, United States

PE28/20  
**The Good and Bad of PrEP: a 14 month follow up on awareness, adherence, efficacy and sexually transmitted diseases at Hospital de Curry Cabral**  
Marta Leal dos Santos, Portugal

PE28/21  
**PrEP for life: new challenges and barriers in PrEP uptake among men who have sex with men (MSM) and transgender people (TG) in Kyiv, Ukraine**  
Dzmitry Filippau, Ukraine

PE28/22  
**Analysis of the need for pre-exposure prophylaxis of HIV among people that have high risk to be infected**  
Vitaliy Andres, Ukraine

PE28/23  
**Lesson learnt from a combined HIV prevention using HIV self-testing and oral pre-exposure prophylaxis (PrEP) demonstration project in the United Republic of Tanzania**  
Neema Makyao, Tanzania, United Republic of

Parallel session  
10:00 - 12:00  
Event Hall

**PS8, Antiretroviral therapy: Today and in the future**

Session interpreted in Russian

**Chairs:**  
Jose Arribas, Spain  
Alexandra Calmy, Switzerland

PS8/1  
**Adherence and clinical outcomes in asymptomatic patients starting ART: the Swiss HIV Cohort Study**  
Tracy R Glass, Switzerland  
10:00 - 10:15

PS8/2  
**Assessments of very low level HIV replication for dolutegravir+lamivudine (DTG+3TC) vs dolutegravir+tenofovir disoproxil/emtricitabine (DTG+TDF/FTC) in the GEMINI 1&2 studies through week 96**  
Mark Underwood, United States  
10:15 - 10:30

PS8/3  
**Dolutegravir/emtricitabine dual therapy is non-inferior to standard combination antiretroviral therapy in maintaining HIV suppression throughout 48 weeks (SIMPL’HIV study)**  
Delphine Sculier, Switzerland  
10:30 - 10:45

PS8/4  
**Risk of failure in dual therapy versus triple therapy in naive HIV-patients: a meta-analysis**  
Antonio Russo, Italy  
10:45 - 11:00
Scientific Programme

PS8/5  11:00 - 11:15  Shorter time to treatment failure in PLHIV switched to dolutegravir plus either rilpivirine or lamivudine compared to integrase inhibitor-based triple therapy in a large Spanish cohort - VACH  
Ramón Teira, Spain

PS8/6  11:15 - 11:30  Five-year follow-up of patients enrolled in NEAT001/ANRS 143 randomized clinical trial (NEAT001 LONG TERM (NLT) study)  
Francois Raffi, France

ML1  11:30 - 11:45  Panel discussion: Controversies in antiretroviral therapy  
Jacques Reynes, France  
Hans-Jürgen Stellbrink, Germany

PS8/7  11:45 - 11:55  Uptake and discontinuation of Integrase Inhibitors (INSTIs) in a large cohort setting  
Lauren Greenberg, United Kingdom

Parallel session  
10:00 - 12:00  San Francisco

PS9, Emerging issues in public health and epidemiology of HIV in Europe

Chairs:  
Akaki Abutidze, Georgia  
Teymur Noori, Sweden

ML1  10:00 - 10:15  Epidemiology of HIV in Central and Eastern Europe  
Antons Mozalevskis, Denmark

ML2  10:15 - 10:30  Euroguidelines in Central and Eastern Europe  
ECEE network/Euroguidelines group  
Arjan Harxhi, Albania

PS9/1  10:30 - 10:45  Current trends in HIV/AIDS epidemic in Russia  
Natalia Ladnaya, Russian Federation

PS9/2  10:45 - 11:00  A simple tool to evaluate the effectiveness of HIV care for settings with gaps in data availability  
Dorthe Raben, Denmark

PS9/3  11:00 - 11:15  HIV continuum of care: bridging cross-sectional and longitudinal analyses  
Giota Touloumi, Greece

PS9/4  11:15 - 11:30  Reaching the second and third UNAIDS 90-90-90 targets is accompanied by a dramatic reduction in primary HIV infection and in recent HIV infections in a large French nationwide HIV cohort  
Adrien Le Guillou, France

PS9/5  11:30 - 11:45  Similar but different: using combined phylogenies of Austria and Switzerland reveals differences in transmission patterns of the local HIV-1 epidemics  
Katharina Kusejko, Switzerland

PS9/6  11:45 - 12:00  ´Chems4EU´ a study describing chemsex use across 4 European countries in MSM attending HIV services  
Katie Conway, United Kingdom
Scientific Programme

Parallel session
10:00 - 12:00
Boston 1-3

**PS10, Severe infections co-organised with the European Society of Clinical Microbiology and Infectious Diseases (ESCMID)**

**Chairs:**
Nathalie de Castro, France
Winfried Kern, Germany

**ML1**
**The burden of histoplasmosis and HIV: Connecting the dots**
Mathieu Nacher, French Guiana
10:00 - 10:15

**ML2**
**Hemophagocytic syndrome during HIV infection: How to sail to weather the storm?**
Lionel Galicier, France
10:15 - 10:30

**ML3**
**Tuberculosis and HIV: recent advances and perspectives**
Nathalie de Castro, France
10:30 - 10:45

**PS10/1**
**Frequency, presentation and predictors of strongyloidiasis in HIV-infected migrants at the Institute of Tropical Medicine Antwerp (ITM), Belgium**
Caroline Theunissen, Belgium
10:45 - 11:00

**PS10/2**
**Diagnosing tuberculosis in people living with HIV in a rural district of Mozambique: yield of TB-LAM, digital chest X ray and Xpert® Ultra**
Santiago Izco, Spain
11:00 - 11:15

**PS10/3**
**A New Health Care Index independently predicts 12-month mortality among HIV positive individuals diagnosed with tuberculosis**
Ashley Roen, United Kingdom
11:15 - 11:30

**PS10/4**
**Comparison of TB drug susceptibility, treatment regimens and outcome among TB/HIV-patients in a setting with high prevalence of resistant TB: results from a national and supranational reference laboratories**
Daria Podlekareva, Denmark
11:30 - 11:45

**PS10/5**
**Influence of vitamin D deficiency on development of opportunistic infection in people living with HIV/AIDS (PWHA)**
Shinwon Lee, Korea, Republic of
11:45 - 12:00

Industry sponsored session
12:15 - 13:45
San Francisco

**Industry sponsored session**
(For more details, please visit the [conference website](https://eacs-conference2019.com/index.php?article_id=166))


Scientific Programme

Special session
12:45 - 13:45

EACS General Assembly
Chair: Jürgen Rockstroh, EACS President

Special session
12:45 - 13:45

Best poster discussion I - Antiretroviral (ARV)

Chairs:
Christine Katlama, France
Vadim Rassokhin, Russian Federation

BPD1/1 Causes of treatment failure in independent and industry-funded clinical trials of dolutegravir for HIV, and outcomes of unsuppressed patients continued on treatment in the ADVANCE study
Toby Pepperrell, United Kingdom

BPD1/2 Evolution of drug interactions with antiretroviral medications in HIV-infected patients
Majdouline El Moussaoui, Belgium

BPD1/3 Drug interaction profiles for first line antiretroviral therapy and selected fixed-dose antiretroviral combinations over 20 years of the Liverpool Drug Interaction website
Best Poster
Sara Gibbons, United Kingdom

BPD1/4 Retrospective analysis of co-medication patterns among patients treated for HIV, and potential interactions with antiviral treatment, in Norway during 2012-2018 using the Norwegian population-based prescription database
Lars Heggelund, Norway

BPD1/5 TDF/FTC is a cost-saving maintenance option in HIV-infected people with low reservoir
Thierry Prazuck, France

Special session
12:45 - 13:45

Best poster discussion II - Ageing: Long-term complications

Chairs:
Antonella d'Arminio Monforte, Italy
Serhat Ünal, Turkey

BPD2/1 DXA Scan vs. FRAX score for the evaluation of fracture risk in a cohort of elderly people living with HIV
Maria Mazzitelli, United Kingdom
Scientific Programme

BPD2/2  Prevalence of and risk factors for low bone mineral density assessed by central quantitative computed tomography in people living with HIV and uninfected controls 12:57 - 13:09  
Best poster  
Magda Teresa Thomsen, Denmark

BPD2/3  Restless legs syndrome and health-related quality of life in HIV: results from the POPPY sleep substudy 13:09 - 13:21  
Ken Kunisaki, United States

BPD2/4  Depression and kynurenine/tryptophan ratio in people living with HIV 13:21 - 13:33  
Ninna Drivsholm, Denmark

BPD2/5  Antiretroviral therapy and clearance of oncogenic HPVs in HIV positive MSM 13:33 - 13:45  
Carmen Hidalgo-Tenorio, Spain

Special session  
12:45 - 13:45  
Darwin

Best poster discussion III - Hot topics

Chairs:  
Marta Vasylyev, Ukraine  
Casper Rokx, Netherlands

BPD3/4  Novel highly potent CD4bs bNAb with restricted pathway to HIV-1 escape 12:45 - 12:52  
Best poster  
Philipp Schommers, Germany

BPD3/2  Harnessing big data on Indonesian MSM and transgender individuals using temanteman.org platforms to assess their vulnerabilities, HIV support seeking patterns and immediate HIV prevention needs 12:52 - 12:59  
Tarandeep Anand, Thailand

BPD3/3  Prescription of antimicrobials in primary health care as a marker to identify people living with undiagnosed HIV infection 12:59 - 13:06  
Raquel Martin-Iguacel, Denmark

BPD3/1  HIV infection in individuals seeking post-exposure prophylaxis (PEP): a retrospective data linkage study 13:06 - 13:13  
Frédérique Hovaguimian, Switzerland

BPD3/5  Effect of norethisterone, combined contraceptive vaginal ring (CCVR) and COCPs on HIV cervical target cells in adolescent girls: a randomized crossover study 13:13 - 13:20  
Iyaloo Konstantinus, South Africa
Parallel session
14:00 - 16:00

**PS11, Where do we stand with HIV prevention today?**

Session interpreted in Russian

**Chairs:**
Diane Ponscarme, France
Ann Sullivan, United Kingdom

**ML1**
Combination prevention - The overview of what is being done in Europe
Claudia Estcourt, United Kingdom
14:00 - 14:15

**PS11/1**
PrEP persistence and associated factors: an analysis from the ANRS Prvenir study
Dominique Costagliola, France
14:15 - 14:30

**PS11/2**
Monitoring PrEP implementation in Belgium: national surveillance results, 2017-2018
Jessika Deblonde, Belgium
14:30 - 14:45

**PS11/3**
Awareness gaps on pre-exposure prophylaxis among late adolescents and young adults in the region characterised by high HIV prevalence and sexual violence
Eyitayo Omolara Owolabi, South Africa
14:45 - 15:00

**PS11/4**
Risk factors for inadequate HIV and STI testing among German PrEP users
Janna Seifried, Germany
15:00 - 15:15

**PS11/5**
Changes in bone mineral density over 2 years in men who have sex with men on tenofovir disoproxil fumarate-based HIV pre-exposure prophylaxis: longitudinal cohort data
Andrew Carr, Australia
15:15 - 15:30

**PS11/6**
Can HIV epidemics be eliminated using PrEP?
Sofia Jijon, France
15:30 - 15:45

**PS11/7**
Drop in HIV diagnoses among MSM in Paris: combined effect of PrEP, testing and political support to the communities
Eve Plenel, France
15:45 - 16:00

Parallel session
14:00 - 16:00

**PS12, Viral co-infection and liver disease**

**Chairs:**
Sanjay Bhagani, United Kingdom
Milosz Parczewski, Poland

**ML1**
Micro-elimination of HCV - A reality?
Graham Cooke, United Kingdom
14:00 - 14:15
PS12/1  “Giving HepC a place and letting it go again”: response to a sexual risk reduction intervention in HIV/HCV co-infected men who have sex with men  14:15 - 14:30
Patrizia Künzler-Heule, Switzerland

PS12/2  Impairment of CD8 T cell memory in DAA treated HCV/HIV co-infected patients  14:30 - 14:45
Matthias Hoffmann, Switzerland

PS12/3  Evolution of non-invasive markers of liver fibrosis in HIV-hepatitis C virus (HCV) co-infection before and after sustained virologic response (SVR): results from the Canadian co-infection cohort  14:45 - 15:00
Marina Klein, Canada

PS12/4  HIV/HBV coinfection in Spain: prevalence and clinical characteristics  15:00 - 15:15
Juan Berenguer, Spain

PS12/5  Outcomes after switching from TDF to TAF in HIV/HBV-coinfected individuals with renal impairment: a nationwide cohort study  15:15 - 15:30
Bernard Surial, Switzerland

PS12/6  Hepatic steatosis in HIV monoinfected individuals: which impact has baseline BMI and treatment with integrase inhibitors?  15:30 - 15:45
Jenny Bischoff, Germany

PS12/7  Evolutive NAFLD predicts frailty in people living with HIV (PLWH)  15:45 - 16:00
Jovana Milic, Italy

Parallel session
14:00 - 16:00
Boston 1-3

PS13, Liverpool/EACS pharmacology workshop - Pharmacology today and tomorrow

Chairs:
Saye Khoo, United Kingdom
Catia Marzolini, Switzerland

ML1  Introduction  14:00 - 14:05
Saye Khoo, United Kingdom
Catia Marzolini, Switzerland

ML2  Long-acting antiretroviral drugs  14:05 - 14:30
Marta Boffito, United Kingdom

ML3  Clinical case 1 - Complex DDIs  14:30 - 14:50
José Moltó, Spain

ML4  Clinical case 2 - Administration of drugs through feeding tube & absorption/DDIs issues  14:50 - 15:10
Ales Chrdle, Czech Republic

ML5  Clinical case 3 - Cancer drugs DDIs  15:10 - 15:30
Caroline Solas, France

PS13/1  Safety and PK of subcutaneous GS-6207, a novel HIV-1 capsid inhibitor  15:30 - 15:40
Rebecca Begley, United States
PS13/2  A multicentred randomised controlled open study of the utility and acceptability of a medicines optimisation review (MOR) toolkit compared to standard pharmaceutical care in HIV outpatients
Jaime Vera, United Kingdom

PS13/3  Prevalence of potential drug-drug interactions in patients of the Swiss HIV cohort study in the era of HIV integrase inhibitors
Elisabeth Deutschmann, Switzerland

Industry sponsored session
16:15 - 17:45  San Francisco

Industry sponsored session
(For more details, please visit the <a href="https://eacs-conference2019.com/index.php?article_id=166" target="_blank">conference website</a>)

Workshop/Symposium
17:45 - 19:15  Sydney

YING symposium - Growing your research
Convener: EACS
Session interpreted in Russian

Chairs:
Nathan Clumeck, Belgium
Annemarie Wensing, Netherlands

YING intro and how (not) to network
Casper Rokx, Netherlands
17:45 - 18:05

Developing a good research question; how to search and some common pitfalls
Christoph Spinner, Germany
18:05 - 18:25

Anca Streinu-Cercel, Romania
18:25 - 18:45

What’s happening in clinical research on HIV/AIDS in Europe
Agnès Libois, Belgium
18:45 - 18:55

Roundtable and discussion
18:55 - 19:15
Saturday, 09 November 2019

Meet-the-expert/Clinical cases  
07:30 - 08:30  
Montreal

Clinical cases II

Session interpreted in Russian

Chairs:  
Hansjakob Furrer, Switzerland  
David Jilich, Czech Republic

CC2/1  
A case of rash in MSM patient - overlapping epidemics in Central and Eastern Europe can challenge a doctor  
Justyna Kowalska, Poland  
07:30 - 07:50

CC2/2  
Intestinal talaromycosis in an AIDS patient: a very rare presentation  
Sireethorn Nimitvilai, Thailand  
07:50 - 08:10

CC2/3  
Failure of daily PrEP with low peak levels of TDF/FTC with identification of the 184I mutation  
Benjamin Hampel, Switzerland  
08:10 - 08:30

Roundtable discussion  
08:30 - 09:45  
Montreal

Roundtable discussion: UNAIDS goals after 2020 - What next?  
Session interpreted in Russian

Chairs:  
Valerie Delpech, United Kingdom

UNAIDS goals after 2020 - What next?  
Peter Ghys, Switzerland  
08:30 - 08:40

Roundtable discussion: UNAIDS goals after 2020 - What next?  
Nikos Dedes, Greece  
Peter Ghys, Switzerland  
Jean-Michel Molina, France  
Teymur Noori, Sweden  
Nicole Seguy, Denmark  
Liliya Ten, Kyrgyzstan  
Marco Vitoria, Switzerland  
08:40 - 09:45
Scientific Programme

Workshop/Symposium
10:00 - 10:45
Montreal

Fast-track cities. Calculus for success: Fast-track cities on a pathway from 90-90-90 to getting to zero
Convener: IAPAC
Session interpreted in Russian

Chairs:
Bertrand Audoin, France

- **Equity-based data to support a strategic focus of HIV resource and programme prioritization**
  Philippe Bouvet de la Maisonneuve, France
  10:00 - 10:06

- **Community engagement to generate demand for and deliver HIV and supportive services**
  Olga Rudnieva, Ukraine
  10:06 - 10:12

- **Addressing HIV and intersectional stigma as enemies of public health and barriers to progress**
  Jorge Garrido, Spain
  10:12 - 10:18

- **Mobilizing financial resources for sustained urban AIDS responses to support getting to zero**
  Helen Corkin, United Kingdom
  10:18 - 10:24

- **Question & answer period**
  10:24 - 10:44

Special session
11:00 - 12:45
Montreal

Status report and standard of care   co-organised with the European Centre for Disease Prevention and Control (ECDC) and the British HIV Association (BHIVA)
Session interpreted in Russian

Chairs:
Nikoloz Chkhartishvili, Georgia
Cristiana Oprea, Romania
Chloe Orkin, United Kingdom

- **Tuberculosis**
  Cristiana Oprea, Romania
  11:00 - 11:15

- **Hepatitis**
  Mojca Maticic, Slovenia
  11:15 - 11:30

- **BHIVA late presentation audit: What can we learn?**
  David Chadwick, United Kingdom
  11:30 - 11:45

- **Pilot TB audit: Where are we?**
  Georg Behrens, Germany
  11:45 - 11:55

- **Results of the European pilot audit on Hepatitis screening, prevention and management in people living with HIV**
  Ann Sullivan, United Kingdom
  11:55 - 12:05
Panel discussion 12:05 - 12:35
Georg Behrens, Germany
Nikoloz Chkhartishvili, Georgia
Cristiana Oprea, Romania
Chloe Orkin, United Kingdom
Anastasia Pharris, Sweden
Ann Sullivan, United Kingdom
Elena Vovc, Denmark

Ceremony 12:45 - 13:00 Montreal

Closing remarks
Session interpreted in Russian
Manuel Battegay, Local Conference Co-Chair
Jürgen Rockstroh, EACS President and Conference Co-Chair